TABLES

Table 1: Findings of Chinese herbal medicine intervention.

Types of	Outcomes of intervention			
intervention				
Chinese herbal	Effectiveness:	Adverse effects:		
medicines	Forty-two trials with 4462 patients compared	Only seventeen studies		
combined with	Chinese herbal medicines combined with	reported adverse effects		
other	pharmaceuticals versus other	with fourteen of them		
pharmaceuticals	pharmaceuticals reported better outcomes in	reporting the results of		
versus other	the treatment group (Chinese herbal	examinations for testing		
pharmaceuticals	medicines combined with pharmaceuticals)	adverse effects, such as		
	than in the control group (hypoglycemic	routine blood test, liver and		
	Western medicines) with all or some of the	kidney function test or		
	following outcomes: glycated haemoglobin,	ECG [14]. Another three		
	glycemic level, blood lipid profiles, BMI [11],	trials only reported no		
	insulin resistance level and TCM [1] clinical	observed clinical		
	symptoms score.	symptoms indicating		
		adverse effects without		
		mention of what kind of		
		examinations performed for		
		identifying adverse effects		
Chinese herbal	Effectiveness:	Adverse effects:		
medicines	Ten trials with 1201 patients compared	Only two studies reported		
	Chinese herbal medicines with	adverse effects with		
	pharmaceuticals that were mainly	detailed information of		

versus other what kind of examination hypoglycemic western medicines. Eight pharmaceuticals studies reported better outcomes in treatment performed for identifying group (Chinese herbal medicines) than that adverse effects. The in control group (hypoglycemic western remaining studies had no medicines) with all or some of the following information reported in terms of adverse effects outcomes: glycated haemoglobin, glycemic level, blood lipid profiles, BMI [11], insulin resistance level and TCM [1]clinical symptoms score. The outcomes are especially significant at blood sugar control (FBG [5], 2hPBG [6]) in Chinese herbal medicine group in above eight trials. Two studies only reported fasting insulin Fins and leptin etc. but not blood glucose outcomes. One study reported there was no statistical difference of blood sugar control between two groups. All ten trials reported statistical significant improvement of TCM [1] clinical symptom score Chinese herbal Effectiveness: Adverse effects: medicines or Four trials with 794 patients compared All four trials reported adverse effects with combined with Chinese herbal medicines or combined with other other interventions to placebo. Other detailed information of what kinds of examinations interventions or interventions were diet control and other programmed daily exercise alone or in performed for identifying

pharmaceuticals	combination with hypoglycemic agents and	adverse effects, such as
versus placebo	lipid treatment. All four studies reported	routine blood test, liver and
	significant outcomes in treatment group	kidney function test or
	(Chinese herbal medicines) than that in	ECG [14] as well as clinical
	control group (placebo) with glycated	symptoms
	haemoglobin and glycemic level control. TCM	
	[1] symptoms score improved significantly in	
	treatment groups in two studies	
Combined	Effectiveness:	Adverse effects:
Chinese herbal	One study with 90 patients performed three	There was no information
medicines with	groups comparison of Chinese herbal	in terms of adverse effects
other	medicines combined with other	
pharmaceuticals	pharmaceuticals versus Chinese herbal	
versus Chinese	medicine versus pharmaceuticals, reported	
herbal	that combining TCM [1] and western	
medicines	medicine was more effective at controlling	
versus other	glycated haemoglobin and glycemic level	
pharmaceuticals	than other two groups	
Chinese herbal	Effectiveness:	Adverse effects:
medicines	One study with 90 patients performed three	There was no information
versus other	groups comparison of Chinese herbal	was reported in terms to
pharmaceuticals	medicines versus pharmaceuticals versus	adverse effect
versus other	other interventions (including diabetes	
interventions	education, diet control and exercise therapy),	
	reported that Chinese herbal medicine group	

and western medicine group were more	
effective at controlling glycated haemoglobin	
and glycemic level than other intervention	
group	

 Table 2 Characteristics of included studies [ordered by study ID]

Zhu LQ 2009

Clinical research on improving insulin resistance in type 2 diabetes mellitus with Chinese medicine Tangmaikang

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine			
	+ other pharmaceuticals) compared with other pharmaceuticals alone			
	Randomisation ratio: 1:1			
Participants	Ethnic: Chinese n=138			
	Inclusion criteria: T2DM WHO 1999; insulin resistance (HOMA-IR); TCM			
	differentiation China 1993: Qi and Yin deficiency, Qi and blood deficiency; informed			
	consent			
	Exclusion criteria: have diabetes ketosis, ketoacidosis and infections, pregnancy			
	diabetes, hyperthyroidism or hepatitis and other diseases which can lead to			
	hyperglycemia within one month; psychotic and senile dementia cannot cooperate;			
	severe heart, brain, liver, kidney complications or severe primary complications;			
	pregnancy or breastfeeding; long-term or current use insulin treatment			
Interventions	Number of study centres: 1			
	Location: China			
	Setting: outpatients and inpatients in TCM hospital			
	Intervention:			
	Basic treatment: diet control, exercise therapy and oral intake of hypoglycemic			
	medicine: metformin sustained-release tablet, sulfonylurea and acarbose.			
	Treatment group: basic treatment plus TCM medicine: Tangmaikang (TMK) including			
	Huangqi, Shengdihuang, Shudihuang, Danshen, Niuxi, Chishao, Huanglian,			
	Huangjing, Gegen, Yinyanghuo			
	Control group: use basic treatment to control FBG 4.5-6.5mmol/L and 2hPBG 4.5-			
	8.0mmol/L			
Outcomes	FBG, 2hBG, Fins, HbAlc, HOMA-IR, blood fat and blood coagulation had obvious			
	improvement in varied level after treatment and treated group had better			
	improvement than control group.			

	Measured safety index by general physique examination (BMI, BP, and Pulse etc.),		
	blood routine examination, urine routine examination, liver function and kidney		
	function examination etc.		
	Outcomes were assessed at baseline and trial completion		
Study details	Duration of inter		·
Olddy doldlis	Duration of Follo		
			ieu
Otata di aire af	Run-in period: n		ing a greatistic TMALC on improve time ID in TODAA"
Stated aim of study	"A Research on	the effect of Chi	nese medicine TMK on improving IR in T2DM"
Risk of bias			
Bias		Authors	Support for judgement
		judgement	
Random sequer	nce generation	Unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into 2 groups", no described
			information in sufficient detail to allow a definite
			judgement
Allocation concealment		Unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into 2 groups", no described
			information in sufficient detail to allow a definite
			judgement
Blinding of participants and		Unclear risk	The information was not reported in this study
personnel (performance bias)			
All outcomes	,		
Blinding of outcome assessment Un		Unclear risk	The information was not reported in this study
(detection bias)			
All outcomes			
Incomplete outcome data		Low risk	Two cases lost follow up in treated group and eight
(attrition bias)			cases lost in control group before the
All outcomes			interventions. No exclusion or losses were
			reported after the interventions, and the number of
			participants remained the same at the endpoint of
			study

Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)		possibility of selection outcome reporting could not
		be examined by the review authors
Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on sex, age, medical
		condition and disease course. Other aspects of
		bias were unclear

Wu JJ 2015

Curative effect of therapy with Chinese medicine on type 2 diabetes of damp-heat type and life quality

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=120
	Inclusion criteria: T2DM WHO 1999; TCM differentiation: damp-heat type
	Exclusion criteria: patients used insulin before were selected in study, psychotic,
	dementia, anemia, severe infection, myocardial infarction, heart failure, severe renal
	dysfunction, active hepatitis, tumour, pregnancy, breastfeeding, diabetes ketosis
	acidosis, hypertonicity coma
Interventions	Number of study centres: 1
	Location: China
	Setting: inpatients in TCM hospital
	Intervention: diet control, diabetes health education and exercise instruction
	Treatment group was treated with differential therapy with Chinese medicine jia wei
	gan lu xiao du dan (include: Hua Shi Fen, Yinchen, Huangqin, Shichangpu,
	Huoxiang, Chuanbeimu and Lianqiao) on the basis of treatment in control group
	Control group use oral hypoglycemic western medicine alone: metformin, acarbose,
	glipizide, sulfonylurea, rosiglitazone and so on.
Outcomes	The life quality score (QLICD-DM, SF-36FBG) of the patients in both group after
	treatment were improved significantly, and the improvement in treatment group was

	I		
	better than that in the control group. The improvement of blood sugar (FBG, 2hPG),		
	blood fat and HbAlc were better in treatment group than that in the control group.		
	No information was reported in terms to adverse effect in this study		
	Outcomes we	re assessed at l	baseline and trial completion
Study details	Duration of int	ervention: 12 we	eeks
	Duration of Fo	ollow-up: not rep	orted
	Run-in period	: none	
Stated aim of	"to observe th	e curative effect	t of differential therapy with Chinese medicine on type 2
study	diabetes of da	amp-heat type a	nd life quality of the patients"
Risk of bias			
Bias		Authors	Support for judgement
		judgement	
Random sequer	nce generation	Unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into 2 groups"
Allocation conce	alment	Unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into 2 groups"
Blinding of participants and		Unclear risk	The information was not reported in this study
personnel (performance bias)			
All outcomes			
Blinding of outcome		Unclear risk	The information was not reported in this study
assessment (detection bias)			
All outcomes			
Incomplete outc	ome data	Low risk	No exclusion or losses were reported, but the number
(attrition bias)			of participants remained the same at the endpoint of
All outcomes			study
Selection report	ing (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)			possibility of selection outcome reporting could not be
,			examined by the review authors
Other bias		Unclear risk	The intervention groups were comparable, as it
			mentioned in the trial "no significant difference was
			found between groups on sex, age, medical condition
			and disease course. Other aspects of bias were
			unclear

Cao YJ 2013

Jiangtangjing Granule Treatment of Type 2 Diabetes Clinical Observation and Mechanism Research

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine			
	+ other pharmaceuticals) compared with other pharmaceuticals alone			
	Randomisation ratio: 1:1			
Participants	Ethnic: Chinese n=40			
	Inclusion criteria: T2DM WHO 1999: FPG≥7.0mmol/L, or 2hPG≥11.1mmol/L; TCM			
	differentiation: qi and yin deficiency			
	Exclusion criteria: ≤18 y or ≥65y; pre-diabetes; pregnancy or breastfeeding, patients			
	combine with other severe primary diseases or psychotic, patients with diabetic			
	ketoacidosis and other acute metabolism disorders as well as associated infections			
	within one month			
Interventions	Number of study centres: 1			
	Location: China			
	Setting: outpatients in TCM hospital			
	Intervention:			
	Basic treatment: exercise intervention and diet intervention			
	Treatment group: basic treatment + Chinese medicine Jiangtangjing granule (mainly			
	include: Huangqi, Huangjing, Yiyiren, Gegen, Shanyao, shanzha, Shuizhi, baijiezi			
	etc.) on the basis of treatment in control group			
	Control group use western medicine alone: Saxagliptin			
Outcomes	Both groups show significant difference in fasting blood sugar (FBG), blood sugar			
	(2hPG), 2h postprandial glycosylated haemoglobin (HbAlc) compared with before,			
	but the TCM symptoms integral change of Jiangtangjing granule group patients			
	significantly reduced compared with the control group.			
	Measured liver and kidney metabolism related indexes after the treatment and no			
	abnormal was observed.			
	Outcomes were assessed at baseline and trial completion			
Study details	Duration of intervention: 8 weeks			
	Duration of Follow-up: not reported			
	Run-in period: none			
	· · ·			

Stated aim of	"To observe the Jiangtangjing granule in effect of treatment for type 2 diabetes and		
study	its hypoglyce	poglycemic mechanism of the initial study"	
Risk of bias			
Bias		Authors	Support for judgement
		judgement	
Random sequer	ce generation	Unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into Jiangtangjing group and control
			group"
Allocation conce	alment	Unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into Jiangtangjing group and control
			group"
Blinding of partic	ipants and	Unclear risk	The information was not reported in this study
personnel (perfo	rmance bias)		
All outcomes			
Blinding of outcome		Unclear risk	The information was not reported in this study
assessment (de	tection bias)		
All outcomes			
Incomplete outcome data		Low risk	No exclusion or losses were reported, but the number
(attrition bias)			of participants remained the same at the endpoint of
All outcomes			study
Selection reporti	ng (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)			possibility of selection outcome reporting could not be
			examined by the review authors
Other bias		Unclear risk	The intervention groups were comparable, as it
			mentioned in the trial "no significant difference was
			found between groups on sex, age, medical condition
			and disease course. Other aspects of bias were
			unclear

Zhou JG 2012

Influence on insulin Resistance of Type 2 diabetes mellitus with Lijian Decoction

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine		
	+ other pharmaceuticals) compared with other pharma	aceuticals alone	
	Randomisation ratio: 1:1		
Participants	Ethnic: Chinese n=96	:: Chinese n=96	
	Inclusion criteria: T2DM WHO 1999; HOMA-IR (FPGx	FINS/22.5) ≥28;	
	Exclusion criteria: liver and renal dysfunction, type 1 d	liabetes, tumour, hematopoiesis	
	system disease as well as psychotic, acute myocardia	se as well as psychotic, acute myocardial infarction, severe heart	
	rhythm abnormal, acute heart failure or chronic heart of	dysfunction over level 3	
Interventions	Number of study centres: 1		
	Location: China		
	Setting: patients in TCM college hospital		
	Intervention: two groups used sulphonylureas, metfor	min, and alpha glucosidase	
	inhibitor conventional therapy for 4 weeks. When fasti	ng glucose<7.0mmol/L, the	
	treatment group combined with Lijian Decoction (Lizhi	he, Huoxiang, Peilan,	
	Cangzhu, Jixuecao, Guijianyu)		
	Control group maintained the original conventional treatment		
Outcomes	Compare to control group, blood cholesterol (TC), triglyceride (TG), low-density		
	lipoprotein (LDL-C), high-density lipoprotein (HDL-C), fasting plasma glucose (FBG),		
	fasting insulin (FINS) and insulin sensitivity index (ISI)	were significantly decreased in	
	treatment group after treatment.		
	Blood, urine, stool routine examination and liver, kidney function examination,		
	measured adverse effect. No adverse effect observed during the intervention.		
	Outcomes were assessed at baseline and trial completion		
Study details	Duration of intervention: 8 weeks		
	Duration of Follow-up: not reported		
	Run-in period: 4 weeks		
Stated aim of	"To observe the effect of treatment of eliminating dampness with aromatics for type 2		
study	diabetes mellitus"		
Risk of bias			
Bias	Authors Support for judgemen	t	
	judgement		

Random sequence generation	Unclear risk	It only mentioned in the trial that "patients were
(selection bias)		randomly divided into treatment group and control
		group"
Allocation concealment	Unclear risk	It only mentioned in the trial that "patients were
(selection bias)		randomly divided into treatment group and control
		group"
Blinding of participants and	Unclear risk	The information was not reported in this study
personnel (performance bias)		
All outcomes		
Blinding of outcome	Unclear risk	The information was not reported in this study
assessment (detection bias)		
All outcomes		
Incomplete outcome data	Low risk	No exclusion or losses were reported, but the number
(attrition bias)		of participants remained the same at the endpoint of
All outcomes		study
Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)		possibility of selection outcome reporting could not be
		examined by the review authors
Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial that "no significant difference
		was found between groups on sex, age, medical
		condition and disease course Other aspects of bias
		were unclear.
	1	1

Nie JT 2010

Effects of combing traditional Chinese medicine with Western medicine on life quality and carbohydrate metabolism in patients with type 2 diabetes

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine		
	+ other pharmaceuticals) compared with other pharmaceuticals alone		
	Randomisation ratio: 1:1		
Participants	Ethnic: Chinese n=118		
	Inclusion criteria: T2DM TCM differentiation: qi and yin deficiency with blood stasis		

	Exclusion criteria: not described			
Interventions	Number of study centres: 1			
	Location: China			
	Setting: inpatients in TCM hospital			
	Intervention:			
	Basic treatment: controlling blood pressure, adjusting blood lipid and having diabetic			
	diet			
	Combining TCM and western medicine group: added TCM herbs according to			
	syndrome differentiation (Huangqi, Huaishangyao, Fuling plus Gegen, Tianhuafen or			
	Shengshigao, Huanglian, Zhimu, Shengdihuang, Maidong and Gegeng or Fuzi,			
	Rougui, Lurong and Fupengzi or Taoren, Honghua or Shenqu, Maiya and Yiyiren or			
	Yanhuoshuo, Jiangchan, Quangxie and Yujin) on the basis of western medicine			
	group			
	Western medicine (WM) group: insulin or oral blood sugar control medicine only in			
	addition to basic treatment (no details information about the medicine)			
Outcomes	After treatment, physiological and psychological/spiritual functions of QOL in both			
	groups were improved markedly, variation of physiological and treatment functions in			
	combing TCM with WM group in pre and post treatment had significant difference			
	comparing with those in WM group. FPG, 2hPG, HbA1c obviously decreased and			
	variation of observation indexes in combining TCM with WM in pre and post			
	treatment had a significant decrease comparing with those in WM group.			
	No information was reported in terms to adverse effect in this study			
	Outcomes were assessed at baseline and trial completion			
Study details	Duration of intervention: 3 months			
	Duration of Follow-up: not reported			
	Run-in period: none			
Stated aim of	"To study the effects of combing traditional Chinese medicine with Western medicine			
study	on life quality (QOL) and carbohydrate metabolism in patients with type 2 diabetes"			
Risk of bias				
Bias	Authors Support for judgement			
	judgement			

Random sequence generation	Unclear risk	It only mentioned in the trial that "patients were
(selection bias)		randomly divided into combing TCM with WM group
		and WM group"
Allocation concealment	Unclear risk	It only mentioned in the trial that "patients were
(selection bias)		randomly divided into combing TCM with WM group
		and WM group"
Blinding of participants and	Unclear risk	The information was not reported in this study
personnel (performance bias)		
All outcomes		
Blinding of outcome	Unclear risk	The information was not reported in this study
assessment (detection bias)		
All outcomes		
Incomplete outcome data	Low risk	No exclusion or losses were reported, but the
(attrition bias)		number of participants remained the same at the
All outcomes		endpoint of study
Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)		possibility of selection outcome reporting could not
		be examined by the review authors
Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on sex, age, medical
		condition and disease course. Other aspects of bias
		were unclear
(attrition bias) All outcomes Selection reporting (reporting bias)	Unclear risk	number of participants remained the same at the endpoint of study The protocol of the trial was not available, so the possibility of selection outcome reporting could not be examined by the review authors The intervention groups were comparable, as it mentioned in the trial "no significant difference was found between groups on sex, age, medical condition and disease course. Other aspects of bia

Hu YT 2014

Effect observation of integrated Chinese and western medicine in the treatment of obesity and type 2 diabetes mellitus

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=150

	Inclusion criteria: T2DM ADA 2003, TCM diagnostic criteria, obesity diagnostic		
	criteria China	2003; age: 40-7	5 years old; stable condition and complications under
	ideal control; clear consciousness; informed consent;		
	Exclusion crite	eria: type 1 diabe	etes; tumour, combine with ketoacidosis or
	hypertonicity coma or severe infections, combine with severe disturbance of		
	consciousness, severe heart, liver and renal failure; cannot take medicine according		
	prescription; to	ake other TCM;	outcome is not clear; cannot cooperate
Interventions	Number of stu	dy centres: 1	
	Location: Chin	a	
	Setting: inpation	ents in TCM hos	pital
	Intervention:		
	Treated group	added TCM trea	atment (Dangshen, Shashen, Taizishen, Huangbai,
	Shengdi, Huai	ngqi, Chuangxio	ng, Dilong, Maidong, Zhimu, Tianhuafen) based on
	treatment in co	ontrol group	
	Control group	: conventional w	estern medicine treatment: diabetic diet, rational
	exercise, emotional and psychological therapy, oral taking metformin		
Outcomes	The curative effect (FPG, 2hPG) and the total effective rate of the decrease of body		
	weight (waistline, BMI) in treatment group were better than that in control group, and		
	the difference was statistically significant.		
	No information was reported in terms to adverse effect in this study		
	Outcomes were assessed at baseline and trial completion		
Study details	Duration of int	ervention: 12 we	eeks
	Duration of Fo	llow-up: not rep	orted
	Run-in period	: none	
Stated aim of	"To observe th	ne clinical curativ	ve effect of integrated traditional Chinese and western
study	medicine in the treatment of obese type 2 diabetes"		
Risk of bias	I		
Bias		Authors	Support for judgement
		judgement	
Random sequence generation		Unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into treatment group and control
			group"
<u></u>			1

Allocation concealment	Unclear risk	It only mentioned in the trial that "patients were
(selection bias)		randomly divided into treatment group and control
		group"
Blinding of participants and	Unclear risk	The information was not reported in this study
personnel (performance bias)		
All outcomes		
Blinding of outcome	Unclear risk	The information was not reported in this study
assessment (detection bias)		
All outcomes		
Incomplete outcome data	Low risk	No exclusion or losses were reported, but the number
(attrition bias)		of participants remained the same at the endpoint of
All outcomes		study
Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)		possibility of selection outcome reporting could not be
		examined by the review authors
Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on sex, age, medical condition
		and disease course. Other aspects of bias were
		unclear

Fu NY 2012

Insulin Resistance of Type 2 Diabetes Mellitus Diagnosis and Treatment of Traditional Chinese Medicine Clinical Observation

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 1:6
Participants	Ethnic: Chinese n=140 (20 in control group, 120 in treatment group)
	Inclusion criteria: T2DM WHO 1999, IR, TCM differentiation: yin deficiency with
	dryness-heat, damp-heat restrain spleen, qi and yin deficiency, blood stasis
	resistance of meridians

	Exclusion criteria: type 2 diabetes with severe damage of heart, brain, kidney and				
	other vital organs; life signs unstable, cannot cooperate with examination				
Interventions	Number of study centres: 1				
	Location: China				
	Setting: inpatients in TCM hospital				
	Intervention:	Intervention:			
	Treatment gro	up added TCM	formula according to TCM differential patterns on the		
	basis of treatm	nent in control g	roup (Yin deficiency with dry heat: Shengdi, Shashen,		
	Shihu, Tianhua	afen, Gegen, Tia	andong, Maidong, Zhimu, Huangqin, Huanglian; Damp -		
	heat restrict sp	oleen: Chenpi, E	Banxia, Fuling, Juemingzi, Zhexie, Ganchao, Zhuru,		
	Dangnanxing;	Qi and yin defic	eiency: Shenghuangqi, Shanyao, Dangshen, Shengdi,		
	Xuanshen, Ma	nidong, Digupi, S	Shanzhuyu, Changzhu, Wuweizi, Wumei; Phlegm		
	stagnation: Da	angshen, Sheng	di, Xuanshen, Danggui, Baishao, Chuanxiong,		
	Jixueteng, Da	nshen, Tianhuaf	en, Gegen, Rendongteng, Honghua)		
	Control group: metformin				
Outcomes	Significant change with index (FPG, IAI, FINS, TG, HDL-C, TNF-α) was observed				
	after treatment and treatment group has larger indexes variations than the control				
	group.				
	No information was reported in terms to adverse effect in this study				
	Outcomes were assessed at baseline and trial completion				
In Study	Duration of intervention: 8 weeks				
details	Duration of Follow-up: not reported				
	Run-in period: none				
Stated aim of	"To explore the pathogenesis of insulin resistance of traditional Chinese medicine				
study	and TCM treatment effect characteristics of insulin resistance type 2 diabetes cases				
	by differentiation of TCM clinical observation"				
Risk of bias	Risk of bias				
Bias		Authors	Support for judgement		
		judgement			
Random sequence generation		Unclear risk	It only mentioned in the trial that "patients were		
(selection bias)			randomly divided into treatment group and control		
			group"		
			I		

Allocation concealment	Unclear risk	It only mentioned in the trial that "patients were
(selection bias)		randomly divided into treatment group and control
		group"
Blinding of participants and	Unclear risk	The information was not reported in this study
personnel (performance bias)		
All outcomes		
Blinding of outcome	Unclear risk	The information was not reported in this study
assessment (detection bias)		
All outcomes		
Incomplete outcome data	Low risk	No exclusion or losses were reported, but the number
(attrition bias)		of participants remained the same at the endpoint of
All outcomes		study
Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)		possibility of selection outcome reporting could not be
		examined by the review authors
Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on sex, age, medical condition
		and disease course. Other aspects of bias were
		unclear

Zhang Y 2010

Influence on insulin resistance of Type 2 Diabetes Mellitus by the Treatment of Yangyin Qingre method

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=80
	Inclusion criteria: T2DM WHO 1999, TCM diagnostic criteria: Xiaoke yin deficiency
	with heat, FPG≥5.8mmol/L ≤13.8mmol/L, BMI:21-35kg/m², HOMA-IR≥2.8; age: 35-
	85; T2DM over 6 months since diagnose, no insulin and other medicine affecting
	glycolipid metabolism; TCM pattern: yin deficiency with excess heat

	Exclusion crite	ria: type 1 diabete	es; severe cardio diseases, myocardial infarction,	
	unstable steno	cardia, chronic he	art dysfunction; severe diabetic complications and	
	liver, kidney disease, other endocrine disease; recent acute infectious disease			
	acute diabetic	complications; sy	stolic pressure≥160mmHg and /or diastolic	
	pressure≥100	mmHg; current wit	h insulin treatment	
Interventions	Number of stud	dy centres: 1		
	Location: China	a		
	Setting: outpat	ients and inpatien	ts in TCM hospital	
	Intervention: tv	vo groups' patient	s were by diet control, lipid-lowing drugs,	
	hypoglycemic	drug sulfonylurea	and metformin for two weeks as observation	
	platform period	d.		
	Treatment gro	oup were added n	ourishing Yin and clear heat Chinese herbal	
	decoction (She	engdi, Shanzhuyu	, Huaishanyao, Mudanpi, Fuling, Zelan, Zhimu,	
	Huangbai, Hua	nglian, Huangqin	, Zhizi, Banxia, Chenpi, Yiyiren, Danshen, Taoren,	
	Dangshen, Bai	izhu, Yujin, Chaihu	u)	
	Control group remain the original treatment.			
Outcomes	nes Treatment group observed better results in efficiency and FPG, 2hPG,		er results in efficiency and FPG, 2hPG, HbA1C, TC,	
	TG, Fins, HOM	1-IR and the differ	ence was significant.	
ECG, urine routine examination		utine examination,	liver and kidney function examination, ALT, SCR,	
	BUN and UA, measured safety. No adverse effect observ		No adverse effect observed during the intervention.	
	Outcomes were assessed at baseline and trial completion			
Study details	Duration of intervention: 8 weeks		S	
	Duration of Fo	llow-up: not repor	ted	
	Run-in period: 2 weeks			
Stated aim of	"To observe th	e law YangyinQin	gre Chinese medicine for the effects of insulin	
study	resistance type 2 diabetes mellitus"			
Risk of bias				
Bias		Authors	Support for judgement	
		judgement		
Random sequer	nce generation	Unclear risk	It only mentioned in the trial that "patients were	
(selection bias)			randomly divided into treatment group and control	
			group"	

Allocation concealment	Unclear risk	It only mentioned in the trial that "patients were
(selection bias)		randomly divided into treatment group and control
		group"
Blinding of participants and	Unclear risk	The information was not reported in this study
personnel (performance bias)		
All outcomes		
Blinding of outcome	Unclear risk	The information was not reported in this study
assessment (detection bias)		
All outcomes		
Incomplete outcome data	Low risk	Exclusion or losses were reported before the study
(attrition bias)		and the number of participants remained the same
All outcomes		at the endpoint of study
Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)		possibility of selection outcome reporting could not
		be examined by the review authors
Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on sex, age, medical
		condition and disease course. Other aspects of
		bias were unclear

Xu Q 2007

A Clinical observation on Treatment of Integrated Chinese and Western Medicine for 35 cases of type 2 Diabetes

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=69
	Inclusion criteria: T2DM WHO 1999; have typical diabetes symptoms with once
	FPG≥7.0mmol/L or 2hPG≥11.1mmol/L or blood sugar≥11.1mmol/L; have no typical
	diabetes symptoms with twice FPG≥7.0mmol/L; or twice blood sugar ≥11.1mmol/L
	after OGTT, or once FPG≥7.0mmol/L and blood sugar≥11.1mmol/L after OGTT;

	TCM diagnost	c criteria (China	1993): TCM differentiation: qi and yin deficiency;	
	blood sugar<2	0mmol/L, age:4	0-75, voluntary to study and can take medicine	
	according to p	rescription		
	Exclusion crite	ria: FPG≤7mmo	ol/L or 2hPG≤11.1mmol after diet control and exercise	
	therapy; comb	therapy; combine with severe heart, liver, kidney complications or other severe		
	primary diseases, or psychotic; have diabetic ketoacidosis and other acute			
	metabolism disorders as well as with associated infections within one month;			
	pregnancy, bre	eastfeeding and	drug allergy; type 2 diabetes with insulin treatment	
Interventions	Number of stud	dy centres: 1		
	Location: China	а		
	Setting: outpat	ients in TCM ho	spital	
	Intervention:			
	Treatment gro	up added TCM o	lecoction of lower blood sugar and nourishing yin	
	decoction (She	eng Huangqi, Xu	anshen, Shanyao, Dangshen, Maidong, Sheng	
	Dihuang, Shu	Dihuang, Wuwei	zi, Tianhuafen, Gegen, Danshen, Chishao,	
	Chuanxiong)	on the basis of tr	eatment in control group	
	Control group: oral intake of hypoglycemic drug sulfonylurea (metformin)			
Outcomes	FPG, 2hPG and GHbA1c decreases significantly in both groups especially in			
	treatment group; blood lipid (TC, TG, LDL-C, and HDL-C) and score of Chinese			
	medical pattern and therapeutic effect improved significantly in treatment group.			
	No information was reported in terms to adverse effect in this study			
	Outcomes were assessed at baseline and trial completion			
Study details	Duration of inte	ervention: 8 wee	ks	
	Duration of Fo	llow-up: not repo	orted	
	Run-in period:	none		
Stated aim of	"To observe th	e therapeutic eff	fect of integrated therapy of Chinese and western	
study	medicine for type 2 diabetes"			
Risk of bias	L			
Bias		Authors	Support for judgement	
		judgement		
Random sequer	nce generation	Unclear risk	It only mentioned in the trial that "patients were	
(selection bias)			randomly divided into treatment group and control	
			group"	
L			1	

Allocation concealment	Unclear risk	It only mentioned in the trial that "patients were
(selection bias)		randomly divided into treatment group and control
		group"
Blinding of participants and	Unclear risk	The information was not reported in this study
personnel (performance bias)		
All outcomes		
Blinding of outcome	Unclear risk	The information was not reported in this study
assessment (detection bias)		
All outcomes		
Incomplete outcome data	Low risk	No exclusion or losses were reported, but the
(attrition bias)		number of participants remained the same at the
All outcomes		endpoint of study
Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)		possibility of selection outcome reporting could not
		be examined by the review authors
Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on sex, age, medical
		condition and disease course. Other aspects of bias
		were unclear

Wang YG 2013

Clinical Observation on Si-huang Hypoglyycemic Granule (SHHG) improving Patients Symptoms of TCM with T2DM

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals and placebo
	Randomisation ratio: 2:1
Participants	Ethnic: Chinese n=126 (82 in treatment group, 44 in control group)
	Inclusion criteria: T2DM WHO 1999; TCM diagnostic criteria; T2DM patients with
	long-term hyperglycosemia with HbA1c≥7.5%; patients not include in exclusion
	cases

	Exclusion criteria: pregnancy or breastfeeding; severe heart, liver, kidney and brain		
	complications	, or combine othe	r severe primary diseases; have diabetes ketosis or
	hypertonicity of	coma or infections	within 1 month; not satisfy with TCM diagnostic
	criteria		
Interventions	Number of stu	dy centres: 1	
	Location: Chir	na	
	Setting: inpation	ents and outpatie	nts in TCM university hospital
	Intervention:		
	Treated group	added Sihuang h	nypoglycemic granule (SHHG) (Huangqi, Sheng
	Dihuang, Dah	uang, Huanglian,	Guijianyu) on the basis of conventional western
	medicine hyp	oglycemic therapy	/
	Control group	: conventional we	stern medicine hypoglycemic therapy (glipizide and
	metformin ora	l intake) with plac	ebo
Outcomes	Two groups h	nad good curative	effect in reducing blood glucose and glycosylated
	haemoglobin	(FPG, 1hPG, 2hP	G, HbA1C), the treatment group is better than the
	control group in improving the TCM clinical symptoms (TCM symptom score).		
	No information was reported in terms to adverse effect in this study		
	Outcomes were assessed at baseline and trial completion		
Study details	Duration of intervention: 6 months		
	Duration of Follow-up: not reported		
	Run-in period: none		
Stated aim of	"To observe the effect of Dangua prescription on type 2 diabetes patients with long-		
study	term hyperglycosemia"		
Risk of bias			
Bias		Authors	Support for judgement
		judgement	
Random sequer	nce generation	Unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into treatment group and control
			group"
Allocation conce	ealment	Unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into treatment group and control
			group"

Blinding of participants and	Unclear risk	It only motioned when allocating patients in two
personnel (performance bias)		groups, no report in intervention.
All outcomes		
Blinding of outcome	Unclear risk	The information was not reported in this study
assessment (detection bias)		
All outcomes		
Incomplete outcome data	Low risk	No exclusion or losses were reported, but the
(attrition bias)		number of participants remained the same at the
All outcomes		endpoint of study
Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)		possibility of selection outcome reporting could not
		be examined by the review authors
Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on sex, age, medical
		condition and disease course. Other aspects of bias
		were unclear

Luo YY 2010

Clinical Effect of Prescription for Invigorating spleen to reduce Sugar on the Insulin Resistance of Type 2 Diabetes Patients

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal
	medicine + other pharmaceuticals) compared with other pharmaceuticals
	alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=80
	Inclusion criteria: T2DM WHO 1999; T2DM patients with insulin resistance,
	FPG>7mmol/L, FINS>15IU/L after basic treatment
	Exclusion criteria: type 1 diabetes; pregnancy or breastfeeding or plan
	pregnancy; over sensitive to the treatment drug or the ingredients; have
	surgery or other emergency circumstance; have diabetic ketoacidosis or

	hypertonicity	coma: severe li	ver, kidney diseases, severe coronary heart	
	disease; over 70 years old			
Interventions	Number of study centres: 1			
	Location: China			
	Setting: inpatients and outpatients in TCM hospital			
		Intervention: conventional diet and exercise therapy		
		Treatment group added TCM prescription for invigorating spleen to reduce		
		•	iyu, Shouwu, Huaishanyao, Chaihu, Yujin,	
			Dangshen, Baizhu for Qi deficiency; Sheng	
			deficiency; Huanglian for heat; Danggui for	
	blood deficie	ncy; Tusizi for Ya	ang deficiency; Changzhu, Fuling and Yiyiren for	
	Phlegm dam	oness) on the ba	sis of control group	
	Control group	o: oral intake of n	netformin hydrochloride	
Outcomes	More significa	ant difference wa	s observed in indicators (FPG, 2hBG,	
	FINS,HbA1C	TC, TG, HDL-C	, LDL0C and HOMA-IR) before and after	
	treatment in treatment group			
	No adverse effect observed through liver, kidney, heart function examination			
	and blood, urine and stool routine examination.			
	Outcomes were assessed at baseline and trial completion			
Study details	Duration of intervention: 3 months			
	Duration of Follow-up: not reported			
	Run-in period: none			
Stated aim of	"To observe the clinical effect of prescription for invigorating spleen to reduce			
study	sugar on the insulin resistance of type 2 diabetes patients"			
Risk of bias		<u> </u>		
Bias		Authors	Support for judgement	
		judgement Unclear risk		
'	Random sequence		It only mentioned in the trial that "patients	
generation (sele	generation (selection bias)		were randomly divided into treatment group	
		Unclear risk	and control group"	
	Allocation concealment		It only mentioned in the trial that "patients	
(selection bias)			were randomly divided into treatment group	
			and control group"	

Blinding of participants and	Unclear risk	The information was not reported in this study
personnel (performance bias)		
All outcomes		
Blinding of outcome	Unclear risk	The information was not reported in this study
assessment (detection bias)		
All outcomes		
Incomplete outcome data	Low risk	No exclusion or losses were reported, but the
(attrition bias)		number of participants remained the same at
All outcomes		the endpoint of study
Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so
bias)		the possibility of selection outcome reporting
		could not be examined by the review authors
Other bias	Unclear risk	The intervention groups were comparable, as
		it mentioned in the trial "no significant
		difference was found between groups on sex,
		age, and disease course BMI, laboratory text
		indexes, insulin resistant index etc. Other
		aspects of bias were unclear

Xu CX 2006

Clinical observation of Qi-Enriching and Yin-Nourishing, Heat-clearing and Blood-activating Therapy for 30 Cases of Type 2 Diabetes Insulin Resistance

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal
	medicine + other pharmaceuticals) compared with other pharmaceuticals
	alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=60
	Inclusion criteria: T2DM WHO 1999; FPG≥7mmol/L; blood sugar ≥
	11.1mmol/L; random blood sugar ≥11.1mmol/L; OGTT 2hPG ≥ 11.1mmol/L;
	blood sugar cannot be controlled to ideal level after diet control, exercise
	therapy and western medicine treatment for over two weeks

	Exclusion criteria: type 1 diabetes; pregnancy diabetes; other type diabetes		
	and diabetes with acute or severe complications within one month; over 75		
	years old		
Interventions	Number of study centres: 1		
	Location: China		
	Setting: inpatients and outpatients in hospital		
	Intervention:		
	Treated grou	ıp added TCM pro	escription for qi-enriching, yin-nourishing, heat-
	clearing and	blood-activating	(Taizishen, Huangqi, Guijianyu, Cangzhu,
	Xuanshen, D	ihuang, Gegen,	Shanyao, Tianhuafen, Zhimu, Shanzhuyu,
	Huanglian; a	dd Maidong for s	evere Yin deficiency; add Yinyanghuo for cold
	aversion) on	the basis of cont	rol group
	Control grou	p: diet control and	d exercise therapy with oral intake berberine
	tablet		
Outcomes	The total clinical effect and insulin resistance improving were significant		
	higher in treatment group than in control group. 2hPG, FINS, HbA1C, TG,		
	and ISI improved more obviously in treatment group than in control group.		
	No information was reported in terms to adverse effect in this study		
	Outcomes were assessed at baseline and trial completion		
Study details	Duration of intervention: 2 months		
	Duration of Follow-up: not reported		
	Run-in period: none		
Stated aim of	"To observe the clinical efficacy of qi-enriching, yin-nourishing, heat-clearing		
study	and blood-activating therapy in treating type 2 diabetes insulin resistance"		
Risk of bias			
Bias		Authors	Support for judgement
Random seque	Random sequence		It only mentioned in the trial that "patients
generation (sele	generation (selection bias)		were randomly divided into two groups"
Allocation concealment		Unclear risk	It only mentioned in the trial that "patients
(selection bias)	(selection bias)		were randomly divided into two groups"

Blinding of participants and	Unclear risk	The information was not reported in this study
personnel (performance		
bias)		
All outcomes		
Blinding of outcome	Unclear risk	The information was not reported in this study
assessment (detection bias)		
All outcomes		
Incomplete outcome data	Low risk	No exclusion or losses were reported, but the
(attrition bias)		number of participants remained the same at
All outcomes		the endpoint of study
Selection reporting	Unclear risk	The protocol of the trial was not available, so
(reporting bias)		the possibility of selection outcome reporting
		could not be examined by the review authors
Other bias	Unclear risk	The intervention groups were comparable, as
		it mentioned in the trial "no significant
		difference was found between groups on
		general background. Other aspects of bias
		were unclear

Li HM 2011

Effect of a prescription for tonifying kidney and spleen combination with conventional western medicine on blood sugar and hemorheology of patients with type 2 diabetes

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal
	medicine + other pharmaceuticals) compared with other pharmaceuticals
	alone
	Randomisation ratio: 3:4
Participants	Ethnic: Chinese n=160 (60 in control group, 80 in treatment group)
	Inclusion criteria: T2DM WHO 1999; TCM differentiation: spleen and kidney
	deficiency type
	Exclusion criteria: ≤18 y or ≥75y; critical medical history within 6 months:
	myocardial infarction, cerebrovascular accident, diabetes ketoacidosis;
	pregnancy or breastfeeding; diabetic ketoacidosis.

Interventions	Number of study centres: 1			
	Location: China			
	Setting: inpatients and outpatients in TCM hospital			
	Intervention:			
	Treated group added TCM decoction for tonifying kidney and spleen			
	(Bajitian, Yinyanghuo, Duzhong, Taizishen, Biandou, Shanyao, Heshouwu,			
	Mohanlian, D	Dangshen, Baizhu	ı, Fuling, Danshen, Shen Dahuang) on the	
	basis of conf	rol group		
	Control grou	p: diabetes conv	entional treatment (diet control, exercise	
	therapy, diab	etes education a	and mental adjustment plus no more than two	
	kinds of hype	oglycemic wester	n medicine: insulin inhibitor, alpha glucosidase	
	inhibitor, me	tformin and glime	piride etc.	
Outcomes	The total effective rate in treatment group was higher than that in control			
	group. The le	evels of FPG and	2hPG decreased after treatment in comparison	
	with those before treatment in two groups but was superior in treatment			
	group. Whole	e blood viscosity,	plasma viscosity, haematocrit and fibrinogen in	
	treatment group significantly decreased in comparison with those in control			
	group after treatment.			
	Blood, urine and stool routine examination have been measured before and			
	after treatment and no adverse effect has been observed. 7 cases in control			
	group used to have hypoglycemic symptom and it was relieved by having			
	food.			
	Outcomes were assessed at baseline and trial completion			
Study details	Duration of intervention: 2 months			
	Duration of Follow-up: not reported			
	Run-in period: none			
Stated aim of	"To observe the effect of a prescription for tonifying kidney and spleen			
study	combination with conventional western medicine on blood sugar and			
	hemorheology of type 2 diabetes patients with spleen and kidney deficiency			
	type"			
Risk of bias				
Bias		Authors	Support for judgement	
		judgement		

Random sequence	Unclear risk	It only mentioned in the trial that "patients
generation (selection bias)		were randomly divided into two groups"
Allocation concealment	Unclear risk	It only mentioned in the trial that "patients
(selection bias)		were randomly divided into two groups"
Blinding of participants and	Unclear risk	The information was not reported in this study
personnel (performance		
bias)		
All outcomes		
Blinding of outcome	Unclear risk	The information was not reported in this study
assessment (detection bias)		
All outcomes		
Incomplete outcome data	Low risk	No exclusion or losses were reported, but the
(attrition bias)		number of participants remained the same at
All outcomes		the endpoint of study
Selection reporting	Unclear risk	The protocol of the trial was not available, so
(reporting bias)		the possibility of selection outcome reporting
		could not be examined by the review authors
Other bias	Unclear risk	The intervention groups were comparable, as
		it mentioned in the trial "no significant
		difference was found between groups on
		general background. Other aspects of bias
		were unclear

Lin JJ 2014

Effect of Compound Hypoglycemic Yuye Oral Liquor combined with Metformin and glimepiride on Type 2 diabetes Mellitus

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=80
	Inclusion criteria: T2DM WHO 1999; T2DM blood sugar≥11.1mmol/L or
	FPG≥7.0mmol/L or 2hPG≥11.1mmol/L; TCM diagnostic criteria, China 2002. TCM

	differentiation: qi and yin deficiency; have never used blood sugar controlled
	medicine before, age:20-65 years old, informed consent, voluntary to examination
	and treatment
	Exclusion criteria: not cooperated and psychotic; pregnancy or breastfeeding;
	combine other severe primary diseases; have diabetes ketoacidosis and other
	acute metabolism disorder as well as combine with infections within one month;
	need insulin treatment; sensitive to treatment drug
Interventions	Number of study centres: 1
	Location: China
	Setting: outpatients in TCM hospital
	Intervention: both groups have diet control, exercise therapy, diabetes education
	and other lifestyle adjustment.
	Treatment group added TCM compound hypoglycemic Yuye oral liquor (Huangqi,
	Sheng Dihuang, Zhi Heshouwu, Huangjing, Taizishen, Zhimu, Yuzhu) on the basis
	of control group
	Control group: metformin hydrochloride tablets and glimepiride tablets
Outcomes	FPG, 2hPG, and HbA1C were decreased after treatment and the decrease was
	more notable in treatment group than that in control group with statistically
	significant; TCM syndrome score was lower and clinical efficiency was higher in
	treatment group compared to control group with statistically significant.
	One case had mild hypoglycemic symptom and two cases had mild nausea
	symptom in control group, one case had mild nausea in treatment group. The
	symptoms were disappeared after heteropathy. No difference observed between
	two groups about the adverse effect. Liver and kidney function examination were all
	normal. No severe adverse effect observed.
	Outcomes were assessed at baseline and trial completion
Study details	Duration of intervention: 12 weeks
	Duration of Follow-up: not reported
	Run-in period: none
Stated aim of	"To observe the clinical efficacy and safety of compound hypoglycemic Yuye oral
study	liquor combined with metformin hydrochloride and glimepiride in the treatment of
	type 2 diabetes mellitus (deficiency of both Qi and Yin)."
Risk of bias	

Bias	Authors	Support for judgement
	judgement	
Random sequence generation	Unclear risk	It only mentioned in the trial that "patients were
(selection bias)		randomly divided into treatment group and control
		group"
Allocation concealment	Unclear risk	It only mentioned in the trial that "patients were
(selection bias)		randomly divided into treatment group and control
		group"
Blinding of participants and	Unclear risk	The information was not reported in this study
personnel (performance bias)		
All outcomes		
Blinding of outcome	Unclear risk	The information was not reported in this study
assessment (detection bias)		
All outcomes		
Incomplete outcome data	Low risk	No exclusion or losses were reported, but the
(attrition bias)		number of participants remained the same at the
All outcomes		endpoint of study
Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)		possibility of selection outcome reporting could not
		be examined by the review authors
Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on general backgrounds.
		Other aspects of bias were unclear

Zhu LY 2015

Clinical Curative Effect of Self-made herbal Medicine Combined with Western Medicine on Diabetes

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal
	medicine + other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=70

	Inclusion criteria	a: T2DM internal	medicine 7 th edition 2007, FPG≥7.0mmol/L or
	2hPG≥11.1mm	ol/L; voluntary to	study and informed consent; take medicine
	according to pr	escription; TCM	diagnostic criteria 2002, TCM differentiation: yin
	deficiency with excess heat; can stick to take drug according to the prescription		
	Exclusion crite	ria: liver and kidr	ney dysfunction; pregnancy and breastfeeding;
	psychotic; seve	ere diabetes com	nplications; cannot cooperate; drop off due to no
	effect with the s		
Interventions Number of study centres: 1			
	Location: China		
	Setting: outpation	ents in TCM hos	pital
	Intervention: bo	oth groups have	lifestyle improvement, health education, proper
	exercise, quits	moking, limit alc	ohol and other non-drug therapy
	Integrated grou	ıp: self-made TC	M prescription (Shanyao, Sheng Shigao, Huangqi,
	Tianhuafen, Sh	eng Dihuang, Zh	nimu, Xuanshen, Maidong, Huainiuxi, Fuling, Zexie,
	Tusizi, Taizishen, Biazhu, Cangzhu, Tiandong, Chishao, Danshen, Shanzhizi) on		
	the basis of we	stern group	
	Western medicine group: oral intake metformin hydrochloride enteric coa		
	tablets and gliclazide tablets		
Outcomes	The combination group was significantly better than the control group in TCM		
	syndromes score. FPG, 2hPG, FINS, 2hINS levels in integrated group were		
	significantly lower than those in the western medicine group		
	The adverse reactions occurred lower in integrated group than that in the western		
	group.		
	Outcomes were assessed at baseline and trial completion		
Study details	Duration of intervention: 12 weeks		
	Duration of Follow-up: not reported		
	Run-in period: none		
Stated aim of	"To investigate the clinical efficacy of self-made prescription of traditional Chinese		
study	medicine combined with western medicine in the treatment of patients with		
	diabetes mellitus"		
Risk of bias			
Bias		Authors	Support for judgement

low risk	It mentioned in the trial that "patients were
	randomly divided into combination group and
	western medicine group by using random number
	table"
low risk	It mentioned in the trial that "patients were
	randomly divided into combination group and
	western medicine group by using random number
	table"
Unclear risk	The information was not reported in this study
Unclear risk	The information was not reported in this study
Low risk	No exclusion or losses were reported, but the
	number of participants remained the same at the
	endpoint of study
Unclear risk	The protocol of the trial was not available, so the
	possibility of selection outcome reporting could
	not be examined by the review authors
Unclear risk	The intervention groups were comparable, as it
	mentioned in the trial "no significant difference
	was found between groups on sex, age
	distribution, medical condition and other general
	backgrounds. Other aspects of bias were unclear
	low risk Unclear risk Low risk Unclear risk

Kong M 2009

Qi-invigorating, Yin-nourishing and Blood circulation activating prescription Improving Insulin Resistance in patients with Type 2 Diabetes Mellitus

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 1:1

Participants	Ethnic: Chinese n=70
	Inclusion criteria: T2DM WHO 1999; Homa-IR≥2.8 with insulin resistance; TCM
	diagnostic criteria 1993: qi and yin deficiency, qi and blood stagnation; informed
	consent; run-in period with lifestyle therapy and stop other medicine for one month
	with stable blood sugar but above normal
	Exclusion criteria: have diabetes ketosis, ketoacidosis and infections, pregnancy
	diabetes, hyperthyroidism or hepatitis and other diseases which can lead to
	hyperglycemia within 1 month; psychotic and senile dementia cannot cooperate;
	severe heart, brain, liver, kidney complications or severe primary complications;
	pregnancy or breastfeeding; long-term or current use insulin
Interventions	Number of study centres: 1
	Location: China
	Setting: outpatients and inpatients in TCM hospital
	Intervention:
	Treatment group: TCM prescription of qi-invigorating, yin-nourishing and blood
	circulation-activating (Huangqin, Sangbaipi, Sangye, Sangzhi, Sheng Dihuang,
	Shanyao, Danggui, Chishao) on the basis of control group
	Control group: basic treatment: diet control, exercise therapy, health education and
	oral intake one of hypoglycemic drug: metformin, glipizide or diamicron
Outcomes	FPG, 2hPG, FINS, HbA1c, Homa-IR, blood fat and blood coagulation (PT, Fib,
	APTT, TC, TG) were all significantly improved and the improvement degree of
	treatment group was better than that of control group. The hypoglycemic and
	therapeutic effects on TCM syndrome in treatment group were superior to those in
	control group.
	No information was reported in terms to adverse effect in this study
	Outcomes were assessed at baseline and trial completion
Study details	Duration of intervention: 3 months
	Duration of Follow-up: not reported
	Run-in period: one month
Stated aim of	"To explore the mechanism of recipe of qi-invigorating, yin-nourishing and blood
study	circulation-activating in the improvement of insulin resistance in patients with type 2
	diabetes mellitus"
Risk of bias	

Bias	Authors	Support for judgement
	judgement	
Random sequence generation	Unclear risk	It only mentioned in the trial that "patients were
(selection bias)		randomly divided into treatment group and control
		group"
Allocation concealment	Unclear risk	It only mentioned in the trial that "patients were
(selection bias)		randomly divided into treatment group and control
		group"
Blinding of participants and	Unclear risk	The information was not reported in this study
personnel (performance bias)		
All outcomes		
Blinding of outcome	Unclear risk	The information was not reported in this study
assessment (detection bias)		
All outcomes		
Incomplete outcome data	Low risk	No exclusion or losses were reported, but the
(attrition bias)		number of participants remained the same at the
All outcomes		endpoint of study
Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)		possibility of selection outcome reporting could not
		be examined by the review authors
Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on sex, age, medical
		condition and disease course. Other aspects of
	_	bias were unclear

Yu ZM 2015

Therapeutic Effect of Xiaoke Jiangtang Fang Combined with Pioglitazone Hydrochloride and Metformin Hydrochloride tablets on Patients with type 2 Diabetes

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 1:1

Participants	Ethnic: Chinese n=96
	Inclusion criteria: T2DM WHO 1999; TCM diagnostic criteria: yin and yang
	deficiency, blood stasis with fluid stagnation; HbA1c 7%-11%; have never used other
	medicine before the study
	Exclusion criteria: type 1 diabetes; comply with cardiovascular, cerebrovascular and
	nervous system disease; severe heart dysfunction, liver and kidney primary disease;
	have medical history of surgery and severe trauma; psychotic
Interventions	Number of study centres: 1
	Location: China
	Setting: inpatients and outpatients in hospital
	Intervention: both groups have diet control and oral intake of pioglitazone
	hydrochloride and metformin hydrochloride tablets
	Observation group: TCM prescription Xiaoke Jiangtang Fang (Tianhuafen, Zhimu,
	Huanglian, Shichangpu, Shihu, Chuanxiong, Guijianyu; add Ouzhi, Maidong,
	Tiandong, Dihuang, Gegen for Lung heat; add Huangqin, Zhizi, Xuanshen, Maidong,
	Sheng Dihuang, Huainiuxi for stomach heat; add Huangqi, Fuling, Baizhu,
	Huaishanyao, Dangshen, Ganchao for Qi and Yin deficiency; add Shanyurou,
	Gouqizi, Shu Dihuang, Huaishanyao for liver kidney Yin deficiency) plus pioglitazone
	hydrochloride and metformin hydrochloride tablets
Outcomes	The effective rate of observation group was significantly higher than control group.
	BMI, FBG, 2hPG, HbA1c, TG, high/midst/low shear rate of blood viscosity, plasma
	viscosity, fibrinogen in two groups were significant decreased after treatment, and
	the decrease in observation group were significant lower than those of control group
	were. The score of TCM symptom in observation group was also significant lower
	than that of control group after treatment.
	No information was reported in terms to adverse effect in this study
	Outcomes were assessed at baseline and trial completion
Study details	Duration of intervention: 3 months
	Duration of Follow-up: not reported
	Run-in period: none
Stated aim of	"To evaluate the therapeutic effect of Xiaoke Jiangtang Fang combined with
study	pioglitazone hydrochloride and metformin hydrochloride tablets on patients with type
	2 diabetes"

Risk of bias			
Bias	Authors	Support for judgement	
	judgement		
Random sequence generation	low risk	It mentioned in the trial that "patients were randomly	
(selection bias)		divided into observation group and control group by	
		using random number table"	
Allocation concealment	low risk	It mentioned in the trial that "patients were randomly	
(selection bias)		divided into observation group and control group by	
		using random number table"	
Blinding of participants and	Unclear risk	The information was not reported in this study	
personnel (performance bias)			
All outcomes			
Blinding of outcome	Unclear risk	The information was not reported in this study	
assessment (detection bias)			
All outcomes			
Incomplete outcome data	Low risk	No exclusion or losses were reported, but the	
(attrition bias)		number of participants remained the same at the	
All outcomes		endpoint of study	
Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so the	
bias)		possibility of selection outcome reporting could not	
		be examined by the review authors	
Other bias	Unclear risk	The intervention groups were comparable, as it	
		mentioned in the trial "no significant difference was	
		found between groups on sex, age, disease course	
		and medical history of hypertension. Other aspects	
		of bias were unclear	

Zheng HX 2014

An observation of the clinical effect of Taohong Siwu decoction in the treatment of T2DM $\,$

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 1:1

Participants	Ethnic: Chinese n=54
	Inclusion criteria: T2DM ADA; age>18 years old; first diagnosis of diabetes; no other
	vital organs damage; no recent acute diabetes complications; patients are agree with
	treatment and can stick with long-term treatment, also with informed consent
	Exclusion criteria: type 1 diabetes; have diabetes ketoacidosis or hyperglycemia
	hypertonicity syndrome and other acute complications; combine with acute
	cardiovascular and cerebrovascular disease; combine tumour, infection, active
	infection, immune system disease, hemopoietic system disease; T2DM with severe
	heart, liver and kidney dysfunction; pregnancy or breastfeeding; allegory or intolerant
	to all drugs; combine clinical proteinuria, dominance proteinuria or persistent
	proteinuria; psychotic cannot cooperate; age<18 years; medical history not
	completed
Interventions	Number of study centres: 1
	Location: China
	Setting: outpatients in hospital
	Intervention: both two groups have diabetes dietary therapy and oral intake
	metformin hydrochloride sustained-release tablets
	Observation group: TCM prescription Taohong Siwu decoction modified (Zhimu,
	Huangqi, Shanyao, Shu Dihuang,Rougui, Duzhong for Ying and Yang Deficiency;
	Xiyangshen, Huangqi, Gegen, Shu Dihuang, Maidong for Qi and Yin deficiency;
	Shanyao, Niuxi, Sheng Dihuang, Gouqi, Fuling for Liver and Kidney Yin deficiency;
	Sheng Dihuang, Huangbai, Baizhu, Zhimu, Huanglian, Danggui, Maidong for Yin
	deficiency with heat; Yiyiren, Xingren, Baikouren, Huanglian, Banxia, Tongcao for
	Damp-heat) plus metformin hydrochloride sustained-release tablets
Outcomes	FBG, 2hPG and HbA1c significantly decreased after treatment in both two groups.
	The decrease of 2hPG in observation group was significantly lower than the control
	group. The occurrence of clinical symptoms in observation group was significantly
	lower than the control group
	No information was reported in terms to adverse effect in this study
	Outcomes were assessed at baseline and trial completion
Study details	Duration of intervention: 3 months
	Duration of Follow-up: not reported
	Run-in period: none

Stated aim of	"To explore and observe the clinical curative of Taohong Siwu decoction using by		
study	TCM in the treatment of type 2 diabetes mellitus on the basis of taking metformin		
	hydrochloride sustained-release tablets "		
Risk of bias			
Bias		Authors	Support for judgement
		judgement	
Random sequer	nce generation	Unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into observation group and control
			group"
Allocation conce	alment	Unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into observation group and control
			group"
Blinding of partic	ipants and	Unclear risk	The information was not reported in this study
personnel (perfo	rmance bias)		
All outcomes			
Blinding of outco	me	Unclear risk	The information was not reported in this study
assessment (de	tection bias)		
All outcomes			
Incomplete outco	ome data	Low risk	No exclusion or losses were reported, but the
(attrition bias)			number of participants remained the same at the
All outcomes			endpoint of study
Selection reporti	Selection reporting (reporting		The protocol of the trial was not available, so the
bias)	bias)		possibility of selection outcome reporting could not
			be examined by the review authors
Other bias	Other bias		The intervention groups were comparable, as it
			mentioned in the trial "no significant difference was
			found between groups on age, FBG, 2hPBG,
			HbA1C. Other aspects of bias were unclear

Liu YH 2008

Clinical research on effect of YiqiYangyinHuoxue (supplementing Qi, nourishing Yin and activating Blood circulation decoction) in improving insulin resistance in patients with type 2 diabetes

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=110
	Inclusion criteria: T2DM WHO 1999; insulin resistance HOMA-IR criteria; TCM
	diagnosis criteria China 2006, TCM differentiation: qi and yin deficiency, qi and blood
	stagnation
	Exclusion criteria: have diabetes ketosis, ketoacidosis and infections, pregnancy
	diabetes, hyperthyroidism or hepatitis and other diseases which can lead to
	hyperglycemia within 1 month; psychotic and senile dementia cannot cooperate;
	severe heart, brain, liver, kidney complications or severe primary complications;
	pregnancy or breastfeeding; long-term or current use insulin
Interventions	Number of study centres: 1
	Location: China
	Setting: outpatients and inpatients in TCM hospital
	Intervention: basic treatment: diet control and exercise therapy and oral intake of
	hypoglycemic western medicine: metformin, sulfonylurea , acarbose or glipizide
	Observation group: TCM prescription of supplement qi, nourish yin and active blood
	circulation (Huangqi, Danggui, Shanyao, Sangbaipi, Snagye, Sangzhi, Chishao,
	Dilong) on the base of basic treatment
	Control group: basic treatment
Outcomes	FBG, 2hBG, FINS, HOMA-IR, blood fat and blood coagulation (PT, APTT, Fib, TC,
	TG) of treatment group was distinctly improved compared with that of control group
	No information was reported in terms to adverse effect in this study
	Outcomes were assessed at baseline and trial completion
Study details	Duration of intervention: 3 months
	Duration of Follow-up: not reported
	Run-in period: stop other TCM medicine over 2 weeks
Stated aim of	"To study the therapeutic effect of integrated use of Chinese and Western medicine
study	on the improvement of insulin resistance in patients with both deficiency of vital
	energy and yin and blood stasis in patients of type 2 diabetes"
Risk of bias	

Bias	Authors	Support for judgement
	judgement	
Random sequence generation	Unclear risk	It only mentioned in the trial that "patients were
(selection bias)		randomly divided into two groups"
Allocation concealment	Unclear risk	It only mentioned in the trial that "patients were
(selection bias)		randomly divided into two groups"
Blinding of participants and	Unclear risk	The information was not reported in this study
personnel (performance bias)		
All outcomes		
Blinding of outcome	Unclear risk	The information was not reported in this study
assessment (detection bias)		
All outcomes		
Incomplete outcome data	Low risk	No exclusion or losses were reported, but the
(attrition bias)		number of participants remained the same at the
All outcomes		endpoint of study
Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)		possibility of selection outcome reporting could not
		be examined by the review authors
Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on sex, age, disease course,
		medical condition. Other aspects of bias were
		unclear

Deng HL 2012

Clinical observation of Tangwei capsule combined with Metformin in treatment of patients with Type 2 Diabetes Mellitus

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine		
	+ other pharmaceuticals) compared with other pharmaceuticals alone		
	Randomisation ratio: 5:6		
Participants	Ethnic: Chinese n=110 (50 in control group, 60 in treatment group)		
	Inclusion criteria: T2DM WHO 1999; TCM diagnosis criteria China 1993		

	Exclusion criteria: severe kidney dysfunction, diabetes combine with ketoacidosis,		
	insulin resistar	nce patients and	pregnancy or breastfeeding
Interventions	Number of study centres: 1		
	Location: China		
	Setting: outpatients in TCM hospital		
	Intervention: both two groups have diet control and diabetes education and other		
	secondary trea	atment	
	Control group:	metformin hydro	ochloride tablets orally intake
	Observation g	roup: TCM preso	cription Tangwei capsule (Huangqi, Xiyangshen,
	Huangjing, Tia	nhuafen, Geger	, Huanglian, Danshen) on the basis of control group
Outcomes	The total effect	ctive rate in treat	ment group was higher than that in control group.
	FPG, 2hPG, H	bA1c,TG, BMI, h	nemorheology index: whole blood viscosity, plasma
	viscosity, plate	elet adhesion rate	e and LDL-C were all more significantly decreased
	after treatment	and the treatme	ent group has better clinical effect compared to control
	group		
	3 cases have i	nausea in treatm	ent group, 4 cases have stomach discomfort and all
	relieve without intervention. No kidney function damage after the treatment have		
	been observed in both groups		
	Outcomes were assessed at baseline and trial completion		
Study details	Duration of intervention: 3 months		
	Duration of Follow-up: not reported		
	Run-in period:	not described	
Stated aim of	"To observe th	ne clinical effect o	of Tangwei capsule combined with metformin in
study	treatment of patients with type 2 diabetes mellitus "		
Risk of bias			
Bias		Authors	Support for judgement
		judgement	
Random sequer	nce generation	Unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into two groups"
Allocation conce	ealment	Unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into two groups"
Blinding of partic	Blinding of participants and		The information was not reported in this study
personnel (perfo	ormance bias)		

All outcomes		
Blinding of outcome	Unclear risk	The information was not reported in this study
assessment (detection bias)		
All outcomes		
Incomplete outcome data	Low risk	No exclusion or losses were reported, but the
(attrition bias)		number of participants remained the same at the
All outcomes		endpoint of study
Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)		possibility of selection outcome reporting could not
		be examined by the review authors
Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on general backgrounds.
		Other aspects of bias were unclear

Zhang YL 2012

Pei Ruixia's Modified Er Dong Tang Combined with Western Medicine Therapy to treat Type 2 Diabetes of Lung and Kidney Qi Yin Deficiency Randomized Controlled Study

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=80
	Inclusion criteria: T2DM WHO 1999; DM clinical symptoms + random blood
	sugar≥11.1mmol/L or FPG≥7.0mmol/L or OGTT 2hPG≥11.1mmol/L; age:30-70
	years old; informed and signed consent
	Exclusion criteria: age<30 years or > 70 years old; cannot take medicine according
	to prescription and hard to judge treatment effect; allergic constitution or allergy to
	ingredients of study drugs; no enough data to support the rapeutic effects and safety;
	use others drug which influence the treatment
Interventions	Number of study centres: 1
	Location: China
	Setting: inpatients in TCM hospital

	Intervention: both groups have conventional therapy: diabetic die, exercise and			
	lifestyle, blood	pressure, blood	d glucose, expansion of the crown etc.	
	Control group: pioglitazone capsule, metformin enteric coated tablets			
	Observation group: TCM prescription modified Er Dong Tang (Tiandong, Maidong,			
	Tianhuafen, Huangqin, Zhimu, Gancao, Beishashen, Heye) on the basis of control			
	group			
Outcomes	Treatment gro	oup is more effe	ctive than the control group in clinical effects. FPG,	
	2hPG and HbA	A1c were signific	cantly lower but no significant difference between two	
	groups			
	No information	was reported in	n terms to adverse effect in this study	
	Outcomes we	re assessed at l	paseline and trial completion	
Study details	Duration of inte	ervention: 3 mor	nths	
	Duration of Fo	llow-up: notrep	orted	
	Run-in period: not described			
Stated aim of	"Observe the	efficacy of Pei Ri	uixia's Modified Er Dong Tang combined with western	
study	medicine therapy to treat lung and kidney qi yin deficiency pattern type 2 diabetes"			
Risk of bias				
Bias		Authors	Support for judgement	
		judgement		
Random sequer	nce generation	low risk	It mentioned in the trial that "randomized parallel	
(selection bias)			controlled is used and patients were randomly	
			divided into two groups by random number table"	
Allocation conce	alment	low risk	It mentioned in the trial that "randomized parallel	
(selection bias)			controlled is used and patients were randomly	
			divided into two groups by random number table"	
Blinding of participants and		Unclear risk	The information was not reported in this study	
personnel (performance bias)				
All outcomes				
Blinding of outcome		Unclear risk	The information was not reported in this study	
assessment (detection bias)				
All outcomes				

Incomplete outcome data	Low risk	No exclusion or losses were reported, but the
(attrition bias)		number of participants remained the same at the
All outcomes		endpoint of study
Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)		possibility of selection outcome reporting could not
		be examined by the review authors
Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on demography data and
		clinical features (sex, age, and disease course).
		Other aspects of bias were unclear

Lu PY 2013

Clinical Research of combined Traditional Chinese and Western Medicine in the Treatment of Type 2 Diabetes

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=128
	Inclusion criteria: T2DM, age:31-77 years old; others not described
	Exclusion criteria: not described
Interventions	Number of study centres: 1
	Location: China
	Setting: inpatients in hospital
	Intervention:
	control group: oral intake metformin and glipizide
	Observation group: TCM hypoglycemic 1 (no mention of detailed herbs) based on
	control group
Outcomes	FPG, 2hPG, and HbA1c all significantly decreased after treatment and much lower
	in treatment group. hospitalization days and cost are also lower in treatment group

	4 cases in cor	cases in experimental group had hypoglycemic	
	symptom in the early stage of treatment and it had disappeared after had some food.		
	No information reported about liver and kidney function.		
	Outcomes were assessed at baseline and trial completion		
Study details	Duration of inte	ervention: 12 we	eks
	Duration of Fo	llow-up: not rep	orted
	Run-in period:	notdescribed	
Stated aim of	"To explore the	e clinical curative	e effect of combined traditional Chinese and western
study	medicine in the	e treatment of ty	pe 2 diabetes"
Risk of bias			
Bias		Authors	Support for judgement
		judgement	
Random sequer	nce generation	low risk	It mentioned in the trial that "patients were randomly
(selection bias)			divided into control group and experimental group by
			using random number table method"
Allocation conce	ealment	low risk	It mentioned in the trial that "patients were randomly
(selection bias)			divided into control group and experimental group by
			using random number table method"
Blinding of partic	cipants and	Unclear risk	The information was not reported in this study
personnel (perfo	rmance bias)		
All outcomes			
Blinding of outcome		Unclear risk	The information was not reported in this study
assessment (detection bias)			
All outcomes			
Incomplete outcome data		Low risk	No exclusion or losses were reported, but the
(attrition bias)			number of participants remained the same at the
All outcomes			endpoint of study
Selection reporting (reporting		Unclear risk	The protocol of the trial was not available, so the
bias)			possibility of selection outcome reporting could not
			be examined by the review authors
Other bias		Unclear risk	The intervention groups were comparable, as it
			mentioned in the trial "no significant difference was
		I	

	found between groups on general backgrounds.
	Other aspects of bias were unclear

Xie PF 2009

The clinical research on treatment of type 2 diabetes mellitus by western medicine combining with traditional Chinese medicine

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=60
	Inclusion criteria: T2DM WHO 1999; therapeutic effects are not ideal with western
	medicine of sulfonylurea, metformin or alpha glucosidase inhibitor; TCM
	differentiation: qi and yin deficiency with abundance heat
	Exclusion criteria: combined with severe acute diabetes complication
Interventions	Number of study centres: 1
	Location: China
	Setting: outpatients or inpatients in TCM hospital
	Intervention:
	Treatment group: TCM prescription Jinqijiangtangpian (Huangqi, Huanglian,
	Jinyinhua) on the basis of control group
	Control group: dietary and exercise therapy + western medicine: sulfonylurea,
	metformin or alpha glucosidase inhibitor
Outcomes	FBG, 2hPBG, HbA1C, TC and TG in treatment group were significantly lower than
	that in the control group. No difference found in fasting insulin, C peptide. 2h
	postprandial insulin and C peptide rose. HOM A-β rose, HOMA-R declined.
	Liver, kidney function, blood and urine routine examination were measured for
	adverse effect. No abnormal was observed from above test
	Outcomes were assessed at baseline and trial completion
Study details	Duration of intervention: 12 weeks
	Duration of Follow-up: not reported
	Run-in period: not described

Stated aim of	"To investigate the effect of western medicine combining with traditional Chinese		
study	medicine on patients with T2DM and function of islet β cell"		
Risk of bias	<u> </u>		
Bias		Authors	Support for judgement
		judgement	
Random sequer	nce generation	unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into two groups"
Allocation conce	ealment	unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into two groups"
Blinding of partic	cipants and	Unclear risk	The information was not reported in this study
personnel (perfo	ormance bias)		
All outcomes			
Blinding of outcome		Unclear risk	The information was not reported in this study
assessment (detection bias)			
All outcomes			
Incomplete outcome data		Low risk	No exclusion or losses were reported, but the
(attrition bias)	(attrition bias)		number of participants remained the same at the
All outcomes	All outcomes		endpoint of study
Selection report	ing (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)			possibility of selection outcome reporting could not
			be examined by the review authors
Other bias	Other bias		The intervention groups were comparable, as it
			mentioned in the trial "no significant difference was
			found between groups on disease course, age, sex,
			blood sugar, HbA1C and insulin. Other aspects of
			bias were unclear

Gao ZT 2015 Clinical Efficacy of Yupujiangtang Decoction in treatment of 50 Patients with T2DM

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 2:3

Participants	Ethnic: Chines	e n=50 (20 in co	ontrol group, 30 in treatment group)
	Inclusion criter	ia: T2DM WHO	1999: DM clinical symptoms plus random blood sugar
	≥11.1mmol/L o	or FPG≥7.0mmo	ol/L or OGTT2hPG≥11.1mmol/L; TCM differentiation
	China 2002 : q	i and yin deficie	ncy; 31-72 years old; informed and signed consent
	Exclusion crite	ria: type 1 diabe	etes; diabetes with severe heart, brain, kidney and
	retinal diseases; tumour and cancer patients; pregnant and breastfeeding diabetes		
	allergy to the s	tudy drugs.	
Interventions	Number of stu	dy centres: 1	
	Location: Chin	a	
	Setting: outpat	ients or inpatien	ts in TCM hospital
	Intervention: o	diet control and r	ational exercise
	Treatment gro	up: TCM prescri	ption Yupujiangtang decoction (Renshen, Huangqi,
	Huanglian, Qu	mai, Gualougen	, Shanyao, Fangji, Fuling, Gouqizi, Zexie, Cijili, Yuzhu,
	Wubeizi, Nvzh	enzi, Yvmixv) o	n the basis of control group
	Control group: Novolin 50 R Penfill injection and take metformin tablets		
Outcomes	Blood glucose level (FPG, OGTT2h, GHbA1c) had significant difference and the		
	total effective rate of TCM syndrome was 95%		
	No detail information was reported in terms to adverse effect in this study		
	Outcomes were assessed at baseline and trial completion		
Study details	Duration of intervention: 8 weeks		
	Duration of Follow-up: not reported		orted
	Run-in period: not described		
Stated aim of	"To observe th	ne clinical efficac	y and safety of Yupujiangtang decoction in treatment
study	of patients with type 2 diabetes mellitus"		
Risk of bias	l		
Bias		Authors	Support for judgement
		judgement	
Random sequer	Random sequence generation		It mentioned in the trial that "patients were divided
(selection bias)			into treatment group and control group by random
			number method"
Allocation conce	ealment	low risk	It mentioned in the trial that "patients were divided
(selection bias)			into two treatment group and control group by
			random number method"
		1	

Blinding of participants and	Unclear risk	The information was not reported in this study
personnel (performance bias)		
All outcomes		
Blinding of outcome	Unclear risk	The information was not reported in this study
assessment (detection bias)		
All outcomes		
Incomplete outcome data	Low risk	No exclusion or losses were reported, but the
(attrition bias)		number of participants remained the same at the
All outcomes		endpoint of study
Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)		possibility of selection outcome reporting could not
		be examined by the review authors
Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on general backgrouds.
		Other aspects of bias were unclear

Shu Q 2013 Dan Melon Decoction in Treating phlegm and Blood Stasis Type of Type 2 Diabetes: clinical Analysis of 50 Cases

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=100
	Inclusion criteria: T2DM ,TCM differentiation: phlegm stagnation; age:43-75 y,
	disease course 1-17 year
	Exclusion criteria: not described
Interventions	Number of study centres: 1
	Location: China
	Setting: patients in hospital
	Intervention:

	Observation group: TCM prescription Dan melon decoction (Danshen, Gualou,		
	Xiebai, Chuan	xiong, Danggui,	Chishao, Banxia) on the basis of control group
	Control group: conventional treatment of western medicine: metformin sustained -		
	release tablets and /or rosiglitazone with insulin		
Outcomes	FBG, 2hPG, H	HbA1C, TC, TG,	LDL-C and HDL-C decreased in observation group
	compared with	the control grou	up with significant difference.
	No information	was reported in	n terms to adverse effect in this study
	Outcomes we	re assessed at b	paseline and trial completion
Study details	Duration of inte	ervention: 90 da	ys
	Duration of Fo	llow-up: not rep	orted
	Run-in period:	not described	
Stated aim of	"Effect of Chine	ese medicine in	the treatment of type 2 and application value"
study			
Risk of bias			
Bias		Authors	Support for judgement
		judgement	
Random sequer	nce generation	low risk	It mentioned in the trial that "patients were divided
(selection bias)			into observation group and control group by random
			number method"
Allocation concealment		low risk	It mentioned in the trial that "patients were divided
(selection bias)			into two observation group and control group by
			random number method"
Blinding of partic	cipants and	Unclear risk	The information was not reported in this study
personnel (performance bias)			
All outcomes			
Blinding of outcome		Unclear risk	The information was not reported in this study
assessment (detection bias)			
All outcomes			
Incomplete outcome data		Low risk	No exclusion or losses were reported, but the
(attrition bias)			number of participants remained the same at the
All outcomes			endpoint of study

Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)		possibility of selection outcome reporting could not
		be examined by the review authors
Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on general backgrounds.
		Other aspects of bias were unclear

Sun H 2013

Modified Lianmei Granule Treatment for Type 2 Diabetes with Obesity in Early Satage

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=60
	Inclusion criteria: T2DM China 1994 and combine with obesity:BMI≥25kg/m²; TCM
	differentiation: qi and yin deficiency , phlegm and turbid stagnation; cases which are
	not in exclusion criteria
	Exclusion criteria: not meet above diagnostic criteria; age:<18y, >65y; pregnancy or
	breastfeeding; TCM herb and metformin, ARB allergy; have severe heart, liver,
	kidney complications or combine other severe primary diseases, psychosis; have
	diabetes ketoacidosis, hypertonicity coma and combine with infections within one
	month; type 1 diabetes
Interventions	Number of study centres: 1
	Location: China
	Setting: outpatients and inpatients in TCM hospital
	Intervention:
	treatment group: TCM prescription modified Lianmei granule (Huanglian, Renshen,
	Wumei, Dahuang, Maidong, Sheng Dihuang, Shanzhuyu, Danshen, Cangzhu) on the
	basis of control group
	control group: diet control and exercise therapy + oral intake western medicine:
	raigor column nai

Outcomes	The improvement of the clinical symptoms and weight loss in treatment groups for		
	obese patients	s with type 2 diab	petes with high blood sugar, high cholesterol are better
	than that in control group.		
	No detail information was reported in terms to adverse effect in this study		
	Outcomes wer	re assessed at b	aseline and trial completion
Study details	Duration of inte	ervention: 12 we	eks
	Duration of Fo	llow-up: not rep	orted
	Run-in period:	notdescribed	
Stated aim of	"To observe m	nodified Lianmei	granule the clinical curative effect of early treatment of
study	obesity with ty	pe 2 diabetes"	
Risk of bias			
Bias		Authors	Support for judgement
		judgement	
Random sequer	nce generation	unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into two groups"
Allocation conce	alment	unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into two groups"
Blinding of partic	Blinding of participants and		The information was not reported in this study
personnel (performance bias)			
All outcomes			
Blinding of outcome		Unclear risk	The information was not reported in this study
assessment (detection bias)			
All outcomes			
Incomplete outcomplete	ome data	Low risk	No exclusion or losses were reported, but the
(attrition bias)			number of participants remained the same at the
All outcomes			endpoint of study
Selection reporting (reporting		Unclear risk	The protocol of the trial was not available, so the
bias)			possibility of selection outcome reporting could not
			be examined by the review authors
Other bias		Unclear risk	The intervention groups were comparable, as it
			mentioned in the trial "no significant difference was
			found between groups on general backgrounds.
			Other aspects of bias were unclear

Gao SQ 2015

Clinical Application Study of Yiqi yangyin huoxue Method in Type 2 Diabetes

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine			
METHORS	, the state of the			
	+ other pharmaceuticals) compared with other pharmaceuticals alone			
	Randomisation ratio: 1:1			
Participants	Ethnic: Chinese n=100			
	Inclusion criteria: T2DM WHO, FBG≥7mmol/L, 2hPG≥11.1mmol/L, diagnosis as type			
	2 diabetes by laboratory test. TCM diagnostic criteria China 1992, TCM differentiation			
	: qi and yin deficiency , blood stasis			
	Exclusion criteria: diabetes ketoacidosis and severe infection, hyper thyroidism or			
	hepatitis or other diseases which can cause hyperglycemia; have severe			
	complications with heart, brain, liver, kidney and so on; pregnancy and breastfeeding			
Interventions	Number of study centres: 1			
	Location: China			
	Setting: inpatients in TCM hospital			
	Intervention:			
	experimental group: yiqi yangyi huoxue herbal treatment programs (Huangqi,			
	Taizishen, Danshen, Mudanpi, Suoyanghua, Shanyao, Sheng Dihuang, Wuweizi,			
	Hesouwu, Huangjing, Dahuang) on the basis of control group			
	control group: extension of diabetic knowledge, dietary and exercise therapy auxiliary			
	metformin			
Outcomes	Both groups have FBG, 2hPG and GHbA1c under control. The experimental group			
	had significant statistical difference in the changed improve the efficacy of TCM			
	symptoms compare to control group			
	No information was reported in terms to adverse effect in this study			
	Outcomes were assessed at baseline and trial completion			
Study details	Duration of intervention: 4 months			
	Duration of Follow-up: not reported			
	Run-in period: not described			
Stated aim of	"To explore the effects of Yiqi yangyi huoxue method of type 2 diabetes, summarize			
study	new clinical thinking"			

Risk of bias		
Bias	Authors	Support for judgement
	judgement	
Random sequence generation	unclear risk	It only mentioned in the trial that "patients were
(selection bias)		randomly divided into experimental group and control
		group"
Allocation concealment	unclear risk	It only mentioned in the trial that "patients were
(selection bias)		randomly divided into experimental group and control
		group"
Blinding of participants and	Unclear risk	The information was not reported in this study
personnel (performance bias)		
All outcomes		
Blinding of outcome	Unclear risk	The information was not reported in this study
assessment (detection bias)		
All outcomes		
Incomplete outcome data	Low risk	No exclusion or losses were reported, but the
(attrition bias)		number of participants remained the same at the
All outcomes		endpoint of study
Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)		possibility of selection outcome reporting could not
		be examined by the review authors
Other bias	Unclear risk	No clear information mentioned in the trial "no
		significant difference was found between groups on
		general backgrounds. Other aspects of bias were
		unclear

Jia QL 2014

Clinical observation of 45 cases of Qingreyiqi decoction compatibility in the treatment of type 2 diabetes

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 1:1

Participants	Ethnic: Chinese n=90		
	Inclusion criteria: T2DM WHO, voluntary to the study and signed consent form, first		
	diagnosed with	n type 2 diabetes,	Age: 53-67 years
	Exclusion crite	ria: not described	
Interventions	Number of study centres: 1		
	Location: China		
	Setting: inpati	ents in TCM hosp	ital
	Intervention:		
	Observation g	roup: oral Qingrey	iqi decoction Sheng Dahuang, Sheng Huangqi,
	Shanyao, Geg	en, Danshen, She	eng Dihuang, Sheng Huangqi, Gouqizi, Chishao,
	Danggui, Zhim	u, Chuanxiong, Ti	anma) on the basis of control group
	Control group:	conventional trea	tment: health education, dietary and exercise therapy
	and conventio	nal oral hypoglyce	emic agents like metformin etc.
Outcomes	Total effective	rate of observatio	n group was apparently higher than the control
	group. The fas	ting blood glucos	e (FBG), 2 hours postprandial blood glucose
	(2hPG), glycosylated haemoglobin (GHbA1c), and blood lipid index (TG, TC, LDL-		
	C0 of two group were obviously decreased, but the observation group decreased		
	more significantly.		
	Blood routine examination, liver and kidney function were supervised to measure		
	adverse effect of drug. No abnormal observed in blood routine examination, liver and		
	kidney function. One case had nausea and vomiting.		
	Outcomes were assessed at baseline and trial completion		
Study details	Duration of intervention: 12 weeks		
	Duration of Fo	llow-up: not repo	rted
	Run-in period: not described		
Stated aim of	"To discuss the efficacy and safety of the Qingreyiqi decoction compatibility in the		
study	treatment of type 2 diabetes"		
Risk of bias			
Bias		Authors	Support for judgement
		judgement	
Random sequer	nce generation	low risk	It mentioned in the trial that "patients were divided
(selection bias)			into observation group and control group by
			random file number method"

Allocation concealment	low risk	It mentioned in the trial that "patients were divided
(selection bias)		into observation group and control group by
		random file number method"
Blinding of participants and	Unclear risk	The information was not reported in this study
personnel (performance bias)		
All outcomes		
Blinding of outcome	Unclear risk	The information was not reported in this study
assessment (detection bias)		
All outcomes		
Incomplete outcome data	Low risk	No exclusion or losses were reported, but the
(attrition bias)		number of participants remained the same at the
All outcomes		endpoint of study
Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)		possibility of selection outcome reporting could not
		be examined by the review authors
Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on sex, age, disease
		course, FBG and blood lipid. Other aspects of bias
		were unclear

Zhang XL 2013

Clinical Observation of traditional Chinese Medicine Combing with Insulin on Treating 38 Cases of Asymptomatic Type 2 Diabetes

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=74
	Inclusion criteria: T2DM China 2012, asymptomatic type 2 diabetes, agree with
	insulin treatment; age: 28-76y, average age 54.3 y; average FBG=13.4mmol/L
	(treatment group), 13.1mmol/L (control group), average blood sugar after three
	meals=18.4mmol/L (treatment group), 17.9mmol/L (control group)

	Exclusion criteria: not described				
Interventions	Number of stud	dy centres: 1			
	Location: China				
	Setting: inpatients in TCM hospital				
	Intervention:				
	treatment group: TCM prescription Erzhi Siwu decoction (Nvzhenzi, Hanliancao,				
	Sheng Dihuan	g, Chishao, Chu	angxiong, Danggui, Huanglian, Gegen, Huangqi,		
	Tianhuafen an	d add Shigao, X	uanshen, Dahuang, Zhimu, Shanzhuyu,		
	Sangpiaoxiao,	, Xianlingpi, Fulir	ng, Baizhu, Dangshen, Cangzhu based on syndrome		
	differentiation)	on the basis of	control group		
	control group:	conventional dia	abetes health education, diabetes diet and insulin		
	therapy				
Outcomes	Fasting blood	glucose was co	ntrolled within 3.9-7mmol/L and postprandial blood		
	glucose 2 hours was less 10mmol/L, observing the difference of the amount of				
	insulin and inc	insulin and incidence of hypoglycemia between two groups. The incidence of			
	hypoglycemia	of the treatment group was lower than the controlled group.			
No detail infor		nation was reported in terms to adverse effect in this study			
	Outcomes were assessed at baseline and trial completion				
Study details	Duration of inte	ervention: 3 mor	nths		
	Duration of Follow-up: no		orted		
	Run-in period: not described				
Stated aim of	"To observe th	ne curative effect	of combining traditional Chinese medicine and insulin		
study	to treat asymptomatic type 2 diabetes"				
Risk of bias					
Bias		Authors	Support for judgement		
		judgement			
Random sequer	nce generation	unclear risk	It only mentioned in the trial that "patients were		
(selection bias)			randomly divided into two groups"		
Allocation concealment		unclear risk	It only mentioned in the trial that "patients were		
(selection bias)			randomly divided into two groups"		
Blinding of participants and		Unclear risk	The information was not reported in this study		
personnel (performance bias)					
All outcomes					

Blinding of outcome assessment (detection bias)	Unclear risk	The information was not reported in this study
All outcomes		
Incomplete outcome data	Low risk	No exclusion or losses were reported, but the
(attrition bias)		number of participants remained the same at the
All outcomes		endpoint of study
Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)		possibility of selection outcome reporting could not
		be examined by the review authors
Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on general backgrounds.
		Other aspects of bias were unclear

Jiang YC 2004

Clinical observation on Combination of Chinese Medicine and Western Medicine for the Treatment of 51 Cases of Type 2 Diabetes Mellitus

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 37 in control group, 51 in treatment group
Participants	Ethnic: Chinese n=88
	Inclusion criteria: T2DM WHO 1999; diagnosed with type 2 diabetes after blood
	sugar, urine sugar and insulin function test; can follow up according to doctor's
	advice, informed and signed consent
	Exclusion criteria: combine with nephrosis, ketoacidosis and other severe
	complications
Interventions	Number of study centres: 1
	Location: China
	Setting: outpatients or inpatients in hospital
	Intervention:
	treatment group: TCM prescription compound hypoglycemia decoction (Huangqi,
	Shanzhuyu, Renshen, Jiegeng, Gegeng, Yuzhu, Nvzhenzi, Sheng Dihuang,

	Shanqifen, Gancao, and add Zhimu for thirsty, Digupi for wasting, Sangpiaoxiao for			
	diuresis) on the basis of control group			
	control group: oral intake gliclazide plus strict diet control			
Outcomes	Treatment group had better improvement in clinical effects and glucose metabolism			
	(FBG, PBG, 24h	urine blood sugar)		
	No adverse effect was observed in both groups during the treatment			
	Outcomes were	assessed at ba	aseline and trial completion	
Study details	Duration of inter	vention: 2 mont	ns	
	Duration of Follo	ow-up: notrepo	rted	
	Run-in period: n	ot described		
Stated aim of	"To discuss the	curative effect o	f combining traditional Chinese medicine and	
study	western medicir	ne to treat type 2	2 diabetes"	
Risk of bias				
Bias		Authors	Support for judgement	
		judgement		
Random sequer	nce generation	unclear risk	It only mentioned in the trial that "patients were	
(selection bias)			randomly divided into treatment group and control	
			group"	
Allocation conce	ealment	unclear risk	It only mentioned in the trial that "patients were	
(selection bias)			randomly divided into treatment group and control	
			group"	
Blinding of participants and		Unclear risk	The information was not reported in this study	
personnel (perfo	ormance bias)			
All outcomes				
Blinding of outco	ome assessment	Unclear risk	The information was not reported in this study	
(detection bias)				
All outcomes				
Incomplete outcome data		Low risk	No exclusion or losses were reported, but the	
(attrition bias)			number of participants remained the same at the	
All outcomes			endpoint of study	
Selection reporting (reporting		Unclear risk	The protocol of the trial was not available, so the	
bias)			possibility of selection outcome reporting could not	
			be examined by the review authors	

Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on general backgrounds
		like age, sex and disease course etc. Other
		aspects of bias were unclear

Li Z 2013

Clinical observation on 30 Cases of Type 2 Diabetes Mellitus Treated with the Method of

Relieving Liver and Reinforcing Spleen

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=60
	Inclusion criteria: T2DM ADA 1999, TCM diagnostic criteria China 2002, TCM
	differentiation: liver stagnation and spleen deficiency; age: 18-70 years with both
	sex; no distinct diabetic acute and chronic complications; no insulin treatment before,
	no herb treatment and medicine which affect blood lipid before 2 weeks of study
	Exclusion criteria: type 1 diabetes and diabetes with special causation, pregnant
	diabetes; pregnancy, breastfeeding and allergy to the study drugs and not suitable
	to the study; combine with cardiovascular, renal, he mopoietic system and other
	severe primary diseases, psychosis; have diabetes acute complications within recent
	one month
Interventions	Number of study centres: 1
	Location: China
	Setting: outpatients and inpatients in TCM hospital
	Intervention:
	Basic treatment: life style regulation and diet therapy; control general calorie intake;
	insist rational aerobic exercise, prevent or reduce obese, maintain healthy weight
	Treatment group: TCM prescription: smoothing the liver and strengthening the
	spleen decoction (Sheng Huangqi, Shanyao, Fuling, Yiyiren, Chaihu, Baishao,
	Shanyurou, Suanzaoren, Gegen, Sangye) on the basis of control group

	Control group:	basic treatment	+ conventional treatment: oral intake metformin
	enteric coatel t	tablets or acarbo	ose
Outcomes	There is significant difference between treatment group and control group in glucose		
	and lipid acid l	level (FBG, 2hPf	PG, HbA1c), insulin resistance index (IRI) and
	traditional Chir	nese clinical sym	nptoms
	Blood , urine, a	and stool routine	examination, liver and kidney function test were
	measure for a	dverse effect, an	nd no abnormal and adverse effects were observed
	during the trea	tment	
	Outcomes we	re assessed at l	paseline and trial completion
Study details	Duration of inte	ervention: 8 wee	ks
	Duration of Fo	llow-up: notrep	orted
	Run-in period:	not described	
Stated aim of	"To observe th	ne effect of treatn	nent of smoothing the liver and strengthening the
study	spleen with typ	e 2 diabetes in	clinic"
Risk of bias			
Bias		Authors	Support for judgement
		judgement	
Random sequer	nce generation	unclear risk	It only mentioned in the trial that "patients were
(selection bias)	(selection bias)		randomly divided into two groups"
Allocation conce	alment	unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into two groups"
Blinding of partic	ipants and	Unclear risk	The information was not reported in this study
personnel (performance bias)			
All outcomes			
Blinding of outco	me	Unclear risk	The information was not reported in this study
assessment (detection bias)			
All outcomes			
Incomplete outcome data		Low risk	No exclusion or losses were reported, but the
(attrition bias)			number of participants remained the same at the
Alloutcomes			endpoint of study
Selection reporting (reporting		Unclear risk	The protocol of the trial was not available, so the
bias)			possibility of selection outcome reporting could not
			be examined by the review authors

Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on general backgrounds like
		age, sex and disease course etc. Other aspects of
		bias were unclear

Wang XN 2015

Clinical Observation of Traditional Chinese Medicine Coptis Chinensis Treatment of Type 2 Diabetes Mellitus

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
Methods	, ,
	+ other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=75
	Inclusion criteria: T2DM WHO 1999; have never used other hypoglycemia medicine
	within half month before the study; informed and signed written consent before the
	study
	Exclusion criteria: FBG≥14mmol/L and/or 2hPBG≥18mmol/L; liver and kidney
	function distinct abnormal; younger than 30years; BMI≥30kg/m²
Interventions	Number of study centres: 1
	Location: China
	Setting: patients in TCM hospital
	Intervention:
	observation group: TCM prescription: coptis granules on the basis of control group
	control group: oral intake metformin tablet
Outcomes	FBG and 2hPBG were statistically significant lower in observation group than control
	group after 30 days treatment. The improving of insulin resistance and abnormal
	metabolism of lipid in control group were ineffective; observation group has better
	clinical effect in improving insulin resistance and recovery of islet function, and
	significantly improved in patients with dyslipidemia.
	No information was reported in terms to adverse effect in this study
	Outcomes were assessed at baseline and trial completion
Study details	Duration of intervention: 60 days
	Duration of Follow-up: not reported
	control group: oral intake metformin tablet FBG and 2hPBG were statistically significant lower in observation group than control group after 30 days treatment. The improving of insulin resistance and abnormal metabolism of lipid in control group were ineffective; observation group has better clinical effect in improving insulin resistance and recovery of islet function, and significantly improved in patients with dyslipidemia. No information was reported in terms to adverse effect in this study Outcomes were assessed at baseline and trial completion Duration of intervention: 60 days

	Run-in per	iod: not describe	ed
Stated aim of	"To investigate the clinical effect of coptis chinensis in treating type 2 diabetes		
study	mellitus"		
Risk of bias	<u> </u>		
Bias		Authors	Support for judgement
		judgement	
Random sequer	nce	low risk	It mentioned in the trial that "patients were randomly
generation (sele	ction bias)		divided into observation group and control group by
			using random number table method"
Allocation conce	alment	low risk	It mentioned in the trial that "patients were randomly
(selection bias)			divided into observation group and control group by
			using random number table method"
Blinding of partic	ipants and	Unclear risk	The information was not reported in this study
personnel (perfo	rmance		
bias)			
All outcomes			
Blinding of outco	me	Unclear risk	The information was not reported in this study
assessment (de	tection		
bias)			
All outcomes			
Incomplete outcomplete	ome data	Low risk	No exclusion or losses were reported, but the number
(attrition bias)			of participants remained the same at the endpoint of
All outcomes			study
Selection report	ing	Unclear risk	The protocol of the trial was not available, so the
(reporting bias)			possibility of selection outcome reporting could not be
			examined by the review authors
Other bias		Unclear risk	The intervention groups were comparable, as it
			mentioned in the trial "no significant difference was
			found between groups on general backgrounds of sex,
			age and disease course. Other aspects of bias were
			unclear

Effect of Sanhuang Tang on Insulin Resistance Index and Inflammatory Factors of Obese Type 2 Diabetes

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=69
	Inclusion criteria: T2DM WHO 1999 diabetes diagnostic criteria: clinical symptoms +
	anytime blood sugar≥7.0mmol/L; OGTT2h≥11.1mmol/L; TCM differentiation: phlegm
	hot junction; BMl≥25kg·m⁻²; age: 18-75 year; informed consent
	Exclusion criteria: not accord with inclusion criteria; type 1 diabetes, pregnant
	diabetes and other types of diabetes; have diabetes ketoacidosis, diabetes
	hyperglycemia hypertonicity status and other acute complications; combine with
	heart, brain, liver, kidney and other severe diseases; have used insulin and other
	similar treatment; pregnancy or breastfeeding; not good at comply with treatment or
	psychosis
Interventions	Number of study centres: 1
	Location: China
	Setting: outpatients and inpatients in TCM hospital
	Intervention:
	Sanhuang tang group: plus Sanhuang tang (Huanglian, Huangqin, Dahuang) on the
	basis of control group
	Western medicine group: lifestyle intervention plus metformin
Outcomes	Sanhuang tang group is statistically significant in improving clinical symptoms,
	glucose and lipid metabolism and insulin resistance and reduce the level of
	inflammatory factors (FBG, 2hPBG, HbA1C, TC, TG, TNF-α, IL-6, HOMA-IR)
	compare to western medicine group
	Blood, urine, stool routine examination and liver, kidney function test had taken, but
	no other details were mentioned about adverse effect.
	Outcomes were assessed at baseline and trial completion
Study details	Duration of intervention: 3 months
	Duration of Follow-up: not reported
	Run-in period: not described

Stated aim of	"To observe the efficacy of Chinese herbal formula Sanhuang tang in treating obese		nese herbal formula Sanhuang tang in treating obese
study	type 2 diabetes"		
Risk of bias			
Bias		Authors	Support for judgement
		judgement	
Random sequer	nce generation	unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly distributed into Sanhuang tang group and
			western medicine group"
Allocation conce	alment	unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly distributed into Sanhuang tang group and
			western medicine group"
Blinding of partic	ipants and	Unclear risk	The information was not reported in this study
personnel (perfo	rmance bias)		
All outcomes	All outcomes		
Blinding of outco	Blinding of outcome		The information was not reported in this study
assessment (de	tection bias)		
All outcomes			
Incomplete outcomplete	Incomplete outcome data		No exclusion or losses were reported, but the
(attrition bias)			number of participants remained the same at the
All outcomes			endpoint of study
Selection reporti	ing (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)			possibility of selection outcome reporting could not
			be examined by the review authors
Other bias		Unclear risk	The intervention groups were comparable, as it
			mentioned in the trial "no significant difference was
			found between groups on age, sex and disease
			course etc. Other aspects of bias were unclear

Cai Z 2015

Effects of Fructus Schisandrae Decoction on the Changes of Serum IL-2 and IL-6 of Patients with type 2 Diabetes

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=88
	Inclusion criteria: up-to-date diabetes diagnostic criteria: polydipsia, polyuria,
	polyphagia and no other reasons weight loss plus one of following: random blood
	sugar≥11.1mmol/L; FBG≥7.0mmol/L; OGTT2h≥11.1mmol/L. on the basis of above
	plus one of followings can be diagnosed as T2DM: low insulin level, insulin
	resistance. Age≤70y; involuntary to the study and signed consent and meet with
	ethical criteria
	Exclusion criteria: not meet with T2DM diagnostic criteria; severe liver and
	gallbladder disease; malignant tumour; age ≤40y, ≥70y; have mental disease
Interventions	Number of study centres: 1
	Location: China
	Setting: outpatients and inpatients in TCM hospital
	Intervention:
	Experimental group: TCM herb Schisandra chinensis (Wuweizi) on the basis of
	control group
	Control group: conventional treatment: oral intake of Metformin Hydrochloride
	Capsules
Outcomes	The cytokines (IL-2 and IL-6 levels) improved in both groups after treatment and
	more statistically significantly improved in experimental group. The level of glycated
	haemoglobin (HbA1c) reduced in both groups after treatment and the decrease were
	more statistically significant in experimental group than control group. Level of blood
	lipid (TC, TG and LDL) were improved and the improvement was more statistically
	significant in experimental group
	No information was reported in terms to adverse effect in this study
	Outcomes were assessed at baseline and trial completion
Study details	Duration of intervention: 3 months
	Duration of Follow-up: not reported
	Run-in period: not described
Stated aim of	"To investigate the clinical curative effect of Fructus Schisandra Decoction on type 2
study	diabetes mellitus disease and the change of serum IL-2, IL-6 levels"

Risk of bias		
Bias	Authors	Support for judgement
	judgement	
Random sequence generation	unclear risk	It only mentioned in the trial that "patients were
(selection bias)		randomly divided into two groups"
Allocation concealment	unclear risk	It only mentioned in the trial that "patients were
(selection bias)		randomly divided into two groups"
Blinding of participants and	Unclear risk	The information was not reported in this study
personnel (performance bias)		
All outcomes		
Blinding of outcome	Unclear risk	The information was not reported in this study
assessment (detection bias)		
All outcomes		
Incomplete outcome data	Low risk	No exclusion or losses were reported, but the
(attrition bias)		number of participants remained the same at the
All outcomes		endpoint of study
Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)		possibility of selection outcome reporting could not
		be examined by the review authors
Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on general backgrounds.
		Other aspects of bias were unclear

Guan X 2006

Influence of Liuweidihuang Pill and Ginkgoibca Leave to the Lipotoxicity and Insulin Resistance in Early Time of Type 2 Diabetes Mellitus

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=104

	Inclusion criteria: T2DM WHO 1999, polydipsia, polyuria, weight loss and repetitive
	infection, random blood sugar≥11.1mmol/L; FBG≥7.0mmol/L; OGTT2h≥11.1mmol/L;
	TCM differentiation: internal heat from yin deficiency and blood stasis in meridians;
	age: 30-70 years; have no distinct diabetes complication, diagnosis with diabetes
	over three months; BP≤180/110mmHg; BMI≤30; have used no more than two kinds
	of hypoglycemic medicine and blood sugar is under control when enrolled with the
	study; informed consent and voluntary to the study
	Exclusion criteria: not meet with inclusion criteria; type 1 diabetes and diabetes due
	to special reason and pregnant diabetes; diabetes severe acute complication like
	ketoacidosis, diabetes hypertonicity; vascular complications: myocardial infarction,
	cerebrovascular accident, lower limb angionosis; severe heart, liver, lung, kidney,
	blood or other life-threating disease like tumor or AIDS; pregnancy, breastfeeding;
	easy lost follow-up; current use medicine affect blood sugar, BP and blood lipid; in
	other study currently
Interventions	Number of study centres: 1
	Location: China
	Setting: outpatients in TCM hospital
	Intervention:
	Basic treatment: dietary and exercise therapy + no more than two kinds of
	hypoglycemia medicine: insulin inhibitor, alpha glucosidase inhibitor, metformin,
	insulin, glimepiride
	experimental group: basic treatment plus TCM herb Liuweidihuang capsule and
	Yinxingye tablet
	control group: basic treatment plus TCM herb placebo
Outcomes	TC, TG, LDL-C, FFA and TNF-α had better control in experimental group than
	control group with FFA and TNF- α has statistical difference. No difference for FBG,
	2hPBG, and HbA1c in both groups before and after treatment. Clinical symptoms,
	FINS and IR changes also have no statistically significance.
	No information was reported in terms to adverse effect in this study
	Outcomes were assessed at baseline and trial completion
Study details	Duration of intervention: 6 months
	Duration of Follow-up: not reported
	Run-in period: not described
L	I .

Stated aim of	"evaluate the i	nfluence and clir	nical application of Jinqi hypoglycemic tablet on
study	vascular endothelial cells active factor of patients with diabetes mellitus by observing		
	the change of	correlation factor	about vascular endothelial cells damage before and
	after therapy	"	
Risk of bias			
Bias		Authors	Support for judgement
		judgement	
Random sequence generation		unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into experimental group and
			control group"
Allocation concealment		unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into experimental group and
			control group"
Blinding of participants and		low risk	Double-blinded and placebo controlled for both
personnel (performance bias)			researcher and patients
All outcomes			
Blinding of outcome		low risk	Double-blinded and placebo controlled for both
assessment (detection bias)			researcher and patients
All outcomes			
Incomplete outcome data		Low risk	No exclusion or losses were reported, but the
(attrition bias)			number of participants remained the same at the
All outcomes			endpoint of study
Selection reporting (reporting		low risk	The protocol of the trial was strictly double-blinded
bias)			for both researcher and patients
Other bias		low risk	The intervention groups were comparable, as it
			mentioned in the trial "no significant difference was
			found between groups on general backgrounds of
			sex, age and disease course. SBP, DBP, FBG,
			HbA, TC, TG, ALT, Cr, FFA, TNA, IR and TCM
			symptom score are also have no statistically
			significant difference in both groups before study.

Study on improvement of islet β cell function in patients with type 2 diabetes by integrative Chinese and Western medicine

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine			
	+ other pharmaceuticals) compared with other pharmaceuticals alone			
	Randomisation ratio: 1:1:1			
Participants	Ethnic: Chinese n=65 (group A:23, group B:25, group C:24)			
	Inclusion criteria: T2DM_WHO 1999, age ≤65y, have no pharmacotherapy within 3			
	months; FBG, PG2h and HbA1c are all increase (FBG≤7.0mmol/L,			
	PG2h≤11.1mmol/L, HbA1c≥6.5%)			
	Exclusion criteria: stress status, severe liver and kidney dysfunction, have disease			
	which affect glucose metabolism			
Interventions	Number of study centres: 1			
	Location: China			
	Setting: patients in medical college hospital			
	Intervention: diabetes health education, diet control and proper exercise therapy for			
	all three groups			
	Group A: sulfonylurea oral intake			
	Group B: insulin			
	Group C: insulin + TCM prescription Dachaihu decoction (Chaihu, Huangqin, Zhishi,			
	Huanglian, Dahuang, Banxia)			
Outcomes	After treatment, the damaged islet β cell function was not improved and the secretive			
	peak value of C2 peptide was still low and delayed in group A. But it shifted earlier			
	and indicated a certain degree of improvement and recovery of islet β cell function in			
	group B and C with statistically significant in Group C. FBG, P2BG and HbA1c			
	decreased after treatment in three groups with more decreased in Group B and C			
	and Group C was more significant.			
	No information was reported in terms to adverse effect in this study Outcomes were			
	assessed at baseline and trial completion			
Study details	Duration of intervention: 1 year			
	Duration of Follow-up: not reported			
	Run-in period: not described			
Stated aim of	"evaluate the influence of eliminating heat by nourishing Yin and activating blood and			
study	removing stasis TCM on inflammatory factor of type 2 diabetes in earlier period "			

Risk of bias			
Bias	Authors	Support for judgement	
	judgement		
Random sequence generation	unclear risk	It only mentioned in the trial that "patients were	
(selection bias)		randomly divided into 3 groups"	
Allocation concealment	unclear risk	It only mentioned in the trial that "patients were	
(selection bias)		randomly divided into 3 groups"	
Blinding of participants and	unclear risk	The information was not reported in this study	
personnel (performance bias)			
All outcomes			
Blinding of outcome	unclear risk	The information was not reported in this study	
assessment (detection bias)			
All outcomes			
Incomplete outcome data	Low risk	7 cases lost follow up in three groups (2 in Group A,	
(attrition bias)		3 in Group B and 2 in Group C) with same reasons	
All outcomes		as lost contact with across three groups.	
Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so the	
bias)		possibility of selection outcome reporting could not	
		be examined by the review authors	
Other bias	Unclear risk	The intervention groups were comparable, as it	
		mentioned in the trial "no significant difference was	
		found between groups on general backgrounds.	
		Other aspects of bias were unclear	

Liu HZ 2007

Effects of Danzhi Jiangtang Capsule on β -cell Function of pancreatic Islet in Type 2 Daibetes

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=62

	Inclusion criteria: T2DM WHO 1999; TCM differentiation China Zhengzhou		
	conference 19	86: qi deficiency	, yin deficiency, and China Beijing conference 1988:
	blood stasis. A	.ge: 56-87year;	
	Exclusion criteria: not described		
Interventions	Number of stud	dy centres: 1	
	Location: China	а	
	Setting: outpat	ients and inpatie	nts in TCM university hospital
	Intervention:		
	Conventional h	ypoglycemia tre	atment: sulfonylurea, glucosidase inhibitor or insulin
	treatment; hyp	ertension and c	oronary disease treatment
	Treatment gro	up: conventional	treatment + TCM Danzhi Jiangtang Capsules oral
	intake (Taizish	en, Sheng Dihua	ng, Tusizi, Mudanpi, Zexie, Shuizhi)
	Control group:	conventional tre	atment + rosiglitazone
Outcomes	Comparing wi	th those of contr	ol group, the score of TCM syndrome, indexs of FBG,
	2hPG, blood in	nsulin (empty, 30	min, 2h and 3h), ISI, Homa-IR, Homa-B were
	significantly improved (P<0.05, P<0.01).		
	No information was reported in terms to adverse effect in this study		
	Outcomes were assessed at baseline and trial completion		
Study details	Duration of intervention: 2 months		
	Duration of Follow-up: not reported		
	Run-in period: not described		
Stated aim of	"To observe the effects of Danzhi Jiangtang Capsules on B-cell function of pancreatic		
study	islet in patients with type 2 diabetes and explore its contribution to treating and		
	delaying the development of type 2 diabetes."		
Risk of bias			
Bias		Authors	Support for judgement
		judgement	
Random sequence generation		unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into treatment group and control
			group"
Allocation concealment		unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into treatment group and control
			group"

Blinding of participants and	Unclear risk	The information was not reported in this study
personnel (performance bias)		
All outcomes		
Blinding of outcome	Unclear risk	The information was not reported in this study
assessment (detection bias)		
All outcomes		
Incomplete outcome data	Low risk	No exclusion or losses were reported, but the
(attrition bias)		number of participants remained the same at the
All outcomes		endpoint of study
Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)		possibility of selection outcome reporting could not
		be examined by the review authors
Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on general baseline and
		clinical backgrounds of sex, age, disease course,
		score of TCM syndrome, BMI, FPC and HbA1c.
		Other aspects of bias were unclear

Shi XD 2015

The curative effect observation of Xiaoke pill and glibendamide treatment of type 2 diabetes mellitus

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=100
	Inclusion criteria: T2DM WHO 1999; age: 46-62, all cases≤65 years, 24 cases
	combined with hypertension. FPG mean= 8.4-8.5mmol/L, 2hPG mean=12.5-
	12.8mmol/L, HbA1c mean=7.4-7.6%; both groups have DM clinical symptoms; no
	insulin treatment before, liver and kidney function normal, whole blood test normal
	Exclusion criteria: diabetes complication; combined coronary heart disease and brain
	infarction; weak constitution; hypocortisonism; hypoanteriorpituitarism

Interventions	Number of study centres: 1		
	Location: China		
	Setting: inpatients in hospital		
	Intervention: both groups have general treatment: quit smoking and alcohol, lifestyle		
	intervention and dietary plan, regular exercise and exercise therapy		
	Treatment	group: glibencl	amide and aspirin therapy oral intake
	Control gr	oup: Xiaoke pill(Huangqi, Dihuang, Shanyao, Wuweizi, Tianhuafen, Gegen,
	Yumixu) a	and aspirin thera	py oral intake
Outcomes	The symp	toms of diabetes	s significantly improved with 56% in treatment group and
	82% in co	ntrol group resp	ectively.
	Periphera	al blood sugar, u	rine sugar, urine ketone bodies, urine protein and blood
	picture ob	served for meas	surement of efficacy.
	BP, liver a	and kidney functi	on, fundus examination was measures and no abnormal
	observed	. 4 cases in treat	ment group had hypoglycemic reaction and 2 cases out of
	4 had mild	d nausea and vo	miting. No any adverse effects observed in control group.
	Outcome	s were assesse	d at baseline and trial completion
Study details	Duration of intervention: 90 days		
	Duration of Follow-up: not reported		
	Run-in period: not described		
Stated aim of	"To discus	ss the effect of X	iaoke pill and glibenclamide treatment of type 2 diabetes
study	mellitus"		
Risk of bias			
Bias		Authors	Support for judgement
		judgement	
Random sequen	ice	unclear risk	It only mentioned in the trial that "patients were randomly
generation (selection bias)			divided into treatment group and control group"
Allocation concealment		unclear risk	It only mentioned in the trial that "patients were randomly
(selection bias)			divided into treatment group and control group"
Blinding of participants		Unclear risk	The information was not reported in this study
and personnel			
(performance bias)			
All outcomes			

Blinding of outcome	Unclear risk	The information was not reported in this study
assessment (detection		
bias)		
All outcomes		
Incomplete outcome data	Low risk	No exclusion or losses were reported, but the number of
(attrition bias)		participants remained the same at the endpoint of study
All outcomes		
Selection reporting	Unclear risk	The protocol of the trial was not available, so the
(reporting bias)		possibility of selection outcome reporting could not be
		examined by the review authors
Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was found
		between groups on general backgrounds. Other aspects
		of bias were unclear

Lan KJ 2011

23 Cases of the Traditional Chinese Medicine Combined Insulin Treatment for Type 2 Diabetes of the Clinical Effect of analysis

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine + other pharmaceuticals) compared with other pharmaceuticals alone Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=43 Inclusion criteria: T2DM WHO 1999; need insulin treatment; average age: 58.7±6.4 year, average disease course: 5.4±2.6, BMI: 23.1±3.3 kg/m Exclusion criteria: not described
Interventions	Number of study centres: 1 Location: China Setting: inpatients in army hospital Intervention: dietary control and exercise therapy Combined group: insulin treatment + TCM herb decoction (Huangqi, Dannanxing, Chuanxiong, Gualou, Fuling, Zexie, Xiangfu, Shu Dihuang, Huanglian, Gegen, Danshen)

	Control group: insulin treatment			
Outcomes	Outcomes were assessed at baseline and trial completion at 2 weeks for FPG,			
	2hPBG, and at 3 months for HbA1c			
	Mean 2h PBG	Mean 2h PBG and FBG decreased significantly at endpoint in the combination group		
	compared with	control group (P	<0.05). The HbA1C excursion were significant lower	
	after 3 months	(P<0.05)		
	No information	was reported in t	erms to adverse effect in this study	
Study details	Duration of inte	ervention: 3month	S	
	Duration of Fo	llow-up: notrepo	rted	
	Run-in period:	not described		
Stated aim of	"To compare t	ne level of HbA1c	in insulin-requiring patients with diabetes (T2DM)	
study	treated twice d	aily with Chinese	herbal remedies combined with insulin."	
Risk of bias				
Bias		Authors	Support for judgement	
		judgement		
Random sequer	nce generation	unclear risk	It only mentioned in the trial that "patients were	
(selection bias)			randomly divided into treatment group and control	
			group"	
Allocation concealment		unclear risk	It only mentioned in the trial that "patients were	
(selection bias)			randomly divided into treatment group and control	
			group"	
Blinding of participants and		Unclear risk	The information was not reported in this study	
personnel (performance bias)				
All outcomes				
Blinding of outco	Blinding of outcome		The information was not reported in this study	
assessment (detection bias)				
All outcomes				
Incomplete outcome data		Low risk	No exclusion or losses were reported, but the	
(attrition bias)			number of participants remained the same at the	
All outcomes			endpoint of study	
Selection report	ing (reporting	Unclear risk	The protocol of the trial was not available, so the	
bias)			possibility of selection outcome reporting could not	
			be examined by the review authors	

Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on general backgrounds of
		age, sex, disease course, BMI and so on. Other
		aspects of bias were unclear

Yang LQ 2010

Clinical observation of Dangua Prescription on Type 2 Diabetes Patients with long-term hyperglycosemia

	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 2:1
Participants	Ethnic: Chinese n=126
	Inclusion criteria: T2DM WHO 1999; blood sugar control is not ideal for long time,
	HbA1C>7.5% last for one year; not included in exclusion criteria. TCM differentiation
	China 2002: phlegm dampness symptoms and blood stasis symptoms
	Exclusion criteria: pregnant or breast-feeding; severe heart, liver, kidney and brain
	complications, or combine other severe primary diseases; have diabetes ketosis,
	ketoacidosis, hypertonic coma and infections; not accord with TCM differentiation
Interventions	Number of study centres: 1
	Location: China
	Setting: outpatients and inpatients in TCM university hospital
	Intervention: both groups have diabetes education, diet control and exercise therapy
	Treatment group: Dangua prescription (Danshen, Gualou, Chuanxiong, Chishao,
	Banxia, Xiebai) on the basis of control group
	Control group: insulin, hypoglycemia medicine: gliclazide, metformin and
	rosiglitazone, single or combined.
Outcomes	Compared with control group, 2hPG, HbA1C, c peptide, 2h postprandial C peptide,
	high shear viscosity of whole blood, low shear viscosity of whole blood, fibrinogen
	and cumulative score of symptoms were decreased (P<0.05). The average dosage of
	insulin in treatment group was less than that in control group (P<0.05). The total
	·

	T		
	effective rate was 92.68% in the treatment group and 77.27% in control group with		
	P<0.05		
	Liver and kidney function, ECG were measured before and after the treatment and		
	no adverse effect or complication were observed in both intervention group		
	Outcomes wer	e assessed at b	aseline and trial completion
Study details	Duration of inte	ervention: 90 day	ys
	Duration of Fo	llow-up: not repo	orted
	Run-in period:	none	
Stated aim of	"To observe th	e effect of Dang	ua prescription on type 2 diabetes patients with long -
study	term hyperglyd	cosemia."	
Risk of bias			
Bias		Authors	Support for judgement
		judgement	
Random sequer	nce generation	unclear risk	It only mentioned that the "patients were randomly
(selection bias)			divided into control group and treatment group"
Allocation conce	ealment	unclear risk	It only mentioned that the "patients were randomly
(selection bias)			divided into control group and treatment group"
Blinding of participants and		unclear risk	The information was not reported in this study
personnel (performance bias)			
All outcomes			
Blinding of outco	ome	unclear risk	The information was not reported in this study
assessment (detection bias)			
All outcomes			
Incomplete outc	ome data	low risk	No exclusion or losses were reported, but the
(attrition bias)			number of participants remained the same at the
All outcomes			endpoint of study
Selection reporting (reporting		Unclear risk	The protocol of the trial was not available, so the
bias)			possibility of selection outcome reporting could not
			be examined by the review authors
Other bias	Other bias		The intervention groups were comparable, as it
			mentioned in the trial "no significant difference was
			found between groups on general background of

	sex, age, disease course, complications and so on.
	Other aspects of bias were unclear

Zhang YH 2008

Effect of Didang Tang on type 2 diabetes with insulin resistance

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=73
	Inclusion criteria: T2DM WHO 1999, no sensitive to insulin treatment with high blood
	insulin level. age: 35-77 years
	Exclusion criteria: liver and kidney dysfunction, type 1 diabetes, tumor, hemopoietic
	system disease, psychotic, acute myocardial infarction, severe arythmia, acute heart
	failure or chronic heart dysfunction over grade three.
Interventions	Number of study centres: 1
	Location: China
	Setting: patients in TCM hospital
	Intervention:
	treatment group: sulfonylurea, metformin and alpha glucosidase inhibitor routine
	treatment for 4 weeks and plus TCM formula Didang Tang (Dahuang, Taoren,
	Shuizhi, Mengchong) for 8 weeks
	control group: sulfonylurea, metformin and alpha glucosidase inhibitor routine
	treatment
Outcomes	After treatment, TC, TG, LDL-C, FBG, FINS and ISI in treatment group have
	decreased compared to control group and with statistical significant. Outcomes were
	assessed at baseline and trial completion
	Measured Cchest x-ray, blood and urine routine examination, liver and kidney
	function test for safety and no abnormal had been observed in terms to adverse
	effect related to study drugs. No complication and other severe adverse effects
	observed during the intervention.
Study details	Duration of intervention: 8 weeks
	Duration of Follow-up: 12 weeks

	Run-in period: 4 weeks		
Stated aim of	"to observe the effect of Didang Tang on type 2 diabetes with insulin resistance and		
study	discuss the prevention and treatment of type 2 diabetes with TCM principle of		
	moving blood and clearing stagnation "		
Risk of bias			
Bias		Authors	Support for judgement
		judgement	
Random sequen	ce generation	low risk	It mentioned in the trial that "patients were
(selection bias)			randomly divided into experimental group and
			control group by computer random table method"
Allocation conce	alment	low risk	It mentioned in the trial that "patients were
(selection bias)			randomly divided into experimental group and
			control group by computer random table method"
Blinding of partic	ipants and	unclear risk	The information was not reported in this study
personnel (perfo	rmance bias)		
All outcomes			
Blinding of outco	Blinding of outcome		The information was not reported in this study
assessment (detection bias)			
All outcomes			
Incomplete outcome data		Low risk	No exclusion or losses were reported, but the
(attrition bias)			number of participants remained the same at the
All outcomes			endpoint of study
Selection reporti	ng (reporting	unclear risk	The protocol of the trial was not available, so the
bias)			possibility of selection outcome reporting could not
			be examined by the review authors
Other bias	Other bias		The intervention groups were comparable, as it
			mentioned in the trial that "no significant difference
			was found between groups on general
			backgrounds of sex, age and distribution of
			complications between both groups. Other aspects
			of bias were unclear

Efficacy and Safety of Traditional Chinese Medicine for Diabetes: A Double-Blinded, Randomises, Controlled Trial

Methods	Parallel randomised controlled, double blinded, multicentre non-inferiority clinical trial
	of Chinese herbal medicine with or without other pharmaceuticals compared with
	other pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=800
	Inclusion criteria, drug naïve patients with BMI within 18kg/m²-28kg/m²; patients who
	received treatment with metformin at a stable dose ≥750mg/day for at least 3 months
	before screening with BMI within 18kg/m²-35kg/m²; stable body weight within at least
	3 months before screening; poor glycemic control with FPG between 126-234mg/dl
	(7.0-13mmol/L) and HbA1c≥7.0& at screening.
	Exclusion criteria, FPG≥13mmol/L or HbA1c≥11%, more than 3 episodes of severe
	hypoglycemia within 6 months before screening, allergic to sulfonylureas or their
	ingredients, treatment with glucose-lowing agents other than metformin or insulin
	within 3 months before screening or with exogenous insulin for more than 1 week
	within 3 months before screening, a history of heart disease within 1 year before
	screening, a history of abnormal kidney function or serum creatinine levels reaching
	the upper limit of normal, ALT or AST≥2.5 times the upper limit of normal, suffering
	from acute or chronic hepatitis, haemoglobin disease or chronic anemia, or
	underlying conditions that could lead to poor complication.
Interventions	Number of study centres: 20
	Location: 19 participant centres in China and 1 participant centre in Queensland,
	Australia
	Setting: patients in hospitals
	Intervention: control diet and do exercise
	Drug naive group: Xiaoke Pill (Radix Puerariae, Radix Rehmanniae, Radix Astragali,
	Radix, Trichosanthis, Stylus Zeae Maydis, Fructus Schisandrae Sphenantherar and
	Rhizoma Dioscoreae) in Xiaoke Pill arm, Glibenclamide in Glibenclamide arm
	Metformin group: Xiaoke Pill + Metformin in Xiaoke Pill arm, Glibenclamide +
	Metformin in Glibenclamide arm

Outcomes	Clinical and Bio	ochemical meas	urements: HbA1c, FPG, C-peptide, hsCRP,	
	adiponectin an	d lipids, LDL-C,	HDL-C, triglyceride, liver function test, complete blood	
	count, urine ro	utine assay, kidr	ney function test, twelve-lead ECG, physical	
	examination;			
	Outcome in dru	ւց naïve group։ բ	patients in the Xiaoke Pill arm were 38% less likely to	
	have any hypoglycemia compared to those in the Glibenclamide arm. The average			
	annual rate of hypoglycemia was 24% lower in patients treated with Xiaoke Pill.			
	Patients in Xiao	oke Pill arm were	e also 41% less likely to have a mild hypoglycemic	
	episode comp	ared to those in t	he Glibenclamide arm. All with statistically significant	
	with above out	come.		
	Outcome in Me	etformin Group: p	patients in Xiaoke Pill arm were 24% less likely to	
	have any hypo	glycemia compa	ared to those in the Glibenclamide arm. The average	
	annual rate of I	nypoglycemia wa	as 62% lower in patients treated with Xiaoke Pill. All	
	with statistically	significant with	above outcome.	
	Safety and Effic	cacy outcomes i	measured by incidence of hypoglycaemia, change in	
	HbA1c level, change in fasting glucose level, β-cell function, insulin resistance levels;			
	fasting lipid profiles and TCM symptoms score.			
	No serious adverse event reported during the study.			
	Outcomes were assessed at baseline and trial completion			
Study details	Duration of intervention: 48 weeks			
	Duration of Follow-up: not reported			
	Run-in period: 4 weeks			
Stated aim of	"To establish the safety and efficacy of traditional Chinese medicine combined with			
study	glibenclamide to treat type 2 diabetes mellitus."			
Notes	Randomised controlled trial with 2 arms			
Risk of bias				
Bias		Authors	Support for judgement	
		judgement		
Random sequence generation		low risk	It mentioned in the trial that "randomization was	
(selection bias)			performed centrally and was concealed and	
			stratified in blocks of four"	

Allocation concealment	low risk	It mentioned in the trial that "randomization was
(selection bias)		performed centrally and was concealed and
		stratified in blocks of four"
Blinding of participants and	low risk	Double-blinded and placebo-controlled
personnel (performance bias)		
All outcomes		
Blinding of outcome	low risk	Double-blinded and placebo-controlled
assessment (detection bias)		
All outcomes		
Incomplete outcome data	Low risk	Only 2 patients in TCM group early stopped.
(attrition bias)		
All outcomes		
Selection reporting (reporting	low risk	The protocol of the trial was clear, so the review
bias)		authors could examine the possibility of selection
		outcome reporting.
Other bias	unclear risk	The intervention groups were comparable, as it
		listed characteristics of the patients at baseline in
		the trial and no significant difference found between
		groups on demographics and anthropometric
		characteristics as well as blood pressure, metabolic
		characteristics and lipids. Other aspects of bias
		were unclear

Chen ZH 2014

Treatment of Type 2 Diabetes Mellitus Patients of Qi-Yin Deficiency Phlegm-Stasis Interobstruction Syndrome by Jiangtang Xiaozhi Capsule and Pioglitazone Tablet: a Non-inferiority Randomized Controlled Trial

Methods	3	Randomised parallel controlled prospective clinical trial of Chinese herbal medicine
		compared with other pharmaceuticals alone
		Randomisation ratio: 1:1

Ethnic: Chinese n=73
Inclusion criteria: T2DM WHO 1999, have diabetes history, FBG 7.0-11.1mmol/L or
2hPBG 11.1-16.6 mmol/L and blood sugar keep the same level after 2 weeks run-in-
period; age 30-7- years old, both sex; have no insulin treatment before and good for
comply with therapy; informed and signed consent; TCM diagnostic criteria China
2002, TCM differentiation: qi- yin deficiency phlegm-stasis inter-obstruction syndrome
Exclusion criteria: liver and kidney dysfunction; combine severe cardiovascular and
hemopoietic system disease or other severe primary disease as well as psychosis;
have diabetes ketoacidosis and other acute metabolism disorder within one month;
pregnancy and breastfeeding; combine with severe infections in recent one month;
allergic constitution; not comply in run-in period; have history of excessive drinking
and drug taking; use Pioglitazone or patent herb which can affect the evaluation of
the therapeutic effect
Number of study centres: 1
Location: China
Setting: outpatients in TCM hospital
Intervention:
Run-in period: dietary and exercise therapy under the supervisor of physician and
nutritionist
JTXZC group: TCM prescription: Jiangtang Xiaozhi capsule (Huangqi, Nuzhenzi,
Lizhihe, Kunbu, Jianghuang, Huanglian)
Pioglitazone group: Pioglitazone tablet
BW, BMI (waist circumference, hip circumference, waist-to-hip ratio), HbA1c, FBG or
2h PBG, TNF-α and PAI-1 were lower after treatment in both groups. The level of
NF-kB was apparently lowed after treatment in Pioglitazone group, but also
decreased in JTXZC group with statistical difference. The scoring of TCM symptoms
improved after treatment in both groups with statistically significant in experimental
group.
Measured blood, urine and stool routine examination, liver and kidney function
examination as well as ECG before and after the study. No abnormal were observed
in above test.

		<u> </u>	/ M 10 1 1 1 1 2 1 2
	I case in JTXZC group had nausea symptom after initial take the herb and better later		
		ŭ	al; 3 cases in Pioglitazone group had some mild
	adverse effect	s. No severe ad	verse reactions observed in both intervention groups.
	Outcomes were assessed at baseline and trial completion		
Study details	Duration of inte	ervention: 8 wee	ks
	Duration of Follow-up: every 2 weeks		
	Run-in period: 2 weeks		
Stated aim of	"To evaluate th	ne efficacy and s	afety of Jiangtang Xiaozhi capsule in treating type 2
study	diabetes melli	tus of qi- yin defi	ciency phlegm-stasis inter-obstruction syndrome and
	to observe its	effect on inflamm	atory factors and fibrinolytic factors"
Risk of bias	I		
Bias		Authors	Support for judgement
		judgement	
Random sequer	nce generation	low risk	It mentioned in the trial that "patients were randomly
(selection bias)			divided into two groups by statistical software
			random digit table method "
Allocation conce	ealment	low risk	It mentioned in the trial that "patients were randomly
(selection bias)			divided into two groups by statistical software
			random digit table method "
Blinding of participants and		Unclear risk	The information was not reported in this study
personnel (performance bias)			
All outcomes			
Blinding of outco	ome	Unclear risk	The information was not reported in this study
assessment (de	tection bias)		
All outcomes	All outcomes		
Incomplete outc	Incomplete outcome data		No exclusion or losses were reported, but the
(attrition bias)			number of participants remained the same at the
All outcomes			endpoint of study
Selection reporting (reporting		Unclear risk	The protocol of the trial was not available, so the
bias)	bias)		possibility of selection outcome reporting could not
			be examined by the review authors, except only
			mentioned full analysis set was adopted for the
			outcome

Unclear risk	The intervention groups were comparable, as it
	mentioned in the trial "no significant difference was
	found between groups on general backgrounds of
	sex, age, and disease course, distribution of
	complication in both groups and disease condition.
	Other aspects of bias were unclear
	Unclear risk

Niu XX 2014

Clinical Observation of Panax Quinquefolium Hypoglycemic Pills on Treatment of Type 2

Diabetes

Methods	Randomised controlled clinical trial of Chinese herbal medicine compared with other
	pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=180
	Inclusion criteria: T2DM WHO 1999, average age: 53.80±9.75, average disease
	course: 4.31 year
	Exclusion criteria: not described
Interventions	Number of study centres: 1
	Location: China
	Setting: outpatients in TCM hospital
	Intervention: both groups have exercise therapy and diet control
	Experimental group: Panax quinqueflium hypoglycemic pills (Xiyangshen, Shu
	Dihuang, Sheng Dihuang, Maidong, Tiandong, Huangqi, Shihu, Zhiqiao, Zexie,
	Pipaye) oral intake
	Control group: Metformin Hydrochloride tablet oral intake
Outcomes	The improvement of clinical test result in experimental group was better that that in
	control group with statistically significant. HbA1c rate of experimental group was
	significantly increased, 2hPBG and FBG both decreased significantly. The total
	effects including clinical symptoms in experimental group are statistically higher than
	that in control group.
	No information was reported in terms to adverse effect in this study
	Outcomes were assessed at baseline and trial completion

Study details	Duration of inte	ervention: 4 mor	nths
	Duration of Follow-up: not reported		
	Run-in period: not described		
Stated aim of	"To observe th	ne clinical effect	of type 2 diabetes mellitus with the treatment of Panax
study	quinqueflium F	lypoglycemic pi	"
Risk of bias			
Bias		Authors	Support for judgement
		judgement	
Random sequer	nce generation	unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into two groups"
Allocation conce	ealment	unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into two groups"
Blinding of partic	cipants and	Unclear risk	The information was not reported in this study
personnel (perfo	rmance bias)		
All outcomes			
Blinding of outcome		Unclear risk	The information was not reported in this study
assessment (detection bias)			
All outcomes			
Incomplete outcome data		Low risk	No exclusion or losses were reported, but the
(attrition bias)			number of participants remained the same at the
All outcomes	All outcomes		endpoint of study
Selection report	ing (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)			possibility of selection outcome reporting could not
			be examined by the review authors
Other bias		Unclear risk	The intervention groups were comparable, as it
			mentioned in the trial "no significant difference was
			found between groups on general backgrounds of
			disease course, age and sex. Other aspects of bias
			were unclear.

Song W 2014

Clinical Research of Chinese Medicine in Treating Patients with type 2 Diabetes

Methods	Randomised controlled clinical trial of Chinese herbal medicine compared with other
	pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=128
	Inclusion criteria: T2DM WHO 1999, disease course within 5 years, have never taken
	any hypoglycemia drug and lipid decrease drug before 2 month of study; age: 25-
	80y; informed and signed consent
	Exclusion criteria: FBG>10mmol/L, 2hPGB or random blood sugar>15mmol/L;
	HbA1c>10.0%; have recent distinct liver kidney dysfunction and infection, trauma,
	cardiovascular accident etc. stress status; combine with diabetic acute complications
	and pregnant diabetes or breastfeeding as well as potential pregnancy, hyperthyroid
	or other disease which lead to hyperglycemia and type 1 diabetes; possible allergy to
	study drug or have severe intestine absorption dysfunction
Interventions	Number of study centres: 1
	Location: China
	Setting: outpatients and inpatients in TCM hospital
	Intervention:
	Basic therapy: diet, exercise and diabetic education
	Treatment group: basic therapy + TCM prescription based on syndrome
	differentiation (Kidney tonify:Gouji, Chuanxuduan, Nuzhenzi, Hanliancao; Nourish Qi
	and Yin: Bei Huangqi, Dihuang, Digupi; Soothe liver and regulate Qi: Chaihu,
	Baishao, Bohe, Yujin; clear heat and generate fluid: Shigao, Zhimu, Gegen, Liaoqiao;
	clear fu and reduce heat: Dahuang, Zhishi, Huomaren; nourish heart calm spirit:
	Yejiaoteng, Yuanzhi, Shuanzhaoren; clear ying cool blood: Mudanpi, Maidong,
	Xuanshen, Chishao; clear damp-heat: Cangzhu, Huangbai, Yiyiren, Cheqiancao,
	Mianyinchen, add Fuling, Chaobaizhu, Fabanxia, Shenqu for damp restrict spleen;
	add Laifuzi, Zhiqiao, Chuanxiaopu for stomach bloat; add Gualoupi, Xiebai for
	depressed chest; move blood to clear stasis: Danshen, Sanling, Ezhu, Zelan)
	Control group: basic therapy + acarbose
Outcomes	The total effective rate improved after treatment in both group without significant
	difference. The total effective rate in TCM symptoms improved and showing
	significant difference of better in treatment group. FBG, 2hPBG and HbA1c

		11 1 4	T. DM ALIO: 11 11:11/TO TO 10: 0	
		,	group. The BMI, AUCi, blood lipid (TC, TG, LDL-C,	
	HDL-C) level in treatment group significantly improved compared to control group.			
	Measured blood routine examination, liver and kidney function before and after			
	treatment and no abnormal was observed. 16 case in control group had bloating and			
	diarrhoea and was under control without any impact on study. No adverse effects			
	observed in treatment group.			
	Outcomes were assessed at baseline and trial completion			
Study details	Duration of intervention: 6 months			
	Duration of Fo	llow-up: 3 mont	h	
	Run-in period:	not described		
Stated aim of	"To observe th	e clinical efficac	y on type 2 diabetes treated with professor FAN Guan-	
study	jie's experienced prescription of Chinese medicine."			
Risk of bias				
Bias		Authors	Support for judgement	
		judgement		
Random sequence generation		low risk	It mentioned in the trial that "patients were randomly	
(selection bias)			divided into control group and treatment group by	
			random number table"	
Allocation concealment		low risk	It mentioned in the trial that "patients were randomly	
(selection bias)			divided into control group and treatment group by	
			random number table"	
Blinding of participants and		Unclear risk	The information was not reported in this study	
personnel (performance bias)				
All outcomes				
Blinding of outco	ome	Unclear risk	The information was not reported in this study	
assessment (de	assessment (detection bias)			
All outcomes				
Incomplete outcome data		Low risk	No exclusion or losses were reported, but the	
(attrition bias)			number of participants remained the same at the	
All outcomes	, ,		endpoint of study	
Selection reporting (reporting		Unclear risk	The protocol of the trial was not available, so the	
bias)			possibility of selection outcome reporting could not	
			be examined by the review authors	
		1		

Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on general backgrounds of
		sex, age and disease course. Other aspects of bias
		were unclear.

Ye RQ 2014

Effect of Jianpi Zengmin Decoction on Insulin Resistance in Type 2 Diabetes Mellitus

Methods	Randomised controlled clinical trial of Chinese herbal medicine compared with other
	pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=100
	Inclusion criteria: T2DM WHO 1999, HOMA-IR≥2.8; TCM diagnostic criteria China
	2002, obesity diagnostic criteria China 1997; age: 20-70 year, informed consent with
	the study and can complete the treatment, observation and examinations.
	Exclusion criteria: type 1 diabetes or other kinds of diabetes and pregnant diabetes;
	combine with acute diabetes complication; have severe heart, kidney and liver etc.
	complications, severe hypertension or combine other severe primary disease;
	pregnancy or breastfeeding, psychosis and potential allergy to the study drug; cannot
	comply with prescription, diet and exercise therapy and affect the treatment
Interventions	Number of study centres: 1
	Location: China
	Setting: outpatients in TCM hospital
	Intervention:
	Basic treatment: diet therapy, exercise therapy and same type of hypoglycemic drug
	(apart from metformin etc. which may have relative allergy ingredients as the study
	herb)
	Treatment group: basic therapy + TCM prescription Jianpi Zengmin decoction
	(Dangshen, Fuling, Baizhu, Fabanxia, Chenpi, Huangqi, Danshen, Shanyao, Gegen,
	Shanzha, Chishao, Zhigancao)
	Control group: basic therapy + metformin hydrochloride

Outcomes The total effective rate was 90% in treatment group with significant difference compare to 70% in control group. HOMA-IR, BMI, TG, CHOL, FBG and 2hPG	
reduced significantly in both group. The difference of HOMA-IR and TG levels in	
treatment group compare to control group was statistically significant.	
No information was reported in terms to adverse effect in this study	
Outcomes were assessed at baseline and trial completion	
Study details Duration of intervention: 8 weeks	
Duration of Follow-up: not reported	
Run-in period: not described	
Stated aim of "To observe the effect of Jianpi Zengmin decoction on insulin resistance in type 2	
study diabetes."	
Risk of bias	
Bias Authors Support for judgement	
judgement	
Random sequence generation unclear risk It only mentioned in the trial that "patients were	
(selection bias) randomly divided into treatment group and contro	
group"	
Allocation concealment unclear risk It only mentioned in the trial that "patients were	
(selection bias) randomly divided into treatment group and control	l
group"	
Blinding of participants and Unclear risk The information was not reported in this study	
personnel (performance bias)	
All outcomes	
Blinding of outcome Unclear risk The information was not reported in this study	
assessment (detection bias)	
All outcomes	
Incomplete outcome data Low risk No exclusion or losses were reported, but the	
(attrition bias) number of participants remained the same at the	
All outcomes endpoint of study	
Selection reporting (reporting Unclear risk The protocol of the trial was not available, so the	
bias) possibility of selection outcome reporting could r	ot
be examined by the review authors	

Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on general backgrounds.
		Other aspects of bias were unclear.

Ma CL 2015

Therapeutic Effect of Middle-warming and Spleen-strengthening and Kidney-tonifying therapy for Type 2 Diabetes Mellitus

Methods	Randomised controlled clinical trial of Chinese herbal medicine compared with other
Methous	· ·
	pharmaceuticals alone
	Randomisation ratio: 2:1
Participants	Ethnic: Chinese n=99 (Chinese medicine group 66, control group 33)
	Inclusion criteria: T2DM WHO 1999; 7.8mmol/L≤FBG≤13.9mmol/L and/or
	11.1mmol/L≤2hPBG≤25mmol/L; FINS≥15mU/mL; have done dietary and exercise
	therapy for 2 weeks; age: 30-70 y
	Exclusion criteria: acute stress status like severe infection; severe liver and kidney
	dysfunction
Interventions	Number of study centres: 1
	Location: China
	Setting: outpatients and inpatients in TCM hospital
	Intervention: diet and weight control plan
	Chinese medicine group: TCM prescription: middle-warming, spleen-strengthening
	and kidney-tonifying (Shu Fuzi, Sheng Huangqi, Ganjiang, Zhigancao, Hongshen,
	Rougui, Baizhu, Yunling, Shu Dihuang, Shanyurou, Huaishanyao, Wuzhuyu,
	Danggui, Zhuyizang)
	Control group: metformin tablet oral intake
Outcomes	After treatment, insulin sensitivity index and HDL-C were improved and FBG, 2hPG,
	HbA1c, TG, FINS, BMI decreased in the Chinese medicine group. The effect on
	lowering TG, FINS, BMI and improving efficacy of ISI, HDL-C was better in Chinese
	medicine group than that in control group with statistically significant.

	No examination	n reported in terr	ms to adverse effect in this study. It only mentioned in
	the discussion that no complication or adverse effects were observed in Chinese		
	medicine group.		
	Outcomes were assessed at baseline and trial completion		
Study details	Duration of intervention: 8 weeks		
	Duration of Follow-up: not reported		
	Run-in period: 2 weeks		
Stated aim of	"To observe the effect of middle-warming, spleen-strengthening and kidney-tonifying		
study			ulating blood lipid, increasing insulin sensitivity and
,	, ,		n type 2 diabetes mellitus patients."
Risk of bias			<u>· · · · · · · · · · · · · · · · · · · </u>
Bias		Authors	Support for judgement
		judgement	
Random sequence generation		low risk	It mentioned in the trial that "patients were divided
(selection bias)			into Chinese medicine group and control group by
			random number table method"
Allocation concealment		low risk	It mentioned in the trial that "patients were divided
(selection bias)			into Chinese medicine group and control group by
			random number table method"
Blinding of participants and		Unclear risk	The information was not reported in this study
personnel (performance bias)			
All outcomes			
Blinding of outcome		Unclear risk	The information was not reported in this study
assessment (detection bias)			
All outcomes			
Incomplete outco	ome data	Low risk	Exclusion or losses were reported before the
(attrition bias)			intervention, and the number of participants
All outcomes			remained the same at the endpoint of study
Selection reporting (reporting		Unclear risk	The protocol of the trial was not available, so the
bias)			possibility of selection outcome reporting could not
			be examined by the review authors
Other bias		Unclear risk	The intervention groups were comparable, as it
			mentioned in the trial "no significant difference was

found between groups on clinical backgrounds.
Other aspects of bias were unclear.

Zhu HY 2012

The Chinese Medicine Syndrome Differentiation Treatment of Type 2 Diabetes with Insulin Resistance

Methods	Dandamiand controlled clinical trial of Chinago barbal madicine compared with other
ivietrious	Randomised controlled clinical trial of Chinese herbal medicine compared with other
	pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=80
	Inclusion criteria: T2DM WHO 1999 with insulin resistance, TCM differentiation China
	2004: yin deficiency with excess heat, qi and yin deficiency, yin and yang deficiency
	Exclusion criteria: combine with ketoacidosis, hyperosmolar coma, severe infection
	and other acute complications, or severe heart failure and other severe primary
	disease; heart rate increase no more than 30% after daily continuous exercise for
	half hour; secondary diabetes, psychosis; use insulin treatment
Interventions	Number of study centres: 1
	Location: China
	Setting: patients in TCM hospital
	Intervention:
	Observation group: TCM syndrome differentiation treatment (Sheng Dihuang,
	Maidong, Niuxi, Zhimu and Shigao for yin deficiency with excess heat; Taizishen,
	Huangqi, Huaishanyao, Xuanshen, Maidong, Shanzhuyu for Qi and Yin deficiency;
	Gan Dihuang, Shanyao, Shanzhuyu, Zexie, Fuling, Mudanpi, Paofuzi for Yin Yang
	deficiency)
	Control group: topiramate glibenclamide ketone
Outcomes	Compared with the control group, the fasting insulin (Fins) and pancreatic β cell
	function index (Homa-IS) increased and the total efficacy was improved in
	observation group with statistically significant.
	No information was reported in terms to adverse effect in this study
	Outcomes were assessed at baseline and trial completion
Study details	Duration of intervention: 8 weeks

	Duration of Fo	llow-up: not rep	orted	
	Run-in period: not described			
Stated aim of	"To study the Chinese medicine syndrome differentiation treatment of type 2			
study	diabetes with insulin resistance."			
Risk of bias	Risk of bias			
Bias		Authors	Support for judgement	
		judgement		
Random sequer	nce generation	low risk	It mentioned in the trial that "patients were divided	
(selection bias)			into control group and observation group by random	
			number table method"	
Allocation conce	alment	low risk	It mentioned in the trial that "patients were divided	
(selection bias)			into control group and observation group by random	
			number table method"	
Blinding of partic	Blinding of participants and		The information was not reported in this study	
personnel (performance bias)				
All outcomes				
Blinding of outco	Blinding of outcome		The information was not reported in this study	
assessment (detection bias)				
All outcomes				
Incomplete outco	ome data	Low risk	No exclusion or losses were reported, but the	
(attrition bias)			number of participants remained the same at the	
All outcomes			endpoint of study	
Selection reporti	ing (reporting	Unclear risk	The protocol of the trial was not available, so the	
bias)			possibility of selection outcome reporting could not	
			be examined by the review authors	
Other bias		Unclear risk	The intervention groups were comparable, as it	
			mentioned in the trial "no significant difference was	
			found between groups on general backgrounds.	
			Other aspects of bias were unclear.	

Zheng J 2013

Clinical Study of Qingre Zaoshi Jianpi Traditional Chinese Medicine in the Treatment of Shire Kunpi Syndrome Primary Type Diabetes

pharmaceuticals alone Randomisation ratio: 1:1 Participants Ethnic: Chinese n=82 Inclusion criteria: T2DM WHO 1999, TCM differe			
Participants Ethnic: Chinese n=82			
Inclusion criteria: T2DM WHO 1999, TCM differe			
	physical and psychological		
dampness syndrome primary type 2 diabetes	physical and psychological		
Exclusion criteria: heart, brain and other severe			
disorders; other types diabetes; combine with ke	toacidosis, hypertonic status and		
other diabetes acute complications within one mo	onth		
Interventions Number of study centres: 1			
Location: China			
Setting: outpatients and inpatients in TCM hospit	tal		
Intervention:			
Treatment group: clearing heat and dispelling da	ampness tonifying spleen TCM herb		
formula (Banxia, Cangzhu, Chenpi, Fuling, Huan	formula (Banxia, Cangzhu, Chenpi, Fuling, Huangqin, Huanglian, Xuanshen,		
Ganjiang, Danshen)	Ganjiang, Danshen)		
Control group: metformin hydrochloride tablet	Control group: metformin hydrochloride tablet		
Outcomes The difference of total effective power in two groups	The difference of total effective power in two groups was statistically significant with		
65% in control group and 85.7% in treatment gro	65% in control group and 85.7% in treatment group. FPG, PFG and HbA1c were all		
decreased after treatment and more decrease in	decreased after treatment and more decrease in treatment group with statistical		
significance	significance		
No information was reported in terms to adverse	No information was reported in terms to adverse effect in this study		
Outcomes were assessed at baseline and trial co	Outcomes were assessed at baseline and trial completion		
Study details Duration of intervention: 8 weeks			
Duration of Follow-up: not reported			
Run-in period: not described			
Stated aim of "To observe the clinical curative effect of clearing	"To observe the clinical curative effect of clearing heat and dispelling dampness		
study tonifying spleen traditional Chinese medicine in t	tonifying spleen traditional Chinese medicine in the treatment of heat and dampness		
syndrome primary type 2 diabetes."	syndrome primary type 2 diabetes."		
Risk of bias			
Bias Authors Support for judg	gement		
judgement			

Random sequence generation	low risk	It mentioned in the trial that "patients were divided
(selection bias)		into treatment group and control group according to
		random number table method"
Allocation concealment	low risk	It mentioned in the trial that "patients were divided
(selection bias)		into treatment group and control group according to
		random number table method"
Blinding of participants and	Unclear risk	The information was not reported in this study
personnel (performance bias)		
All outcomes		
Blinding of outcome	Unclear risk	The information was not reported in this study
assessment (detection bias)		
All outcomes		
Incomplete outcome data	Low risk	No exclusion or losses were reported, but the
(attrition bias)		number of participants remained the same at the
All outcomes		endpoint of study
Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)		possibility of selection outcome reporting could not
		be examined by the review authors
Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on general backgrounds of
		sex, age and disease course. Other aspects of bias
		were unclear.

Zhou C 2013

Clinical Curative Effect Observation on TCM Treatment in Different Time of 317 Incident Cases of Type 2 Diabetes

Methods	Randomised controlled clinical trial of Chinese herbal medicine compared with other
	pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=317

	Inclusion criteria: T2DM WHO 1999, new-onset of type 2 diabetes and have never		
	used medicine before; have diabetes education, reasonable exercise and diet, active		
	coordination with the treatment and adhere to treatment for 2 months		
	Exclusion criteria: severe complication such as ketoacidosis, hepatitis, TB, severe		
	infection and so on.		
Interventions	Number of stud	ly centres: 1	
	Location: China	а	
	Setting: outpati	ents and inpatie	nts in TCM hospital
	Intervention: di	abetes educatio	n, reasonable exercise and diet
	Treatment grou	up: TCM formula	of hypoglycemic by regulate qi benefit spleen and
	reinforce kidne	y (Yipijiangtang	wan: Shanyao, Baizhu, Jineijin, Sharen, Yunling,
	Wumei, Zexie,	Peilan, Heye; Ti	aoqijiangtangwan: Chaihu, Yujin, Jiangchan,
	Nuzhenzi, Wuv	veizi, Huangqi, N	Naidong, Xiyangshen, Huangqin, Banxia;
	Tangshenkang	wan: Fuzi, Shan	zhuyu, Sheng Dihuang, Xinyangshen, Bajitian,
	Taoren, Hongh	nua, Yinyanghuo	, Mugua)
	Control group: metformin		
Outcomes	The curative effect and clinical symptoms, blood fat and islet function improvement		
	(FPG, 2hPG, TC, TG, HDL-C, INS, C peptide, GLU) in treatment group were		
	statistically significant compared with control group.		
	No information was reported in terms to adverse effect in this study		
	Outcomes were assessed at baseline and trial completion		
Study details	Duration of intervention: 3 months		
	Duration of Fol	low-up: not repo	orted
	Run-in period: not described		
Stated aim of	"To observe the curative effect of traditional Chinese medicine on treating new-onset		
study	type 2 diabetes."		
Risk of bias			
Bias		Authors	Support for judgement
		judgement	
Random sequer	nce generation	unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into treatment group and control
			group"
			1

Allocation concealment	unclear risk	It only mentioned in the trial that "patients were
(selection bias)		randomly divided into treatment group and control
		group"
Blinding of participants and	Unclear risk	The information was not reported in this study
personnel (performance bias)		
All outcomes		
Blinding of outcome	Unclear risk	The information was not reported in this study
assessment (detection bias)		
All outcomes		
Incomplete outcome data	Low risk	No exclusion or losses were reported, but the
(attrition bias)		number of participants remained the same at the
All outcomes		endpoint of study
Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)		possibility of selection outcome reporting could not
		be examined by the review authors
Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on general backgrounds.
		Other aspects of bias were unclear.

Du LK 2014

Mechanism of improving insulin resistance in type 2 diabetes with the method of supplementing qi and nourishing Yin, removing phlegm to resolve blood stasis

Methods	Randomised controlled clinical trial of Chinese herbal medicine compared with other
	pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=80
	Inclusion criteria: T2DM WHO 1999, IR China Li XJ 2001. TCM differentiation, China
	2002: spleen qi deficiency with phlegm obstructing
	Exclusion criteria: not described
Interventions	Number of study centres: 1
	Location: China

etting: inpatie	nts and outpatien	ts in TCM hospital
Intervention:		
Basic treatment: dietary and exercise therapy, hypertension and regulating lipid		
treatment		
Treatment group: basic treatment + TCM formula of supplementing qi and nourishing		
Yin, removing phlegm to resolve blood stasis (Huangqi, Renshen, Danshen,		
		,
·		
•		
	•	significantly improved blood lipid level (TC, TG, LDL-
•	exes were superio	or to those in control group with statistically
•		anne de adoran a ffectivativa de la catala
	•	·
		<u>'</u>
Duration of intervention: 8 weeks		
Duration of Follow-up: not reported		
Run-in period: not described		
"To discuss the possible mechanism of improving insulin resistance in		
Type 2 diabetes mellitus with the method of supplementing qi and nourishing Yin,		
removing phlegm to resolve blood stasis."		
	Authors	Support for judgement
	judgement	
generation	unclear risk	It only mentioned in the trial that "patients were
		randomly divided into treatment group and control
		group"
ment	unclear risk	It only mentioned in the trial that "patients were
(selection bias)		randomly divided into treatment group and control
		group"
ants and	Unclear risk	The information was not reported in this study
personnel (performance bias)		
′ 1		
	ntervention: lasic treatment leatment leatment grou lin, removing luangjin, Chis control group: he treatment lith statistically lesistance; the lith and the inde lignificance. lo information lutcomes were luration of inte luration of Fol lun-in period: lo discuss the lype 2 diabete lemoving phlese lemoving phlese ment	reasic treatment: dietary and executive eatment group: basic treatment group; basic treatment group; basic treatment group; basic treatment + the treatment group improved The existance; the treatment group improved The existance; the treatment group; and the indexes were superior ignificance. So information was reported in the follow-up: not report extraction of intervention: 8 weeks the possible mechanisty of the existance of the possible mechanisty of the possible mechanism of the po

Blinding of outcome	Unclear risk	The information was not reported in this study
assessment (detection bias)		
All outcomes		
Incomplete outcome data	Low risk	No exclusion or losses were reported, but the
(attrition bias)		number of participants remained the same at the
All outcomes		endpoint of study
Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)		possibility of selection outcome reporting could not
		be examined by the review authors
Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on general backgrounds of
		sex, age and disease course. Other aspects of
		bias were unclear.

Guan Y 2015

Clinical efficacy of spleen-strengthening, heat-clearing and turbidity-eliminating therapy in treatment of insulin resistance type 2 diabetes

Methods	Randomised controlled clinical trial of Chinese herbal medicine compared with other
	pharmaceuticals alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=62
	Inclusion criteria: T2DM WHO 2007; Obesity international obesity organisation 2000,
	BMI≥25kg/m²; insulin resistance China 2007; TCM differentiation China 2002: spleen
	deficiency with dampness excess and phlegm-heat with internal depression; age: 40-
	70 year.
	Exclusion criteria: not described
Interventions	Number of study centres: 1
	Location: China
	Setting: outpatients or inpatients in TCM university hospital
	Intervention:

	Basic treatment: diabetes prevention and treatment education, diet and exercise		
	control		
	Treatment group: basic treatment + TCM formula of spleen-strengthening, heat-		
	clearing and turbidity-eliminating therapy (Fuling, Shanyao, ChaoYiyiren,		
	ChaoBaizhu, Cangzhu, Sharen, Chaozhizi, Juhong, DanJuye, Guijianyu, Heye,		
	Sangye)		
	Control group:	basic treatment	+ metformin enteric-coated tablet
Outcomes	There was a si	gnificant differer	nce in overall response rate between the treatment
	group and the	control group (8	7.5% vs 53.33%, P<0.01). After treatment, both
	groups showe	d significant impi	rovement in FBG, 2hPG, FINS, IRI, TC, and TG
	(P<0.01 or P<0	0.05), and the tre	eatment group showed significant improvements in
	2hPG, TC and	APN than the co	ontrol group (P<0.01 or P<0.05).
	No information	was reported in	terms to adverse effect in this study
	Outcomes wer	e assessed at b	aseline and trial completion
Study details	Duration of intervention: 8 weeks		
	Duration of Follow-up: not reported		
	Run-in period: not described		
Stated aim of	"To observe the clinical efficacy of spleen-strengthening, heat-clearing and turbidity-		
study	eliminating therapy in treating obese patients with type 2 diabetes and insulin		
	resistance."		
Risk of bias			
Bias		Authors	Support for judgement
		judgement	
Random sequer	nce generation	unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into treatment group and control
			group"
Allocation concealment		unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into treatment group and control
			group"
Blinding of partic	Blinding of participants and		No detail information reported in this study, and only
personnel (performance bias)			mentioned it was single-blinded trial.
All outcomes			

Blinding of outcome	Unclear risk	No detail information reported in this study, and only
assessment (detection bias)		mentioned it was single-blinded trial.
All outcomes		
Incomplete outcome data	Low risk	No exclusion or losses were reported, but the
(attrition bias)		number of participants remained the same at the
All outcomes		endpoint of study
Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)		possibility of selection outcome reporting could not
		be examined by the review authors
Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on general backgrounds of
		sex, age and disease course. Other aspects of bias
		were unclear.

Yu DQ 2004

Effect and security of traditional Chinese medicine prescription on urine albumin excreting rate type 2 diabetes

Methods	Randomised controlled clinical trial of Chinese herbal medicine compared with
	placebo
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=71
	Inclusion criteria: T2DM WHO 1999; age: 45-75year; course of diabetes over 3
	months and blood sugar is stable in recent 2 month
	Exclusion criteria: type 1 diabetes or special type of diabetes or combine acute
	diabetic complication and acute or chronic infection; pregnancy or breastfeeding;
	ALT≥113U/L; Cr≥170µmol/L, have history of other chronic renal disease before; had
	malignant tumour before; combine other severe disease, cannot follow up on time;
	have used ACEI or ARB medicine within 1 month
Interventions	Number of study centres: 1
	Location: China
	Setting: outpatients in university hospital

	Intervention: b	oth groups have	diet control, hypoglycemia, hypo tension and hypo
	lipid treatment		
	Treatment grou	up: TCM prescrip	otion of clearing heat and detoxicating, promoting
	blood circulation	on and removing	blood stasis (Huangqi, Baihuasheshecao, Banzhilian,
	Baizhu etc.)		
	control group: placebo		
Outcomes	Albumin excre	ting rate (UAER)	, microcirculation nail bed flow, HbA1c, FBG, 2hPG,
	TC, TG, HDL-c	, LDL-c, Apo-a,	Apo-b and BMI were measured. At the end of trial, the
	treatment grou	p showed decre	ase of UAER level with P=0.000.
	Measured Live	er, kidney functio	n and routine blood test before and after the
	treatment, no a	abnormal observ	red.
	Adverse effect	s observed. Two	cases in treatment group and four cases in control
	group had adv	erse effects of st	tomach and they are tolerable.
	Outcomes wer	e assessed at b	aseline and trial completion
Study details	Duration of inte	ervention: 24 we	eks
	Duration of Follow-up: 4, 8, 12, 16, 20, and 24 weeks after treatment		
	Run-in period: not described		
Stated aim of	"To evaluate the effect and safety of traditional Chinese medicine prescription on		
study	urine albumin excreting rate of type 2 diabetes."		
Risk of bias			
Bias		Authors	Support for judgement
		judgement	
Random sequer	nce generation	unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into treatment group and control
			group"
Allocation conce	Allocation concealment		It only mentioned in the trial that "patients were
(selection bias)	(selection bias)		randomly divided into treatment group and control
			group"
Blinding of participants and		Unclear risk	No detail information reported in this study, and only
personnel (performance bias)			mentioned it was single-blinded trial.
All outcomes			
Blinding of outcome		Unclear risk	No detail information reported in this study, and only
assessment (de	tection bias)		mentioned it was single-blinded trial.

All outcomes		
Incomplete outcome data	Low risk	11 losses were reported (5 in treatment group 6 in
(attrition bias)		control group) with similar reasons for missing data
All outcomes		across groups
Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)		possibility of selection outcome reporting could not
		be examined by the review authors
Other bias	Unclear risk	No information reported in the trial about general
		backgrounds of study groups. Other aspects of bias
		were unclear.

Wang SH 2014

A randomized, double-blinded, multicentre clinical trial for Tangke Soft Capsules in the treatment of Type 2 diabetes

Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
Modiodo	· ·
	+ other pharmaceuticals) compared with placebo alone
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=200
	Inclusion criteria: T2DM China 2007, FPG≥7.0mmol/L, or 2hPG≥11.1mmol/L; or
	random blood sugar≥11.1mmol/L; TCM differentiation China 2002: Qi and Yin
	deficiency; diabetes for over 3 months; have done diet control and/or exercise
	therapy, or oral intake hypoglycemic western medicine besides diet control and
	exercise therapy, and condition is stable for over 2 months but blood sugar is still
	under the normal: 7.0mmol/L ≤FPG≤13.3mmol/L, or
	11.1mmol/L≤2hPG≤22.9mmol/L; age: 18-70 years old; informed and signed consent
	Exclusion criteria: pregnant or breast-feeding woman, patients with severe
	complications on heart, brain, liver and kidney or combine with other severe primary
	diseases, psychotic; sensitivity patients; patients with ketosis and associated
	infections within one month; ALT 1.5 time over than normal; Cr over than normal;
	can't take medicine based on prescription; current attending other clinical trial
Interventions	Number of study centres: multicentre (5)
	Location: China

	Cotting: outpot	ionto and innatio	nto in five TCM university been ital	
	Setting: outpatients and inpatients in five TCM university hospital			
	Intervention: basic treatment: hypoglycemia agents, exercise and dietary therapy			
	Treated group: basic treatment plus TCM medicine: Tangke soft Capsules (Wuweizi)			
	Control group use basic treatment plus placebo soft capsules			
Outcomes	Observed FBG, 2hBG, TCM pattern changes, ECG and adverse events monitor of			
	function of liver and kidney, blood and urine, safety problems. Compared with the			
	baseline, the level of HbA1C, FPG and 2h PG after treatment in the Tangke group			
	decreased significantly (P<0.01), but no markedly compared with placebo group. So			
	was for FPG. There was a significant difference in the drop of 2hPG between Tangke			
	and placebo group (P=0.044).			
	No serious adverse events and hypoglycemic episodes observed in both intervention			
	groups.			
	Outcomes were assessed at baseline and trial completion			
Study details	Duration of intervention: 12 weeks			
	Duration of Follow-up: not reported			
	Run-in period:	none		
Stated aim of	"To evaluate the efficacy and safety of Tangke Soft Capsules (extract of Schisandrae			
study	chinensis Fructus) for the treatment of Type 2 diabetes."			
Risk of bias				
Bias		Authors	Support for judgement	
		judgement		
Random sequence generation		unclear risk	It only mentioned that the trial was randomised in	
(selection bias)			two treatment groups	
Allocation concealment		unclear risk	It only mentioned that the trial was randomised in	
(selection bias)			two treatment groups	
Blinding of participants and		low risk	It mentioned double-blinded, placebo-controlled	
personnel (performance bias)			clinical trial	
All outcomes				
Blinding of outcome		low risk	It mentioned double-blinded, placebo-controlled	
assessment (detection bias)			clinical trial	
All outcomes				
		<u> </u>		

Incomplete outcome data	Low risk	19 losses were reported with 9.5% general lost rate
(attrition bias)		at the endpoint of study with balanced missing
All outcomes		outcome data in numbers across intervention groups
Selection reporting (reporting	Unclear risk	The protocol of the trial was not available, so the
bias)		possibility of selection outcome reporting could not
		be examined by the review authors
Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on baseline data of age, body
		lengths, BMI, disease course and medical
		conditions. Other aspects of bias were unclear

Chao ML 2009

Improving insulin resistance with traditional Chinese medicine in type 2 diabetes patients

Methods	Parallel randomised double-blinded, placebo-controlled, clinical trial of Chinese
	herbal medicine compared with placebo
	Randomisation ratio: 1:1
Participants	Ethnic: Chinese n=43
	Inclusion criteria: newly diagnosed T2DM WHO 1999, FPG≥7mmol/L and/or OGTT
	2h≥11.1mmol/L; age range: 18-70 years; overweight with BMI 23-35 kg/m² and with
	poor glucose level after a 1-month diet control, two FPG concentrations between 7-
	10 mmol/L within a month
	Exclusion criteria: had used any antidiabetic drugs; with health problems of cardiac,
	hepatic, renal, other chronic diseases, or acute diabetic complications including
	diabetic ketoacidosis or hyperosmolar hyperglycemic non-ketotic coma, as
	determined by history, examination and routine blood chemistry; women of
	childbearing age were pregnant or planning for pregnancy
Interventions	Number of study centres: 2
	Location: China
	Setting: patients in university affiliated hospital
	Intervention: diet and exercise advise

	TCM group:	TCM prescriptio	n: compound powder form with 50 mag of Coptis
	chinensis, 30)mg of Astragalu	s mambranesceus and 120mg of Loniceral japonica
	Placebo group: placebo in indistinguishable tablets		
Outcomes	BMI, waist-hip, SBP, DBP, FPG, PPG, HbA1c, TG, TC, HDL, LDL, INS0, INS120,		
	GDR, CRP, I	L-6, RBP4, adip	onectin, ALT were assessed at baseline and trial
	completion		
	Glucose disp	oosal rate in the	TCM group was significantly improved as compared to
	that in the pla	acebo group (P<	<0.05)
	Assessed Re	enal and hepatic	function, blood counts at baseline and the end of the
	study for safe	ety purpose. On	ly mild adverse symptoms observed for 5 cases and the
	frequency of	side effects was	s not significantly different between the two groups. No
	severe side	effect occurred o	during the study; no episode of hypoglycemia reported.
Study details	Duration of ir	ntervention: 3 mo	onths
	Duration of F	ollow-up: not re	eported
	Run-in perio	Run-in period: 2 weeks	
Stated aim of	"To evaluate	the efficacy of T	CM on insulin sensitivity and other related metabolic
study	factors in type 2 diabetes patients."		tients."
Risk of bias			
Bias		Authors	Support for judgement
		judgement	
Random sequer	nce	low risk	It mentioned in the trial that "randomization was
generation (sele	ction bias)		performed centrally and was concealed and stratified
			in blocks of four"
Allocation conce	alment	low risk	It mentioned in the trial that "randomization was
(selection bias)			performed centrally and was concealed and stratified
			in blocks of four"
Blinding of participants and		low risk	Double-blinded and placebo-controlled
personnel (perfo	personnel (performance bias)		
All outcomes			
Blinding of outco	me	low risk	Double-blinded and placebo-controlled
assessment (detection bias)			
All outcomes			

Incomplete outcome data	Low risk	Only 2 patients in TCM group early stopped.
(attrition bias)		
All outcomes		
Selection reporting (reporting	low risk	The protocol of the trial was clear, so the possibility of
bias)		selection outcome reporting could be examined by the
		review authors
Other bias	Unclear risk	The intervention groups were comparable, as it listed
		comparison of clinical characteristics between two
		groups and no significant difference found. Other
		aspects of bias were unclear

Tong XL 2013

The safety and effectiveness of TM81, a Chinese herbal medicine, in the treatment of type 2 diabetes: a randomised double-blind placebo-controlled trial

Methods	Parallel randomised large-scale, placebo-controlled, clinical trial of Chinese herbal
	medicine compared with placebo
	Randomisation ratio: 3:1
Participants	Ethnic: Chinese n=480 (TM81 group 360, placebo group 120)
	Inclusion criteria: T2DM early-stage WHO 1999, 30-65 years old, BMI ≥ 24kg/m².
	After the initial screening, subjects entered a 2-week run-in period with diet control
	and programmed daily exercise. Then subjects still with HbA1C ≥7.0% and FPG
	level between 7.0 and 13.9mM or 2hPG>11.1mM were enrolled. A consent form was
	signed by all subjects prior to enrolment
	Exclusion criteria: have been treated for diabetes for > 1 month by conventional
	medications, physical therapy, psychological therapy, herbal medicine or dietary
	supplements; have been treated with antidiabetic drugs 3 weeks prior to screening;
	have had diabetic ketoacidosis or serious infections within 1 month; have
	uncontrolled hypertension; pregnant females, or those planning to be pregnant;
	breast feeding; have hepatic and renal dysfunctions, pulmonary function
	insufficiency, cardiac failure, acute myocardial infarction and other serious diseases;
	have severe chronic diabetic complications; chronic gastrointestinal diseases, or that
	are generally not healthy; allergic to Chinese herbal medicines; have mental

	disorders; on-going allergic symptoms; participating in other clinical trials or prior
	participation in TM81 trials; alcoholism, taking antipsychotic agents or substance
	abuse or dependence; have factors that may affect trial execution based on
	investigator's judgement, such as changeable working and living environments that
	may lead to withdrawal from the trial; have unstable antihypertension effects during
	drug administration; or taking weight-loss medicines
Interventions	Number of study centres: 10
	Location: China
	Setting: patients in university affiliated hospital
	Intervention: both groups have diet control and programmed daily exercise
	TM81 group: TM81 (Tang-Min-Ling-Wan) formula: quantitative control limits raw
	herbs of Rhizoma Coptidis, Radix Paeoniae Alba, radix Scutellariae, Pericarpium
	Cirtri Reticulatae, Rhizoma Rhei and other Chinese herbs
	Placebo group: placebo capsulated in similar packing, appearance, shape, size and
	colour with TM81 capsule
Outcomes	After treatment, the decrease of HbA1C, FPG and PG is statistically significant in
	TM81 group compared to placebo group. The TM81 was more effective for patients
	with higher baseline HbA1C levels. The TM81 group also showed improved β-cell
	function and increased homeostatic model assessment. Body weight, BMI and waist
	circumstance of subjects in TM81 group reduced and the symptoms related to
	diabetes were improved.
	During the trial, there were no medium or serious adverse events reported. 24 mild
	adverse events reported in the TM81 group versus 7 mild adverse events reported in
	the placebo group. There was one case with abdominal cramping and diarrhoea that
	disappeared shortly without treatment. No abnormal ECG, hepatic functions or rental
	functions observed at week 12. There were no significant differences in the types and
	frequency of adverse reactions between two groups.
	Outcomes were assessed at baseline and trial completion
Study details	Duration of intervention: 12 weeks
	Duration of Follow-up: week 0. Week 4, week 8 and week 12
	Run-in period: 2 weeks
Stated aim of	"To evaluate the safety and effectiveness of TM81 in the treatment of type 2 diabetes
study	patients."
	1

Risk of bias		
Bias	Authors	Support for judgement
	judgement	
Random sequence	low risk	It mentioned in the trial "randomization and blinding
generation (selection bias)		were conducted by personnel who did not participate in
		data acquisition and evaluation. A computer program
		used to generate the subject assignment. Each subject
		was given a unique number and this number was used
		throughout the trial."
Allocation concealment	low risk	It mentioned in the trial "randomization and blinding
(selection bias)		were conducted by personnel who did not participate in
		data acquisition and evaluation. A computer program
		used to generate the subject assignment. Each subject
		was given a unique number and this number was used
		throughout the trial."
Blinding of participants and	low risk	All investigators blinded from the study drug
personnel (performance bias)		assignment, in which only a randomization code
All outcomes		disclosed. Unblinding was conducted only after all study
		data were collected
Blinding of outcome	low risk	All investigators blinded from the study drug
assessment (detection bias)		assignment, in which only a randomization code
All outcomes		disclosed. Unblinding was conducted only after all study
		data were collected
Incomplete outcome data	Low risk	68 subjects in the TM81 group and 13 subjects in the
(attrition bias)		placebo group dropped out. The proportion of missing
All outcomes		outcomes is 16.88% which is not enough to have a
		clinically relevant impact on the intervention effect
		estimate compared with observed event risk
Selection reporting (reporting	low risk	The protocol of the trial was clear, so the possibility of
bias)		selection outcome reporting could be examined by the
		review authors
Other bias	Unclear risk	The intervention groups were comparable, as it listed
		comparison of baseline data between two groups and

no significant difference found for most of baseline
items apart from HbA1C and 2hPG. Other aspects of
bias were unclear

Deng DQ 2015

Study on Treatment of Reinforcing Spleen and dissipating Dampness and Promoting Blood Circulation (TRDP) on the Function of Pancreatic βCells in Patients with Type 2 Diabetes Mellitus

NA (I - I	
Methods	Randomised controlled clinical trial of combined medicine (Chinese herbal medicine
	+ other pharmaceuticals) compared with other pharmaceuticals alone and Chinese
	herbal medicine alone
	Randomisation ratio: 1:1:1
Participants	Ethnic: Chinese n=90 (30 in each of TCM, western medicine and TCM combined with
	western medicine)
	Inclusion criteria: T2DM WHO 1999; TCM differentiations: spleen deficiency with
	dampness stagnation and blood stasis, blood sugar is still abnormal after dietary and
	exercise therapy, initially occurred T2DM
	Exclusion criteria: type 1 diabetes ketoacidosis or diabetes hypertonic coma, or
	combine with moderate or over hypertension, coronary disease myocardial infarction,
	severe arrhythmia, liver kidney hemopoietic system and other severe complications,
	allergy to the study drugs or have acute hyperglycemia due to other diseases
Interventions	Number of study centres: 1
	Location: China
	Setting: patients in TCM university hospital
	Intervention: dietary control and exercise therapy
	TCM group: strengthen spleen eliminate dampness and move the blood
	Western medicine group: Pioglitazone
	TCM combined with western medicine group: TCM (Cangzhu, Baizhu, Fuling,
	Chenpi, Houpo, Cheqianzi, Zexie, Honghua, Sangshen, huzhang, Guijianyu) +
	Pioglitazone
Outcomes	After treatment, FBG, PBG, HbA1c, FINS, IAI, HOMA-IR, HOMA-β, IL-6, TNF-α of
	three groups decreased significantly than those before treatment (P>0.05). TCM
	2.2.2. g. 2.2. 2.2. 2.3

	combined wes	stern medicine a	roup was more effective than the two other groups
	(P<0.05).	otom modiomo g	roup was more emocave than the two ethor groups
	No information was reported in terms to adverse effect in this study		
	Outcomes were assessed at baseline and trial completion:		
Study details	Duration of intervention: 2 months		
Olday dolano		llow-up: notrep	···
		not described	oned
Ctated aim of	'		Dan Caall function in treatment of tune 2 diabetes
Stated aim of		e ellects of TRDI	P on β cell function in treatment of type 2 diabetes
study	mellitus."		
Risk of bias		T	
Bias		Authors	Support for judgement
		judgement	
Random sequer	nce generation	unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into treatment group and control
			group"
Allocation conce	ealment	unclear risk	It only mentioned in the trial that "patients were
(selection bias)			randomly divided into treatment group and control
			group"
Blinding of participants and		Unclear risk	The information was not reported in this study
personnel (performance bias)			
All outcomes			
Blinding of outcome		Unclear risk	The information was not reported in this study
assessment (detection bias)			
All outcomes	,		
Incomplete outc	ome data	Low risk	No exclusion or losses were reported, but the
(attrition bias)			number of participants remained the same at the
All outcomes			endpoint of study
Selection reporting (reporting		Unclear risk	The protocol of the trial was not available, so the
bias)			possibility of selection outcome reporting could not
			be examined by the review authors
Other bias		Unclear risk	The intervention groups were comparable, as it
			mentioned in the trial "no significant difference was
			found between groups on general backgrounds of
			J - 1 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2

	age, sex and medical conditions. Other aspects of
	bias were unclear

Ge SM 2012

Clinical effect of the "Eight method of Fan's in the treatment of early type 2 diabetes in 30 patients

Mathada	Dandamiand controlled clinical trial of Chinago barbal madicine compared with other
Methods	Randomised controlled clinical trial of Chinese herbal medicine compared with other
	pharmaceuticals alone as well as diet control and exercise therapy
	Randomisation ratio: 1:1:1
Participants	Ethnic: Chinese n=90 (30 in each of TCM treatment group, WM treatment group and
	control group)
	Inclusion criteria, T2DM WHO 1999; early diagnosed T2DM within half year; age≥30
	y; have or not used hypoglycemia treatment with western medicine or insulin; stop
	using western medicine, insulin, TCM or patent TCM for over 2 weeks; cooperate
	with diet and exercise therapy; have no significant life event before and after
	treatment; stable emotion, regular life, diet and exercise are stable.
	Exclusion criteria: not described
Interventions	Number of study centres: 1
	Location: China
	Setting: outpatients in medical university hospital
	Intervention:
	Chinese medicine treatment group: pure TCM treatment with The Eight method of
	Fan's method based on syndrome differentiation (Kidney deficiency: Gouji,
	Chuanduan, Nuzhenzi, Hanliancao; Qi and Yin deficiency: Beiqi, Shengdi, Digupi;
	Liver qi stagnation: Chaihu, Baishao, Bohe, Danpi; Lung Stomach heat: Shigao,
	Zhimu, Gegen, Lianqiao; Fuexcess with constipation: Dahuang, Zhishi, Huomaren;
	Heart spirit lose nourishment: Yejiaoteng, Yuanzhi, Suanzhaoren; Heat into blood
	fen: Danpi, Chishao, Maidong, Yimi, Mianyinchen; Excess dampness restrict spleen:
	Fuling, Chaobaizhu, Fabanxia, Shenqu; add Laifuzi, Zhiqiao, Chuanpu for stomach
	bloat; add Gualoupi, Xiebai for chest depression; Blood stasis: Danshen, Sanleng,
	Ezhu, Zelan)
	Acarbose treatment group: acarbose
	Control group: dietary and exercise therapy

Outcomes	FBG, PBG, HbA1c, TG, CH, Cr, clinical symptoms were measured. The effective				
	rates were 83.5	3% in Chinese n	% in Chinese medicine treatment group and 80% in acarbose		
	treatment group with no significant difference. The effective rates of two groups were				
	higher than tha	higher than that of the control group with statistically significant difference.			
	No information	was reported in	terms to adverse effect in this study		
	Outcomes wer	e assessed at b	aseline and trial completion		
Study details	Duration of inte	ervention: 6 mor	ths		
	Duration of Fo	llow-up: not rep	orted		
	Run-in period:	not described			
Stated aim of	"To observe c	linical effect of 'T	he Eight method of Fan's' to treat type 2 diabetes."		
study					
Risk of bias					
Bias		Authors	Support for judgement		
		judgement			
Random sequer	nce generation	unclear risk	It only mentioned in the trial that "patients were		
(selection bias)			randomly divided into Chinese medicine group, the		
			acarbose treatment group and the control group"		
Allocation concealment		unclear risk	It only mentioned in the trial that "patients were		
(selection bias)			randomly divided into Chinese medicine group, the		
			acarbose treatment group and the control group"		
Blinding of participants and		Unclear risk	No detail information reported in this study, and only		
personnel (performance bias)			mentioned it was single-blinded trial.		
All outcomes					
Blinding of outco	ome	Unclear risk	No detail information reported in this study, and only		
assessment (detection bias)			mentioned it was single-blinded trial.		
All outcomes					
Incomplete outcome data		Low risk	No exclusion or losses were reported, but the		
(attrition bias)			number of participants remained the same at the		
All outcomes			endpoint of study		
Selection reporting (reporting		Unclear risk	The protocol of the trial was not available, so the		
bias)			possibility of selection outcome reporting could not		
			be examined by the review authors		

Other bias	Unclear risk	The intervention groups were comparable, as it
		mentioned in the trial "no significant difference was
		found between groups on general backgrounds of
		sex, age and so on. Other aspects of bias were
		unclear.

 Table 3. Characteristics of excluded studies [ordered by study ID]

	Reason for exclusion
Study	Reason for exclusion
Cao YX 2015	Duration of study 30 days
Deng LN 2007	Duration of study 2 weeks
Zeng YP 2006	Duration of study 2 weeks
Fan GJ 2006	Duration of study 4 weeks
Shi YH 2014	Duration of study 4 weeks
Tong BL 2007	Duration of study 6 weeks
Chen ZQ 2006	Duration of study 4 weeks
Lv WZ 2008	Duration of study 1 month
Yu H 2009	Duration of study 2 weeks
Chen XJ 2010	Duration of study 4 weeks
Wang GL 2012	Duration of study 20 days
Han F 2014	Duration of study 4 weeks
Liu YH 2015	Duration of study 30 days
Tian YH 2010	Duration of study 30 days
Wu WY 2004	Duration of study 4 weeks
Hu MF 2008	Duration of study 45 days
Xu MY 2013	Duration of study 30 days
Hu JG 2013	Duration of study 30 days
Shi J 2011	Duration of study 4 weeks
Tang XY 2012	Duration of study 4 weeks
Wang JS 2008	Duration of study 4 weeks
Guo YQ 2015	Duration of study 30 days
Zhong YZ 2012	Not mention the duration of study

Chen Q 2006	Not mention the duration of study, non-randomised study
Zhu YL 2015	Duration of study 4 weeks, non-randomised study
Liu Y 2014	Duration of study 2 weeks, testing TCM herb extract
Xie XN 2012	Duration of study 4 weeks, combined acupoint injection with TCM herb extract
	therapy
Huang TS 2015	Duration of study 1 month, combined acupoint injection with TCM herb extract
	therapy
Yan YJ 2007	Duration of study 1 month, combined with ear acupuncture treatment
Chen DS 2007	Multiple study centre randomized single-blinded controlled trial, duration of study
	4 weeks
Ning HJ 2015	Non-randomized study, combined with acupuncture and Tui Na treatment
Liu HY 2008	RCT testing TCM herb extract berberine
Gan JR 2012	RCT testing TCM herb extract berberine in treatment of adverse effect caused
	by T2DM drug
Zhao MY 2013	Non-randomized controlled study
Zhang LB 2014	Non-randomized controlled study (pseudo RCT)
Li MH 2011	Non-randomized controlled study (pseudo RCT)
Zhou XL 2013	Non-randomized control study (pseudo RCT)
Ren C 2012	Non-randomized controlled study (pseudo RCT)
Lin ZR 2010	Non-randomized controlled study
Mo JF 2013	Non-randomized concurrent controlled trial
Yu ZF 2011	Non-randomized controlled study
Jin YH 2015	Retrospective randomized controlled study
Chen GH 2006	Case series
Zheng M 2006	RCT compared different herbal medicines
Wang WH 2010	Randomized double blinded controlled trial compared different herbal medicines
Su XY 2015	RCT compared different herbal medicines
He CL 2013	Case series study of carotid artery intima-media thickness and lipid of type 2
	diabetes artery atherosclerosis
Ma RW 2010	RCT study of treating T2DM complication – diabetic macro-vascular disease
Fang ZH 2009	RCT study of impaired blood vessel endothelium in prothrombotic state of T2DM
Sun XZ 2011	RCT study of treating T2DM carotid atherosclerotic plaque
Jiang T 2014	RCT study of treating T2dM with carotid plaques

Peng GH 2015	RCT study of treating T2DM with peripheral neuropathy
Li C 2012	Non-randomized controlled trial study of treating T2DM peripheral neuropathy
Zhang XZ 2014	RCT study of treating peripheral neuropathy in T2DM due to damp-heat flowing
	down
Shu JP 2014	RCT study of treating nerve condition velocity in T2DM peripheral nerve
Shen XR 2015	RCT study of treating T2DM angiopathy
Xiao RR 2013	RCT study of treating T2DM with peripheral neuropathy
Chen Y 2014	RCT study of treating T2DM peripheral neuropathy
Sun YR 2012	RCT study of treating T2DM peripheral neuropathy
Wen ZM 2012	Non-randomized controlled trial study of treating T2DM complication – diabetic
	nephropathy
Xu ZL 2014	RCT study of treating early T2DM nephropathy
Li JW 2013	RCT study of preventing early T2DM nephropathy
Kong LX 2014	RCT study of treating T2DM with membranous nephropathy
Du YB 2011	RCT study of treating early and metaphase T2DM nephropathy
Jiang XY 2005	RCT study of treating late T2DM nephropathy
Feng SH 2015	RCT study of treating elderly T2DM nephropathy
Wei QL 2006	RCT study of early diabetic nephropathy
Miao JY 2013	RCT study of treating T2DM complicated with non-alcoholic steatohepatitis
Xiao FY 2012	RCT study of treating T2DM complicated with non-alcoholic fatty liver disease
Wu LK 2012	RCT study of treating T2DM combined with fatty liver disease
Zou H 2012	RCT study of treating T2DM with fatty liver disease
Wu LK 2011	RCT study of treating fatty liver in T2DM
Meng LW 2015	RCT study of treating T2DM and dyslipidemia
Zhao FH 2012	RCT study of treating T2DM with dyslipidemia and its effect to weight, BMI,
	FBG, P2HBG, HbA1c and blood fat
Zhao X 2012	RCT study of treating T2DM complicated with depression
Jia SQ 2009	RCT study of treating T2DM accompanied by depression
Sui JX 2015	RCT study of prevention of diabetic retinopathy
Zhang M 2010	RCT study of treating obese diabetes eyeground hemorrhage
Huo JJ 2015	RCT study of treating T2DM with hyperuricemia
Lu XR 2013	RCT study of treating T2DM and hypertension
Jiang D 2009	RCT study of treating T2DM complicated with hypertension

Dang ZL 2014 RCT study of treating T2DM complicated with gastroesophageal reflux disease Su H 2008 RCT study of treating T2DM gastroparesis Xu HJ 2014 RCT study of treating T2DM secondary constipation Zhang YD 2009 RCT study of treating constipation in T2DM LJ 2015 RCT study of T2DM cardiovascular disease autonomic neuropathy heart rate variability Shi BD 2015 RCT study of treating T2DM urinary tract infection Guan JT 2014 RCT study of treating T2DM with acute cerebral infarction Shen HH 2013 RCT study of treating T2DM and periodontal disease Li SF 2011 Prospective randomised controlled study of treating chronic diabetic foot ulcers Liu Q 2013 RCT study of treating T2DM by pharmaceuticals with total alkali from morus folium jiangtang capsule Xu J 2008 RCT study of changes in vascular endothelial cell active factors in T2DM and
Xu HJ 2014 RCT study of treating T2DM secondary constipation Zhang YD 2009 RCT study of treating constipation in T2DM LJ 2015 RCT study of T2DM cardiovascular disease autonomic neuropathy heart rate variability Shi BD 2015 RCT study of treating T2DM urinary tract infection Guan JT 2014 RCT study of treating T2DM with acute cerebral infarction Shen HH 2013 RCT study of treating T2DM and periodontal disease Li SF 2011 Prospective randomised controlled study of treating chronic diabetic foot ulcers Liu Q 2013 RCT study of treating T2DM by pharmaceuticals with total alkali from morus folium jiangtang capsule Xu J 2008 RCT study of changes in vascular endothelial cell active factors in T2DM and
Zhang YD 2009 RCT study of treating constipation in T2DM RCT study of T2DM cardiovascular disease autonomic neuropathy heart rate variability Shi BD 2015 RCT study of treating T2DM urinary tract infection Guan JT 2014 RCT study of treating T2DM with acute cerebral infarction Shen HH 2013 RCT study of treating T2DM and periodontal disease Li SF 2011 Prospective randomised controlled study of treating chronic diabetic foot ulcers Liu Q 2013 RCT study of treating T2DM by pharmaceuticals with total alkali from morus folium jiangtang capsule Xu J 2008 RCT study of changes in vascular endothelial cell active factors in T2DM and
LJ 2015 RCT study of T2DM cardiovascular disease autonomic neuropathy heart rate variability Shi BD 2015 RCT study of treating T2DM urinary tract infection Guan JT 2014 RCT study of treating T2DM with acute cerebral infarction Shen HH 2013 RCT study of treating T2DM and periodontal disease Li SF 2011 Prospective randomised controlled study of treating chronic diabetic foot ulcers Liu Q 2013 RCT study of treating T2DM by pharmaceuticals with total alkali from morus folium jiangtang capsule Xu J 2008 RCT study of changes in vascular endothelial cell active factors in T2DM and
Shi BD 2015 RCT study of treating T2DM urinary tract infection Guan JT 2014 RCT study of treating T2DM with acute cerebral infarction Shen HH 2013 RCT study of treating T2DM and periodontal disease Li SF 2011 Prospective randomised controlled study of treating chronic diabetic foot ulcers Liu Q 2013 RCT study of treating T2DM by pharmaceuticals with total alkali from morus folium jiangtang capsule Xu J 2008 RCT study of changes in vascular endothelial cell active factors in T2DM and
Guan JT 2014 RCT study of treating T2DM with acute cerebral infarction Shen HH 2013 RCT study of treating T2DM and periodontal disease Li SF 2011 Prospective randomised controlled study of treating chronic diabetic foot ulcers Liu Q 2013 RCT study of treating T2DM by pharmaceuticals with total alkali from morus folium jiangtang capsule Xu J 2008 RCT study of changes in vascular endothelial cell active factors in T2DM and
Shen HH 2013 RCT study of treating T2DM and periodontal disease Li SF 2011 Prospective randomised controlled study of treating chronic diabetic foot ulcers Liu Q 2013 RCT study of treating T2DM by pharmaceuticals with total alkali from morus folium jiangtang capsule Xu J 2008 RCT study of changes in vascular endothelial cell active factors in T2DM and
Li SF 2011 Prospective randomised controlled study of treating chronic diabetic foot ulcers Liu Q 2013 RCT study of treating T2DM by pharmaceuticals with total alkali from morus folium jiangtang capsule Xu J 2008 RCT study of changes in vascular endothelial cell active factors in T2DM and
Liu Q 2013 RCT study of treating T2DM by pharmaceuticals with total alkali from morus folium jiangtang capsule Xu J 2008 RCT study of changes in vascular endothelial cell active factors in T2DM and
folium jiangtang capsule Xu J 2008 RCT study of changes in vascular endothelial cell active factors in T2DM and
Xu J 2008 RCT study of changes in vascular endothelial cell active factors in T2DM and
g.,,
troating of diabetes complications
treating of diabetes complications
Wang X 2007 RCT study of TCM on inflammatory factor of earlier period T2DM. and the
protocol and drugs of the trial are very similar with one of included studies (Guan
X 2006)
Ye X 2014 RCT study of treating T2DM, but have no mention of treatment method and
intervention medicine.
Li XH 2010 RCT study of treating T2DM, but have no mention of intervention medicine for
control group.
Cai HZ 2015 RCT study of testing TCM herb extract
Qiang G 2015 RCT study of treating T2DM with vascular dementia
Shi G 2015 RCT study of treating T2DM complicated with pulmonary tuberculosis
Li ZQ 2013 RCT study of T2DM treatment with TCM herb, but no details of treating herbs
due to full text is not available
Leung P.C 2012 RCT study of TCM herbal formula treatment for T2DM patients with chronic
ulcers
Fang ZH 2013 RCT study of treating T2DM vascular lesions
Ni Q 2012 RCT study of treating type 2 pre-diabetes
Tian GQ 2008 RCT study of treating T2DM complicated with hyperlipidemia, but no details of
treating herbs due to full text is not available

Zuo GL 2009	RCT study of treating T2DM with atherosclerosis
Uno T 2005	Non-RCT study with study duration I month
Zhang Y 2015	RCT study of treating T2DM with multi-centres and big samples, but won't be
	completed until early-2016 (only available for the letter to the editor)

Table 4. List of Chinese herbal medicines used as treatment for type 2 diabetes

No.	Pharmaceutical name	Botanical name	Chinese Pinyin name
1	Astragali Radix	Astragalus membranaceus (Fisch.) Bge.	Huangqi
2	Rehmanniae Radix	Rehmannia glutinosa Libosch.	Shengdihuang
3	Rehmanniae Radix Praeparata	Rehmannia glutinosa Libosch.	Shudihuang
4	Salviae Miltiorrhizae Radix et Rhizoma	Salvia miltiorrhiza Bge.	Danshen
5	Achyranthis Bidentatae Radix	Achyranthes bidentata Bl.	Niuxi
6	Paeoniae Rubra Radix	Paeonia lactiflora Pall.	Chishao
7	Coptidis Rhizoma	Coptis chinensis Franch.	Huanglian
8	Polygonati Rhizoma	Polygonatum sibiricum Red.	Huangjing
9	Puerariae Radix	Pueraria lobata (Willd.) Ohwi	Gegen
10	Epimedii Folium	Epimedium brevicornu Maxim.	Yinyanghuo
11	Talcum	Magnesium Silicate	Hua Shi Fen
12	Artemisiae Scopariae Herba	Artemisia capillaris Thunb.	Yinchen
13	Scutellariae Radix	Scutellaria baicalensis Georgi	Huangqin
14	Acori Tatarinowii Rhizoma	Acorus tatarinowii Schott; Acorus gramineus Soland.	Shichangpu
15	Agastaches Herba	Agastache rugosa (Fisch & Mey.) O. Ktxe.	Huoxiang
16	Fritillariae Cirrhosae Bulbus	Fritillaria cirrhosa D. Don	Chuanbeimu
17	Forsythiae Fructus	Forsythia suspensa (Thunb.) Vahl	Lianqiao
18	Coicis Semen	Coix lacryma-jobi L. var. mayuen (Roman.) Stapf	Yiyiren

19	Dioscoreae Rhizoma	Dioscorea opposita Thunb.	Shanyao
20	Crataegi Fructus	Crataegus pinnatifida Bge.	Shazha
21	Hirudo	Hirudo orientalis, Hirudo troctina, and Hirudo verbana	Shuizhi
22	Semen Sinapsis seu Brassicae	Sinapis alba (L.) Boiss; Brassica Juncea (L.) Czern.	Baijiezi
23	Litchi Semen	Litchi chinensis Sonn.	Lizhihe
24	Ecliptae Herba	Eclipta prostrata L.	Mohanlian
25	Eupatorii Herba	Eupatorium fortunei Turcz.	Peilan
26	Atractylodis Rhizoma	Atractylodes chinensis (DC.) Koidz.	Cangzhu
27	Centellae Herba	Centella asiatica (L.) Urb.	Jixuecao
28	Smilacis Glabrae Rhizoma	Smilax glabra Roxb.	Tufuling
29	Trichosanthis Radix	Trichpsanthes kirilowii Maxim./ Trichosanthes rosthronii Harms	Tianhuafen
30	Gypsum Fibrosum	Gypsum fibrosum	Shigao
31	Anemarrhenae Rhizoma	Anemarrhena asphodeloides Bge.	Zhimu
32	Ophiopogonis Radix	Ophiopogon japonicus (L.f) KerGawl.	Maidong
33	Radix Aconiti Lateralis Praeparata	Aconitum carmichaeli Debx.	Fuzi
34	Cinnamomi Cortex	Cinnamomum cassia Presl	Rougui
35	Cornu cervi pantotrichum	Cervus elaphus, Cervus nippon	Lurong
36	Rubi Fructus	Rubus chingii Hu	Fupenzi
37	Granati Pericarpium	Punica granatum L.	Shiliupi
38	Persicae Semen	Prunus persica (L.) Batsch/ Prunus davidiana (Carr.) Franch.	Taoren
39	Carthami Flos	Carthamus tinctorius L.	Honghua
40	Massa Fermentata Medicinalis	Artemisiae Annuae, Fructus Xanthii, Semen Armeniacae Amarum, Semen Phascoli Calcarati	Shenqu
41	Hordei Fructus Germinatus	Hordeum vulgare L.	Maiya
42	Corydalis Rhizoma	Corydalis yanhusuo W.T. Wang	Yanhusuo

43	Bombyx Batryticatus	Bombyx mori L. (Fam. Bombycidae)	Jiangcan
44			Quanxie
45	Curcumae Radix	Curcuma wenyujin Y.H.Chen et C.Ling	Yujin
46	Codonopsis Radix	Codonopsis pilosula (Franch.) Nannf.	Dangshen
47	Glehniae Radix	Glehnia littoralis Fr. Schmidt ex Miq.	Beishashen
48	Pseudostellariae Radix	Pseudostellaria heterophylla (Miq.) Pax ex Pax et Hoffm.	Taizishen
49	Phellodendri Chinensis Cortex	Phellodendron chinense Schneid.	Chuanhuangbai
50	Chuanxiong Rhizoma	Ligusticum chuangxiong Hort.	Chuanxiong
51	Pheretima Earthworm	Pheretima aspergillum	Dilong
52	Dendrobii Caulis	Dendrobium nobile Lindl.	Shihu
53	Asparagi Radix	Asparagus cochinchinensis (Lour.) Merr.	Tianmendong
54	Citri Reticulatae Pericarpium	Citrus reticulata Blanco	Chenpi
55	Pinelliae Rhizoma	Pinellia ternata (Thunb.) Breit.	Banxia
56	Cassiae Semen	Cassia obtusifolia L.	Juemingzi
57	Alismatis Rhizoma	Alisma orientalis (Sam.) Juzep.	Zexie
58	Bambusae Caulis in Taenia	Bambusa tuldoides Munro	Zhuru
59	Arisaema Cum Bile	Arisaema erubescens (Wall.) Schott	Dannanxing
60	Scrophulariae Radix	Scrophularia ningpoensis Hemsl.	Xuanshen
61	Lycii Cortex	Lycium chinense Mill.	Digupi
62	Corni Fructus	Cornus officinalis Sieb. et Zucc.	Shanzhuyu
63	Schisandrae Chinensis Fructus	Schisandra chinensis (Turcz.) Baill.	Wuweizi
64	Mume Fructus	Prunus mume (Sieb.) Sieb. et Zucc.	Wumei
65	Angelicae Sinensis Radix	Angelica sinensis (Oliv.) Diels	Danggui
66	Paeoniae Alba Radix	Paeonia lactiflora Pall.	Baishao
67	Spatholobi Caulis	Spatholobus suberectus Dunn	Jixueteng
68	Lonicerae Japonicae Caulis	Lonicera japonica Thunb.	Rendongteng
69	Moutan Cortex	Paeonia suffruticosa Andr.	Mudanpi

70	Lycopi Herba	Lycopus lucidus Turcz. var. hirtus Regel	Zelan
71	Gardeniae Fructus	Gardenia jasminoides Ellis	Zhizi
72	Atractylodis Macrocephalae Rhizoma	Atractylodes macrocephala Koidz.	Baizhu
73	Bupleuri Radix	Bupleurum chinense DC.	Chaihu
74	Herba Buchneriae	Winged Euonymus Twig, Ramulus Euonymi	Guijianyu
75	Polygoni Multiflori Radix	Polygonum multiflorum Thunb.	Heshouwu
76	Cuscutae Semen	Cuscuta chinensis Lam.	Tusizi
77	Morindae Officinalis Radix	Morinda officinalis How	Bazitian
78	Eucommiae Cortex	Eucommia ulmoides Oliv.	Duzhong
79	Polygonati Odorati Rhizoma	Polygonatum odoratum (Mill.) Druce	Yuzhu
80	Mori Cortex	Morus alba L.	Sangbaipi
81	Mori Folium	Morus alba L.	Sangye
82	Mori Ramulus	Morus alba L.	Sangzhi
83	Nelumbinis Rhizomatis Nodus	Nelumbo nucifera Gaertn.	Oujie
84	Glycyrrhizae Radix	Glycyrrhiza uralensis Fish.	Gancao
85	Lycii Fructus	Lycium barbarum L.	Gouqizi
86			BaiKouren
87	Tetrapanacis Medulla	Tetrapanax papyrifer (Hook.) K. Koch	Tongcao
	Lablab Album Semen	Dolichos lablab L.	Baibiandou
	Nelumbinis Folium	Nelumbo nucifera Gaertn.	Heye
88	Lonicerae Flos	Lonicera macranthoides Hand Mazz.; Lonicera hypoglauca Miq. ; Lonicera confuse DC.; Lonicera fulvotomentosa Hsu et S.C. Cheng	Jinyinhua
89	Ginseng Radix	Panax ginseng C. A. Mey.	Renshen,
90	Dianthi Herba	Dianthus superbus L.	Qumai
91	Stephaniae Tetrandrae Radix	Stephania tetrandra S. Moore	Fangji

92 Tribuli Fructus Tribulus terrestris L. Cijili 93 Trichosanthis Fructus Trichpsanthes kirilowii Maxim.; Trichosanthes rosthronii Harms Gualou 94 Allii Macrostemonis Bulbus Allium macrostemon Bge.; Allium chinense G. Don Xiebai 95 Cynomorii Herba Cynomorium songaricum Rupr. Suoyang 96 Gastrodiae Rhizoma Gastrodia elata Bl. Tianma 97 Ootheca Mantidis Paratenodera Sinensis, P. augustipennis Saussure, Statilia maculata Sangpiaoxiao 98 Herba Epimedii Epimedium grandiflorum Morr. Xianlingpi 99 Platycodonis Radix Platycodon grandiflorum (Jacq.) A. Dc. Jiegeng 100 Ziziphi Spinosae Semen Ziziphus jujuba Mill. var. spinosa Suanzaoren 101 Aurantii Immaturus Fructus Citrus aurantium L. Zhishi 102 Cyper Rhizoma Cyperus rotundus L. Xiangfu 103 Stylus Zeae Maydis Ligustrum lucidum Ait Nuzhenzi 104 Ligustri Lucidi Fructus Ligustrum lucidum Aresch.; Ecklonia kurome Okam. Kunbu 105				
Allii Macrostemonis Bulbus Alliim macrostemon Bge.; Allium chinense G. Don Scynomorii Herba Cynomorium songaricum Rupr. Suoyang Gastrodiae Rhizoma Gastrodia elata Bl. Tianma Ootheca Mantidis Paratenodera Sinensis, P. augustipennis Saussure, Statilia maculata Herba Epimedii Epimedium grandiflorum Morr. Xianlingpi Platycodonis Radix Platycodon grandiflorum (Jacq.) A. DC. Ziziphi Spinosae Semen Ziziphus jujuba Mill. var. spinosa (Bunge) Hu ex H. F. Chou Ziziphi Spinosae Semen Cyperus rotundus L. Xiangfu Cyperus rotundus L. Xiangfu Stylus Zeae Maydis Yumixu Ligustri Lucidi Fructus Ligustrum lucidum Ait Nuzhenzi Laminariae Thallus Eckloniae Thallus Echlonia kurome Okam. Citrus aurantium L. Zhiqiao Laminariae Thallus Echlonia kurome Okam. Citrus aurantium L. Zhiqiao Dipsaci Radix Dipsacus asper Wall. ex Henry Xuduan Menthae Herba Mentha haplocalyx Briq. Bohe Fructus Cannabis. Cannabis seed, Hemp seed. Cannabis seed, Hemp seed. Cannabis seed, Hemp seed. Polygalae Radix Polyganum multiflorum Thunb. (Polygonaceae). Plantagonis Herba Plantago asiatica L.; Plantago depressa Willd.	92	Tribuli Fructus	Tribulus terrestris L.	Cijili
94 Allii Macrostemonis Bulbus Allium macrostemon Bge.; Allium chinense G. Don Xiebai 95 Cynomorii Herba Cynomorium songaricum Rupr. Suoyang 96 Gastrodiae Rhizoma Gastrodia elata Bl. Tianma 97 Ootheca Mantidis Paratenodera Sinensis, P. augustipennis Saussure, Statilia maculata Sangpiaoxiao 98 Herba Epimedii Epimedium grandiflorum Morr. Xianlingpi 99 Platycodonis Radix Platycodon grandiflorum (Jacq.) A. DC. Jiegeng 100 Ziziphi Spinosae Semen Ziziphus jujuba Mill. var. spinosa (Bunge) Hu ex H. F. Chou Suanzaoren 101 Auranti Immaturus Fructus Citrus aurantium L. Zhishi 102 Cyperi Rhizoma Cyperus rotundus L. Xiangfu 103 Stylus Zeae Maydis Yumixu 104 Ligustri Lucidi Fructus Ligustrum lucidum Ait. Nuzhenzi 105 Laminariae Thallus Laminaria japonica Aresch.; Kunbu Eckloniae Thallus Ecklonia kurome Okam. Kunbu 106 Aurantii Fructus Citrus aurantium L. Zhiqiao 107 Eriobotryae Folium Eriobotrya japonica (T	93	Trichosanthis Fructus		Gualou
95 Cynomorii Herba Cynomorium songaricum Rupr. Suoyang 96 Gastrodiae Rhizoma Gastrodia elata Bl. Tianma 97 Ootheca Mantidis Paratenodera Sinensis, P. augustipennis Saussure, Statilia maculata Sangpiaoxiao 98 Herba Epimedii Epimedium grandiflorum Morr. Xianlingpi 99 Platycodonis Radix Platycodon grandiflorum (Jacq.) A. DC. Jiegeng 100 Ziziphi Spinosae Semen Ziziphus jujuba Mill. var. spinosa (Bunge) Hu ex H. F. Chou Suanzaoren 101 Aurantii Immaturus Fructus Citrus aurantium L. Xiangfu 102 Cyperi Rhizoma Cyperus rotundus L. Xiangfu 103 Stylus Zeae Maydis Yumixu Nuzhenzi 104 Ligustri Lucidi Fructus Ligustrum lucidum Ait. Nuzhenzi 105 Laminariae Thallus Eckloniae Thallus Kunbu Eckloniae Thallus Ecklonia kurome Okam. Kunbu 106 Aurantii Fructus Citrus aurantium L. Zhiqiao 107 Eriobotryae Folium Eriobotryae Japonica (Thunb.) Lindl. Pipaye </td <td>94</td> <td>Allii Macrostemonis Bulbus</td> <td>Allium macrostemon Bge.; Allium</td> <td>Xiebai</td>	94	Allii Macrostemonis Bulbus	Allium macrostemon Bge.; Allium	Xiebai
97 Ootheca Mantidis Paratenodera Sinensis, P. augustipennis Saussure, Statilia maculata 98 Herba Epimedii Epimedium grandiflorum Morr. Xianlingpi 99 Platycodonis Radix Platycodon grandiflorum (Jacq.) A. Dc. 100 Ziziphi Spinosae Semen Ziziphus jujuba Mill. var. spinosa (Bunge) Hu ex H. F. Chou 101 Aurantii Immaturus Fructus Citrus aurantium L. Zhishi 102 Cyperi Rhizoma Cyperus rotundus L. Xiangfu 103 Stylus Zeae Maydis 104 Ligustri Lucidi Fructus Ligustrum lucidum Ait. Nuzhenzi 105 Laminariae Thallus Ecklonia kurome Okam. 106 Aurantii Fructus Citrus aurantium L. Zhiqiao 107 Eriobotryae Folium Eriobotrya japonica (Thunb.) Lindl. Pipaye 108 Hanliancao 109 Cibotii Rhizoma Cibotium barometz (L.) J. Sm. Gouji 110 Dipsaci Radix Dipsacus asper Wall. ex Henry Xuduan 111 Menthae Herba Mentha haplocalyx Briq. Bohe 112 Fructus Cannabis. Cannabis sativa L. Common Name: Cannabis seed, Hemp seed. 113 Caulis Polygoni Multiflori. Polygonum multiflorum Thunb. (Polygonaceae). 114 Polygalae Radix Polygala shibirica L. ; Plantago depressa Willd. : Polygalas chaca Willd. : Polygalas solicia L. ; Plantago depressa Willd.	95	Cynomorii Herba		Suoyang
augustipennis Saussure, Statilia maculata 98 Herba Epimedii Epimedium grandiflorum Morr. Xianlingpi 99 Platycodonis Radix Platycodon grandiflorum (Jacq.) A. DC. 100 Ziziphi Spinosae Semen Ziziphus jujuba Mill. var. spinosa (Bunge) Hu ex H. F. Chou 101 Aurantii Immaturus Fructus Citrus aurantium L. Zhishi 102 Cyperi Rhizoma Cyperus rotundus L. Xiangfu 103 Stylus Zeae Maydis 104 Ligustri Lucidi Fructus Ligustrum lucidum Ait. Nuzhenzi 105 Laminariae Thallus Ecklonia kurome Okam. 106 Aurantii Fructus Citrus aurantium L. Zhiqiao 107 Eriobotryae Folium Eriobotrya japonica (Thunb.) Lindl. Pipaye 108 Hanliancao 109 Cibotii Rhizoma Cibotium barometz (L.) J. Sm. Gouji 110 Dipsaci Radix Dipsacus asper Wall. ex Henry Xuduan 111 Menthae Herba Mentha haplocalyx Briq. Bohe 112 Fructus Cannabis. Cannabis sativa L. Common Name: Cannabis seed, Hemp seed. 113 Caulis Polygoni Multiflori. Polygonum multiflorum Thunb. (Polygonaceae). 114 Polygalae Radix Polygoni multiflori. Polygala sibirica L. ; Plantago depressa Willd.	96	Gastrodiae Rhizoma	Gastrodia elata Bl.	Tianma
99 Platycodonis Radix Platycodon grandiflorum (Jacq.) A. DC. Jiegeng 100 Ziziphi Spinosae Semen Ziziphus jujuba Mill. var. spinosa (Bunge) Hu ex H. F. Chou Suanzaoren 101 Aurantii Immaturus Fructus Citrus aurantium L. Zhishi 102 Cyperi Rhizoma Cyperus rotundus L. Xiangfu 103 Stylus Zeae Maydis Yumixu Nuzhenzi 104 Ligustri Lucidi Fructus Ligustrum lucidum Ait. Nuzhenzi 105 Laminariae Thallus Ecklonia kurome Okam. Kunbu 106 Aurantii Fructus Citrus aurantium L. Zhiqiao 107 Eriobotryae Folium Eriobotrya japonica (Thunb.) Lindl. Pipaye 108 Hanliancao 109 Cibotii Rhizoma Cibotium barometz (L.) J. Sm. Gouji 110 Dipsaci Radix Dipsacus asper Wall. ex Henry Xuduan 111 Mentha Haplocalyx Briq. Bohe 112 Fructus Cannabis. Cannabis sativa L. Common Name: Cannabis seed, Hemp seed. Polygonum multiflorum Thunb. (Polygonaceae). 113 Caulis Polygoni Multiflori. Polygala tenuifolia Willd.; Polygala sibirica L. Yuanzhi	97	Ootheca Mantidis	augustipennis Saussure, Statilia	Sangpiaoxiao
99 Platycodonis Radix Platycodon grandiflorum (Jacq.) A. DC. Jiegeng 100 Ziziphi Spinosae Semen Ziziphus jujuba Mill. var. spinosa (Bunge) Hu ex H. F. Chou Suanzaoren 101 Aurantii Immaturus Fructus Citrus aurantium L. Zhishi 102 Cyperi Rhizoma Cyperus rotundus L. Xiangfu 103 Stylus Zeae Maydis Yumixu Nuzhenzi 104 Ligustri Lucidi Fructus Ligustrum lucidum Ait. Nuzhenzi 105 Laminariae Thallus Ecklonia kurome Okam. Kunbu 106 Aurantii Fructus Citrus aurantium L. Zhiqiao 107 Eriobotryae Folium Eriobotrya japonica (Thunb.) Lindl. Pipaye 108 Hanliancao 109 Cibotii Rhizoma Cibotium barometz (L.) J. Sm. Gouji 110 Dipsaci Radix Dipsacus asper Wall. ex Henry Xuduan 111 Mentha Haplocalyx Briq. Bohe 112 Fructus Cannabis. Cannabis sativa L. Common Name: Cannabis seed, Hemp seed. Polygonum multiflorum Thunb. (Polygonaceae). 113 Caulis Polygoni Multiflori. Polygala tenuifolia Willd.; Polygala sibirica L. Yuanzhi	98	Herba Epimedii	Epimedium grandiflorum Morr.	Xianlingpi
(Bunge) Hu ex H. F. Chou Aurantii Immaturus Fructus Citrus aurantium L. Zhishi Cyperi Rhizoma Cyperus rotundus L. Xiangfu Yumixu 103 Stylus Zeae Maydis Ligustri Lucidi Fructus Ligustrum lucidum Ait. Nuzhenzi 105 Laminariae Thallus Eckloniae Thallus Eckloniae Thallus Citrus aurantium L. Zhiqiao 106 Aurantii Fructus Citrus aurantium L. Zhiqiao 107 Eriobotryae Folium Eriobotrya japonica (Thunb.) Lindl. Pipaye Hanliancao 108 Hanliancao Cibotii Rhizoma Cibotium barometz (L.) J. Sm. Gouji 110 Dipsaci Radix Dipsacus asper Wall. ex Henry Xuduan 111 Menthae Herba Mentha haplocalyx Briq. Bohe 112 Fructus Cannabis. Cannabis sativa L. Common Name: Cannabis seed, Hemp seed. 113 Caulis Polygoni Multiflori. Polygonaceae). 114 Polygalae Radix Polygala tenuifolia Willd.; Polygala sibirica L. Plantago asiatica L.; Plantago depressa Willd.	99		Platycodon grandiflorum (Jacq.) A.	
Cyperi Rhizoma Cyperus rotundus L. Xiangfu 102 Cyperi Rhizoma Cyperus rotundus L. Xiangfu 103 Stylus Zeae Maydis 104 Ligustri Lucidi Fructus 105 Laminariae Thallus Eckloniae Thallus Eckloniae Thallus Citrus aurantium L. Zhiqiao 106 Aurantii Fructus 107 Eriobotryae Folium 108 Eriobotryae Folium 109 Cibotii Rhizoma 109 Cibotii Rhizoma 100 Dipsaci Radix 110 Dipsaci Radix 111 Menthae Herba 112 Fructus Cannabis. 113 Caulis Polygoni Multiflori. 114 Polygalae Radix 115 Plantaginis Herba Cyperus rotundus L. Lianinaria Ligustrum lucidum Ait. Nuzhenzi Kunbu Eckloniae Aresch.; Ecklonia Aresch.; Eckloniae Aresch.; E			(Bunge) Hu ex H. F. Chou	
103 Stylus Zeae Maydis 104 Ligustri Lucidi Fructus 105 Laminariae Thallus Eckloniae Thallus Eckloniae Thallus 106 Aurantii Fructus 107 Eriobotryae Folium 108 Eriobotryae Folium 109 Cibotii Rhizoma 110 Dipsaci Radix 111 Menthae Herba 112 Fructus Cannabis. 113 Caulis Polygoni Multiflori. 115 Plantaginis Herba 116 Laminaria japonica Aresch. ; Ecklonia kurome Okam. 117 Citrus aurantium L. 118 Zeklonia Aresch. ; Eckloniae Aresc	101	Aurantii Immaturus Fructus	Citrus aurantium L.	Zhishi
104Ligustri Lucidi FructusLigustrum lucidum Ait.Nuzhenzi105Laminariae Thallus Eckloniae Thallus Eckloniae ThallusLaminaria japonica Aresch. ; Ecklonia kurome Okam.Kunbu106Aurantii FructusCitrus aurantium L.Zhiqiao107Eriobotryae FoliumEriobotrya japonica (Thunb.) Lindl.Pipaye108Hanliancao109Cibotii RhizomaCibotium barometz (L.) J. Sm.Gouji110Dipsaci RadixDipsacus asper Wall. ex HenryXuduan111Menthae HerbaMentha haplocalyx Briq.Bohe112Fructus Cannabis.Cannabis sativa L. Common Name: Cannabis seed, Hemp seed.Huomaren113Caulis Polygoni Multiflori.Polygonum multiflorum Thunb. (Polygonaceae).Yejiaoteng114Polygalae RadixPolygala tenuifolia Willd. ; Polygala sibirica L.Yuanzhi115Plantaginis HerbaPlantago asiatica L. ; Plantago depressa Willd.Cheqiancao			Cyperus rotundus L.	
105 Laminariae Thallus Eckloniae Thallus Eckloniae Thallus Eckloniae Aresch. ; Eckloniae Thallus Eckloniae Kurome Okam. 106 Aurantii Fructus Citrus aurantium L. Zhiqiao 107 Eriobotryae Folium Eriobotrya japonica (Thunb.) Lindl. Pipaye 108 Hanliancao 109 Cibotii Rhizoma Cibotium barometz (L.) J. Sm. Gouji 110 Dipsaci Radix Dipsacus asper Wall. ex Henry Xuduan 111 Menthae Herba Mentha haplocalyx Briq. Bohe 112 Fructus Cannabis. Cannabis sativa L. Common Name: Cannabis seed, Hemp seed. 113 Caulis Polygoni Multiflori. Polygonum multiflorum Thunb. Yejiaoteng (Polygonaceae). 114 Polygalae Radix Polygala tenuifolia Willd. ; Polygala sibirica L. 115 Plantaginis Herba Plantago asiatica L. ; Plantago depressa Willd.	103	Stylus Zeae Maydis		Yumixu
Eckloniae Thallus Ecklonia kurome Okam. Citrus aurantium L. Zhiqiao Totalia Eriobotryae Folium Eriobotrya japonica (Thunb.) Lindl. Pipaye Hanliancao Cibotii Rhizoma Cibotium barometz (L.) J. Sm. Gouji Dipsaci Radix Dipsacus asper Wall. ex Henry Menthae Herba Mentha haplocalyx Briq. Bohe Fructus Cannabis. Cannabis sativa L. Common Name: Cannabis seed, Hemp seed. Caulis Polygoni Multiflori. Polygonum multiflorum Thunb. (Polygonaceae). Polygalae Radix Polygala tenuifolia Willd.; Polygala sibirica L. Plantago asiatica L.; Plantago depressa Willd.	104	Ligustri Lucidi Fructus	Ligustrum lucidum Ait.	Nuzhenzi
107 Eriobotryae Folium Eriobotrya japonica (Thunb.) Lindl. Pipaye 108 Hanliancao 109 Cibotii Rhizoma Cibotium barometz (L.) J. Sm. Gouji 110 Dipsaci Radix Dipsacus asper Wall. ex Henry Xuduan 111 Menthae Herba Mentha haplocalyx Briq. Bohe 112 Fructus Cannabis. Cannabis sativa L. Common Name: Cannabis seed, Hemp seed. 113 Caulis Polygoni Multiflori. Polygonum multiflorum Thunb. (Polygonaceae). 114 Polygalae Radix Polygala tenuifolia Willd.; Polygala sibirica L. 115 Plantaginis Herba Plantago asiatica L.; Plantago depressa Willd.	105			Kunbu
108	106	Aurantii Fructus	Citrus aurantium L.	Zhiqiao
Cibotium barometz (L.) J. Sm. Gouji Dipsaci Radix Dipsacus asper Wall. ex Henry Mentha Herba Mentha haplocalyx Briq. Bohe Fructus Cannabis. Cannabis sativa L. Common Name: Cannabis seed, Hemp seed. Caulis Polygoni Multiflori. Polygonum multiflorum Thunb. (Polygonaceae). Polygalae Radix Polygala tenuifolia Willd.; Polygala sibirica L. Plantago asiatica L.; Plantago depressa Willd.	107	Eriobotryae Folium	Eriobotrya japonica (Thunb.) Lindl.	Pipaye
110 Dipsaci Radix Dipsacus asper Wall. ex Henry Xuduan 111 Menthae Herba Mentha haplocalyx Briq. Bohe 112 Fructus Cannabis. Cannabis sativa L. Common Name: Cannabis seed, Hemp seed. 113 Caulis Polygoni Multiflori. Polygonum multiflorum Thunb. (Polygonaceae). 114 Polygalae Radix Polygala tenuifolia Willd.; Polygala sibirica L. 115 Plantaginis Herba Plantago asiatica L.; Plantago depressa Willd.	108			Hanliancao
111 Menthae Herba Mentha haplocalyx Briq. Bohe 112 Fructus Cannabis. Cannabis sativa L. Common Name: Cannabis seed, Hemp seed. 113 Caulis Polygoni Multiflori. Polygonum multiflorum Thunb. (Polygonaceae). 114 Polygalae Radix Polygala tenuifolia Willd.; Polygala sibirica L. 115 Plantaginis Herba Plantago asiatica L.; Plantago depressa Willd.	109	Cibotii Rhizoma	Cibotium barometz (L.) J. Sm.	Gouji
112 Fructus Cannabis. Cannabis sativa L. Common Name: Cannabis seed, Hemp seed. 113 Caulis Polygoni Multiflori. Polygonum multiflorum Thunb. (Polygonaceae). Polygala tenuifolia Willd.; Polygala sibirica L. Plantaginis Herba Plantago asiatica L.; Plantago depressa Willd.	110	Dipsaci Radix	Dipsacus asper Wall. ex Henry	Xuduan
Name: Cannabis seed, Hemp seed. 113 Caulis Polygoni Multiflori. Polygonum multiflorum Thunb. (Polygonaceae). Polygala tenuifolia Willd.; Polygala sibirica L. Plantaginis Herba Plantago asiatica L.; Plantago depressa Willd.	111	Menthae Herba	. , , ,	Bohe
(Polygonaceae). 114 Polygalae Radix Polygala tenuifolia Willd.; Yuanzhi Polygala sibirica L. 115 Plantaginis Herba Plantago asiatica L.; Plantago depressa Willd.	112		Name: Cannabis seed, Hemp seed.	Huomaren
Polygala sibirica L. 115 Plantaginis Herba Plantago asiatica L. ; Plantago Cheqiancao depressa Willd.				, ,
depressa Willd.	114	Polygalae Radix	, , ,	Yuanzhi
	115	Plantaginis Herba		Cheqiancao
	116	Raphani Semen		Laifuzi

117			Xiapu
118	Sparganii Rhizoma	Sparganium stoloniferum Buch Ham.	Sanleng
119	Curcumae Rhizoma	Curcuma phaeocaulis Val.	Ezhu
120			Ganjiang
121	Ginseng Radix et Rhizoma Rubra	Panax ginseng C. A. Mey.	Hongshen
122	Endothelium Corneum Gigeriae Galli.	Gallus gallus domesticus Brisson	Jineijin
123	Amomi Fructus	Amomum villosum Lour.; Amomum villosum Lour. var. xanthioides T. L. Wu et Senjen; Amomum longiligulare T. L. Wu	Sharen
124	Chaenomelis Fructus	Chaenomeles speciosa (Sweet) Nakai	Mugua
125	Citri Exocarpium Rubrum	Citrus reticulata Blanco	Juhong
126	Lophatheri Herba	Lophatherum gracile Brongn.	Danzhuye
127			Baihuasheshecao
128	Scutellariae Barbatae Herba	Scutellaria barbata D. Don	Banzhilian
129	Magnoliae Officinalis Cortex	Magnolia officinalis Rehd. et Wils.	Houpo
130	Plantaginis Semen	Plantago asiatica L. ; Plantago depressa Willd.	Cheqianzi
131	Mori Fructus	Morus alba L.	Sangshen
132	Polygoni Cuspidati Rhizoma	Polygonum cuspidatum Sieb. et Zucc.	Huzhang

Table 5. Abbreviations

1	TCM	Traditional Chinese Medicine	
2	WHO	World Health Organisation	
3	ADA	American Diabetes Association	
4	HbA1C	Glycated haemoglobin	
5	FBG	fasting blood glucose	
6	2hPBG	2 hour postprandial blood glucose	
7	TC	Total cholesterol	
8	TG	Triglyceride	
9	LDL-C	Low-density lipoprotein-cholesterol	
10	HDL-C	High-density lipoprotein-cholesterol	
11	ВМІ	Body mass index	
12	HOMA-IR	Homeostatic Model Assessment of Insulin Resistance.	
13	ISI / IAI	insulin sensitivity index	
14	ECG	electrocardiogram	
15	RCT	randomised controlled trial	
16	T2DM	type 2 diabetes mellitus	